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Summary 
Despite major advances in the field of meningococcal pathogenesis research in 
recent decades, Neisseria meningitidis still remains a leading cause of 
meningitis and septicaemia world-wide. The high mortality and morbidity rates 
of meningococcal infection drive further research towards identifying novel and 
more effective therapeutic measures. 
This study focuses on a small secreted protein found to have haem binding 
activity and an ability to interact with red blood cells. Gly1ORF1 protein is highly 
conserved and ubiquitous among the invasive strains of N. meningitidis. The 
crystal structure of the Gly1ORF1 K12A variant, solved in this study, showed 
that the protein possess a novel fold and is present in solution as a dimer. This 
study provides the first quantitative determination of Gly1ORF1 – haem 
interaction and has enabled the estimation of the dissociation constant for 
Gly1ORF1 variants. 
Gly1ORF1’s role in iron acquisition was suggested by a previous study. 
Therefore, the haemoglobin receptor HmbR was expressed in E. coli and was 
tested for the interaction with Gly1ORF1. The preliminary data suggests that 
there is interaction between those proteins. Additionally, this study shows that 
Gly1ORF1 is immunogenic in man and animals and that antibodies against this 
protein are able to direct complement-mediated killing of N. meningitidis.  
A newly identified group of Gly1ORF1 homologs was also studied in this work. 
Two of the potential Gly1ORF1 homologs and one neisserial paralog were 
expressed in E. coli and subjected to functional analysis. The data suggest that 
the Gly1ORF1 homolog protein family is a group of small secreted proteins with 
shared secondary structure characteristics, but may have diverse functions. 
They might constitute a novel family of the bacterial virulence factors that could 
be novel therapeutic targets. 
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CHAPTER 1 INTRODUCTION 
1.1 Epidemiology of Neisseriae 
Neisseria meningitidis is an obligate human pathogen of the family 
Neisseriaceae. The Gram-negative diplococci colonise the human upper 
respiratory tract asymptomatically, with preference for the epithelium of 
nasopharynx. The global carriage rate is estimated to be 10-35%. However, in 
some populations (i.e. university students and military recruits) it can reach up 
to 100% (Hill et al., 2010). Despite the high disease incidence rate in infants, 
carriage is more prevalent in young adults (Rosenstein et al., 2001). Higher 
carriage rate is associated with decreased resistance of the mucosal barrier in 
the nasopharynx which can be observed during the dry season or following flu 
infection. Also, smoking, exposure to dust and overcrowding were identified as 
contributing factors to meningococcal colonisation (Stanwell-Smith et al., 1994; 
Wilder-Smith et al., 2002; Yazdankhah and Caugant, 2004).  
It is not completely understood what triggers the transformation of the carriage 
strains into the invasive state, resulting in systemic invasion of the human blood 
stream. The main clinically important feature of Neisseria meningitidis 
transformation to the invasive state is the ability to rapidly multiply in the blood 
stream. This causes the acute form of septic shock known as purpura 
fulminans, which is associated with leakage of the vascular epithelium, 
disseminated intravascular coagulopathy (DIC) and organ failure. Once in the 
blood stream, meningocci can cross the blood brain barrier and multiply 
uncontrollably in the cerebrospinal fluid. This is manifested as a central nervous 
system disease – meningitis (Coureuil et al., 2013). The similarity of the 
symptoms to the viral infections and rapid progression of the disease provide a 
challenge in the treatment of meningococcemia. Despite available antibiotic 
therapies, the mortality rate across Europe is 8% and higher in developing 
countries. The most serious outcomes are associated with meningococcal 
fulminant septicaemia (55%) and meningitis with septicaemia (25%), with lowest 
mortality rate for meningitis without associated septicaemia (generally 5%) 
(Trotter et al., 2007b). Epidemic outbreaks often caused by hypervirulent strains 
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can reach even higher mortality rates. For example, in Norway between 1985-
2002, the case fatality ratios (CFRs) of the meningococcal disease caused by 
serogroup C strains C:15:P1.7,16/ST-32 and C:2a/ST-11 was 21.1% and 18.2% 
respectively (Smith et al., 2006). A Recently described outbreak in Mexico, 
caused by ST-11 lineage, was associated with a 36.8% mortality rate (Chacon-
Cruz et al., 2014). The survivors are often left with devastating complications 
including limb amputations, hearing loss and neurological disorders (Wong et 
al., 2007).  
The incidence of sporadic cases of meningococcemia varies between 
geographic regions, with <2 cases/100000 population per annum in European 
countries, United States and China and regions with more than 10 cases per 
100000 population per annum in African countries (Jafri et al., 2013). In the sub-
Saharan African meningitis belt, seasonal outbreaks of the disease are 
observed yearly during the dry season. In addition, cyclical pandemics occur 
every 8-10 years, with the incidence rate over >1/1000 population, despite the 
introduction of the meningococcal vaccines (Stephens, 2009). In temperate 
climates, a higher incidence rate of meningococcal disease is observed during 
winters, with the highest peaks two weeks after influenza outbreaks (Cartwright 
et al., 1991). 
Neisseria meningitidis strains are classified into 13 serogroups based on the 
capsule polysaccharide (A, B, C, D, 29E, H, I, K, Y, W-135, X, Z) (Cartwright et 
al., 1991). Meningococcal diseases are caused mainly by serotypes A, B, C, Y, 
W-135, with the geographical variation of prevalence for each serotypes. The 
majority of the meningococcal infection cases in Europe and America arise due 
to serotypes B and C, whereas in the meningococcal belt in Africa the majority 
of the infections are associated with serotypes A and C. Serotype W-135 is 
responsible for diseases worldwide with no regional differences in prevalence, 
whereas serotype Y was mainly reported in Canada (Stephens, 2009). In 1991, 
New Zealand was affected by a meningitis epidemic dominated by serogroup B 
strain B:4:P1.7b,4 (NZ 98/254) (Wong et al., 2007). The introduction of the 
MeNZB vaccine, based on outer membrane vesicles of this strain, proved to be 
effective in controlling the New Zealand epidemic (Arnold et al., 2011). 
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1.2 Pathogenic mechanisms to overcome human defences 
The pathogenesis of meningococci can be divided into five stages (Fig. 1.1):  
1. Colonisation of the nasopharyngeal mucosa  
2. Invasion of the epithelium  
3. Invasion of the blood stream 
4. Crossing of the blood-brain barrier  
5. Survival in the cerebrospinal fluid (CSF)  
 
Figure 1.1 Schematic representation of the neisserial pathogenesis, with two 
different clinical outcomes.  
N. meningitidis first colonises epithelial cells and establishes intimate contact with the 
non-cilliated host cells. N. meningitidis can cross the epithelium by transcytosis, 
through the paracellular route or using the ‘Trojan horse’ strategy – by using migrating 
phagocytes. Once in the blood stream, in susceptible hosts, N. meningitidis can multiply 
rapidly. Only a couple of neisserial microcolonies attached to the endothelium are 
sufficient to invade the blood-brain barrier (BBB) and rapidly disseminate in the 
cerebrospinal fluid, causing meningitis. Rapid and uncontrolled dissemination of the 
meningococci in the blood often results in septicaemia. This can progress within hours 
to the most serious implication of meningococcal disease, purpura fulminans, which has 
a mortality rate of over 50%. Picture adapted from Virji with permission (Virji, 2009), 
with modifications based on Coureuil et al. (Coureuil et al., 2013).  
 
Each stage requires a whole range of virulence factors to evade the human 
immune system and adapt to the challenging conditions during the course of 
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systemic infection. Neisseria meningitidis’ ability to quickly adapt to the different 
hostile niches within the host organisms can be contributed to the flexibility of 
the meningococcal genome (Snyder et al., 2005). The small size of the genome 
(2.2 Mbp), compared to other extracellular pathogenic bacteria, facilitates quick 
replication of the genome. This feature is advantageous for fast colonisation of 
the host mucosal surfaces inhabited with other competing commensal 
microorganisms (Lappann et al., 2006). As a consequence, a fast replication 
rate results in an increased incidence of mutation, especially in a genome with 
an abundance of repetitive fragments. In Neisseria spp., this constitute 20% of 
the chromosomal DNA (Achaz et al., 2002). Among the most important 
examples are short tandem sequence repeats termed ‘simple sequence 
contingency loci’ (SSCL). They are responsible for phase variability of the 
expression of many neisserial genes through slipped strand mispairing during 
replication (Lovett, 2004). Many neisserial genes linked to virulence such as 
PilIV, PorA, Opc, NadA and iron uptake proteins undergo phase variation. 
Neisseria spp. also increases their genetic variability by horizontal gene 
transfer. This is possible due to the existence of an extremely efficient natural 
transformation system, aided by a large number of DNA uptake sequences 
(DUS) located throughout the neisserial genome (Hamilton and Dillard, 2006). 
In addition, the presence of a large number of chromosomally integrated 
prophages, islands of horizontal gene transfer and insertion sequences with 
frequent homologous recombination and genome rearrangement all contribute 
to the high genomic diversity of Neisseria spp. (Schoen et al., 2007). Such 
genome fluidity allows Neisseria spp. to develop a large repertoire of defence 
strategies to successfully colonise and survive within the host.  
The mechanism of neisserial avoidance of the host defence mechanisms will be 
described in section 1.2.6 with the focus on the iron acquisition system as an 
example of withstanding the host nutritional immunity. A summary of host 
defence strategies with the neisserial major virulence factors involved in their 
evasion are shown in Figure 1.2. 
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Figure 1.2 Summary of different host defence mechanisms against meningococcal 
infection with neisserial major virulence factors (MVF). 
Mechanistic stress: Type IV pili is the MVF involved in the initial stages of colonisation 
of the epithelium and endothelium involved in the cellular signalling cascade. It 
promotes the formation of cortical plaques and microvilli, which protect bacteria from 
mucus and blood flow, and allow firmer attachment via other adhesins. Oxidative stress: 
Reactive oxygen and nitrate species (ROS and RNS respectively) are neutralised by a 
series of periplasmic and cytoplasmic enzymes. L-glutamate is converted to glutathione 
to keep the reducing environment in the cytoplasm. DNA oxidative damage is repaired 
with the Base Excision Repair (BER) pathway. Antimicrobials: Meningococci resist the 
antimicrobial activity of LL-37 thanks to the presence of LPS, binding of LL-37 to 
factor H binding protein (fHBP), and active transport of LL-37 via Mtr efflux pump. 
Lactoferrin binding protein (Lbp) protects meningococci from antimicrobial activity of 
lactoferrin (Lf) and simultaneously uses the Fe-complex as an iron source. Nutritional 
immunity: Host iron and haem sequestering proteins (haemoglobin – Hb, Transferrin 
(Tf) and Lf) and siderophores, produced by co-colonising bacteria, are used as an iron 
source via outer membrane single- or bi-partite TonB-dependent transporters. 
Complement cascade: The capsule and LPS prevent binding of the complement 
proteins. Sialic acid, which plays a major role in complement evasion, is produced from 
lactate which is actively transported inside the cells. Many pathogen proteins bind 
complement regulators, like fHbp binds factor H. Adaptive immunity: The presence of 
the α2-8 sialic acid homopolymer, which is identical to the NCAM-1 adhesin in host 
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neural cells, and the presence of L-NNT epitope in LPS, which is identical to the 
antigen in red blood cells, prevents recognition of the meningococci by the immune 
system. Phase variation (PV) of the major surface virulence proteins and their genetic 
variability allows evasion of the adaptive immune response and hinders vaccine 
development. Figure adapted from Lo et al. with modifications (Lo et al., 2009). 
Permission of the publisher was granted. SOD – superoxide dismutase; Kat – catalase; 
AniA- nitrite reductase; NorB – nitric oxide reductase, CycP – cytochrome c’. 
 
1.2.1 Adhesion strategies as an adaptation to the mechanistic stress of 
fluid flow in the mucosal surface and blood stream 
During colonisation of the nasopharyngeal epithelium, a constant flow of 
mucosal fluid, together with the ciliary activity of the epithelial cells and other 
defence mechanisms such as coughing, impose a challenge for the successful 
attachment of pathogen cells and maintaining contact with epithelial cells. Blood 
borne meningococci must also overcome sheer stress of the blood flow in order 
to adhere to the vascular endothelium and progress to the meninges. 
Meningococci have evolved a whole array of outer membrane proteins and 
structures involved in the interaction with host cell receptors, allowing close 
adhesion to the host cells. These features give Neisseria spp. protection from 
mucosilliary clearance during colonisation, and allow successful colonisation of 
the endothelium and progression through the blood brain barrier. 
1.2.1.1 Type IV pili mediated adhesion 
Type IV pili are the main adhesins involved in the initial attachment of Neisseria 
meningitidis to the epithelial cells. Their filamentous structure can extend from 
the bacterial surface, which is of a particular importance for encapsulated 
meningococci with limited surface exposure of other adhesins. Pili have very 
dynamic structures. The constant process of pili extension and retraction, 
facilitated by the coordinated action of PilC and the ATP-ase PilT, is the basis of 
bacterial twitching motility (Merz et al., 2000). In addition, pili are associated 
with competence for DNA transformation (Proft and Baker, 2009), formation of 
microcolonies and signalling to host endothelial cells (Lee et al., 2005).  
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Figure 1.3 Type IV pilus assembly and structure.  
A. Schematic representation of the type IV pilus assembly. The pilus fibre is comprised 
of the pilus subunits PilE, PilX, PilV and CompA, which are assembled by a platform 
complex (PilD, PilM-P,and PilF) located in the cytoplasmic membrane. They are 
transported to the cell surface through a pore formed by PilQ. The ATPase PilF delivers 
the energy for the elongation of the pilus, whereas PilT utilises energy from ATP for 
pilus retraction through the depolymerisation of the type IV pili. PilC (PilC1 and PilC2), 
located in the outer membrane, is involved in pilus retraction. In addition, PilC1 plays a 
role in adhesion to the host cells. PilW, located in the outer membrane, stabilises the 
PilQ structure. Figure adapted from Coureuil et al. with permission (Coureuil et al., 
2014). B. Ribbon representation of the type IV pilus fibre of N. gonorrhoeae. i. 
Structure of the pilus fibre. Pilin subunits are arranged helically with the alpha-helical 
domain (cyan) in the center of the pilus and β-stranded domain (red) exposed to the 
surface of the pilus. ii. An enlarged single pilin subunit. iii. A cross-section of the pilus 
fibre showing the arrangement of the alpha-helices inside the fibre, and the externally 
exposed β-strand domains. Images generated and rendered using Pymol from the PDB 
file 2HIL. 
 
The fibre of the pilus is mainly composed of the phase variable major pilin, PilE, 
the subunits of which are arranged in a helical orientation (Virji et al., 1992a) 
(Fig. 1.3). Several posttranslational modifications, such as the glycosylation or 
phosphorylation of serine residues, were observed in PilE. These alter the pilus 
surface charge, affecting adhesion and the pili’s immunogenic properties (Virji, 
1997). Some minor pilins (PilX, PilV and ComP) are also incorporated in the 
pilus fibre and until recently were believed to directly mediate adhesion, auto-
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aggregation and host membrane reorganisation (Brown et al., 2010). Recently, 
the results of the study by Imhaus and Dumenil demonstrated that the 
modulation of the Type-IV pili-mediated functions in meningococci depends on 
the number of pilis rather than the composition of the minor pilins in the pilus 
fibre. The role of the minor pilis (PilV and PilX), which according to this study 
are mainly located in the periplasm, is attributed to the initiation of the pilus 
biosynthesis and regulation of the number of pilis (Imhaus and Duménil, 2014) 
The PilC proteins are proposed to form a structural tip of the pilus and are 
essential for adhesion to epithelial cells and pilus assembly; however, their 
exact role remains enigmatic. The pore forming PilQ pilins are also thought to 
be involved in adhesion (Rudel et al., 1995).  
The type IV pilus mediates adhesion of the meningococci to the epithelial cells 
via a recently identified receptor, CD147, and allows localised proliferation of 
the bacteria (Bernard et al., 2014). The attachment of the bacteria facilitates the 
formation of membrane structures known as ‘cortical plaques’. These structures 
are formed via the local recruitment of ERM proteins (ezrin-radizin-moeisin 
protein family) and several transmembrane receptors: Erb2 tyrosine kinase, 
CD44 and ICAM receptors which are attachment sites for the polymerised actin 
filaments (Merz et al., 1999; Merz and So, 1997). Localised cortical actin 
polymerisation is activated by Rho GTPase and the Src tyrosine kinase 
signalling cascade, and activation of β-arrestins through β2-adrenergic 
receptors. The signalling cascade leads to the formation of membrane 
protrusions that initially act as a shield for the attached meningococci against 
the sheer force of the mucosal or blood flow. Later, elongation of the microvilli 
allows bacterial engulfment and internalisation (Merz et al., 1996). The cellular 
receptors and signalling pathways used by Neisseria spp. for attachment are 
also implicated in leukocyte adhesion and trans-epithelial migration. Thus, it is 
hypothesized that Neisseria interferes with leukocyte adhesion by hijacking the 
leukocyte’s docking sites (Doulet et al., 2006).   
Close contact with the endothelial cells also opens the para-cellular route for 
neisserial translocation through the endothelium. Activation of the β-adrenergic 
receptor and β-arrestins has been shown to result in the recruitment of proteins 
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from junctional complexes located under the neisserial microcolonies, leading to 
increase leakage of the endothelium (Coureuil et al., 2013). 
1.2.1.2 Opa and Opc 
Although type IV pili are the first means of bacterial adhesion to the host cells, a 
firmer and more stable attachment is necessary for epithelial barrier crossing. 
This is achieved by interaction with two other groups of major adhesins: the 
Opa and Opc proteins, and LPS. Opa proteins belong to a family of 
transmembrane proteins with eight β-strands and four extracellular loops 
(Malorny et al., 1998). The surface exposed loops are immunogenic, but their 
high degree of variability limits their potential as a vaccine candidates. Encoded 
by four to five loci, the proteins are also subjected to phase variation and 
homologous recombination. This greatly increases the repertoire of Opa 
variants expressed by a single strain (Callaghan et al., 2006). Opa proteins bind 
to carcinoembryonic antigen cell adhesion molecules (CEACAM-1), heparan-
sulphate proteoglycans (HSPG), present on some epithelial cells, and integrins 
(Dehio et al., 1998; van Putten and Paul, 1995; Virji et al., 1996). Opc proteins 
are encoded by a single gene, OpcA, and form a β-barrel consisting of ten 
transmembrane β-sheets. Their adhesion to integrins in the endothelial cell 
membrane is mediated via serum vitronectin or fibronectin. It has been shown 
that Opc can mediate cell adhesion independently of pili and Opa proteins in 
unencapsulated meningococci (Virji, 2009; Virji et al., 1993; Virji et al., 1992b; 
Virji et al., 1995). 
 
1.2.2 Evasion of the complement system 
The complement system is a key factor of the host innate immune system, and 
consists of approximately 35 soluble or membrane bound proteins. The 
complement cascade is involved in the recognition and clearance of invading 
pathogens either in concert with antibodies and phagocytes, or independently 
(Morgan et al., 2005). Three different pathways can activate the complement 
cascade: the classical pathway (initiated by the antibody-antigen interactions), 
the lectin pathway (activated by the interaction of mannose-binding-lectin with 
polysaccharide structures on the surface of the bacteria) or the alternative 
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pathway activated by spontaneous hydrolysis of C3. In all three pathways, the 
C3b fragment is released and causes the insertion of the membrane attack 
complex (MAC), increased opsonophagocytosis of invading pathogens, 
modulation of the inflammatory response and chemotaxis (Walport, 2001). 
Excessive activation of the complement cascade can be detrimental to the host, 
thus the activation process is tightly controlled. Several fluid-phase and soluble 
proteins are involved in the modulation of complement function. The negative 
circulating complement regulators include C4b-binding protein, factor H, 
vitronectin and C1q inhibitor (Lewis and Ram, 2014). Also, negative control is 
achieved by the expression of membrane bound complement receptors with 
inhibitory functions, such as Membrane Cofactor Protein (MCP) also known as 
CD46, complement receptor 1 (CR1), CD55 and CD59 (Kim and Song, 2006). 
Components of the complement cascade are mainly produced in the liver and 
circulated in the serum; although epithelial cells have been shown to express 
the complement proteins to protect mucosal surfaces of the nasopharynx and 
urogenital tract from pathogen invasion (Lo et al., 2009). 
Complement deficiencies, whether inherited or acquired, are important 
predisposing factors to meningococcal disease. This is especially evident in 
deficiencies of the complement components activated later in the cascade. For 
example, deficiencies in the membrane attack complex proteins (C5-C9) 
increase the risk of meningococcal disease by 7000 to 10000 fold when 
compared to the normal population (Figueroa and Densen, 1991). Complement 
deficiencies influence susceptibility to meningococcemia, severity and 
recurrence of the disease and mortality rates. Examples of the correlation 
between complement deficiencies with meningococcal disease progression or 
predisposition include: properdin (factor P) deficiencies, which are linked to 
severe fulminant septicaemia and high mortality rate (Braconier et al., 1983), 
the mannose-binding-lectin (MBL) deficiency in children, which is associated 
with higher bacterial load during meningococcemia (Darton et al., 2014), or 
factor H deficiency, which increases susceptibility to serogroup C (Haralambous 
et al., 2006). 
Meningococci have developed a range of strategies that allow it to evade the 
human complement. 
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The capsule is the major determinant of the meningococcal serum resistance 
and virulence. Encapsulated meningococci are more resistant to complement 
mediated killing compared to strains lacking the capsule. Essentially all strains 
isolated from the blood are encapsulated, whereas only 50% of carriage 
isolates expressed a functional capsule (Lewis and Ram, 2014). Capsular 
polysaccharides of the serogroups B, C, W-135 and Y contain sialic acid which 
is also commonly present on the host cells. This makes them less susceptible to 
recognition by the immune system (Walport, 2001). The most effective mimicry 
strategy was developed by serotype B, where the structure of sialic acid 
residues in the capsule is identical to the one present on the neural cell-
adhesion molecule (NCAM) on host cells. This particular feature prevented the 
use of this capsule polysaccharide in the composition of a vaccine against 
serogroup B, due to low immunogenicity and the risk of eliciting an autoimmune 
response (Diaz Romero and Outschoorn, 1994). On the host cells, sialic acid 
plays a role in down-regulating the alternative pathway through the 
enhancement of the interaction between factor H and C3b (Walport, 2001). This 
mechanism has not been proven for meningococci. The most probable function 
of the capsule in complement evasion is hindering the insertion of the 
membrane attack complex by masking the epitopes for the bactericidal 
antibodies (Drogari-Apiranthitou et al., 2002; Lewis and Ram, 2014). 
1.2.2.1 Lipopolysaccharide (LPS) 
Lipopolysaccharide is a primary component of the outer membrane of all Gram-
negative bacteria. It is responsible for outer membrane stability. In Neisseria 
spp. LPS expression is indispensable for the complement resistance (Geoffroy 
et al., 2003). The structure of neisserial LPS consists of an inner and an outer 
core. The inner core contains several heptose molecules and is connected to 
the membrane anchored lipid A via one of the two KDOs (2-keto-3-deoxy-D-
manno-2-octulosonic acids). The outer core is highly heterogeneous and 
consists of up to ten sugar residues. The short outer core of LPS differentiate 
Neisseria spp. from other Gram-negative bacteria, which usually express a 
longer side chain (up to 40 residues) consisting of repetitive sequences of sugar 
residues referred to as “O-antigen”. Therefore, neisserial LPS is also known as 
lipooligosaccharide (LOS) (Jennings et al., 1999). The composition of the LOS 
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side chain is the basis for further classification of N. meningitidis into twelve 
immunotypes (L1-L2) (Scholten et al., 1994). In addition, modification of the 
sugar residues, such as the addition of sialic acid to the terminal lacto-N-
neotetraose (LNT) epitope, increases the repertoire of LPS types, modulating 
the effectiveness in complement evasion (Mandrell et al., 1991). 
LPS modulates the complement cascade by the deposition of C3b and C4b 
(Lewis and Ram, 2014). Furthermore, sialylation of LPS enhances complement 
resistance in Neisseria spp. In N. gonorrhoeae, it hinders antibody binding to 
the neisserial surface (Elkins et al., 1992), and enhances the binding of factor H 
to Porin B (Ram et al., 1998). In N. meningitidis the exact role of LPS sialylation 
remains uncharacterised, although it appears to be involved in the modulation 
of the lectin pathway (Jack et al., 1998; Jack et al., 2001). 
1.2.2.2 Binding of the host complement regulatory protein 
In order to circumvent the complement killing machinery, Neisseria spp., like 
several other pathogens, express a number of proteins involved in hijacking the 
host complement regulatory proteins. 
The negative regulator of the classical pathway, C4 binding protein (C4BP), is 
one of the neisserial targets for inhibition of the classical pathway. Strains of N. 
meningitidis that are able to bind C4BP were more resistant to complement 
killing than non-binders. PorA was identified as a binding partner of C4BP, 
however the interactions were observed under non-physiological conditions, 
undermining the importance of PorA in the modulation of the classical pathway 
(Jarva et al., 2005).  
Down-regulating the alternative pathway by Factor H binding is better 
characterised. Factor H deposition on Neisseria spp. results in the decrease of 
C3b deposition, thus increasing serum resistance of this pathogen (Lewis and 
Ram, 2014). Neisseria spp. expresses factor H binding protein (fHBP), also 
known as GNA1870, which is regarded as the main virulence factor of 
meningococci. Its selective binding to human factor H is one of the reasons for 
the narrow host species specificity of Neisseria spp. (Madico et al., 2006). 
Factor H binding protein is a component of the Bexsero vaccine against 
serogroup B. Also, neisserial NspA, and recentlyPorB2, have been identified as 
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inhibitors of the alternative pathway, with an affinity for factor H (Lewis et al., 
2010; Lewis et al., 2013). Presence of other factor H binding structures in 
Neisseria spp contributes to the limited strain coverage of the Bexsero vaccine. 
Widespread use of the vaccine is predicted to cause positive selection of the 
disease strains lacking fHBP isolated form patients (Giuntini et al., 2013), thus 
prompting the need for a new generation vaccines against serogroup B. 
Neisseria spp. also hijacks regulatory proteins at different levels of the 
complement cascade. The members of the opacity protein family: Opa and Opc 
have been shown to bind vitronectin to prevent the formation of the membrane 
attack complex (Blom et al., 2009). Properdin and membrane-associated-
complement receptor binding are also involved in the increase of serum 
resistance by bacteria (Lewis and Ram, 2014). 
1.2.3 Antimicrobial peptides 
Antimicrobial peptides and proteins are the first series of host innate defence 
mechanisms against pathogens. The antimicrobial peptides are small, cationic 
molecules that are either secreted by epithelial and immune cells into mucosal 
surfaces, or are present in neutrophil granules. They act as innate, broad 
spectrum antibiotics by promoting both the aggregation of bacteria and viruses, 
and their killing. Their role extends to the modulation of the immune response 
by promoting opsonisation and chemotaxis of neutrophils and monocytes, and 
by down-regulating inflammation (Seiler et al., 2014). The antimicrobial peptides 
are divided into two groups: defensins (devided into three groups: α, β and θ) 
and cathelicidin. In the human host, only one cathelicidin has been described: 
LL-37 (Puklo et al., 2008). Neisseria spp. are also subjected to other 
antimicrobial molecules at different stages of infection, such as elastase, 
lysozyme and lactoferrin (Lo et al., 2009). 
Neisseria spp. are largely resistant to the antimicrobial molecules produced by 
the host because they express a number of surface exposed structures. One 
example is the lactoferrin receptor LbpAB, which allows the utilisation of 
lactoferrin as an iron source, and will be further discussed in more detail in 
section 1.2.6.3. 
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The resistance to LL-37 and defensins is contributed to by the presence of the 
capsule, lipid A modifications in LPS, and biofilm formation by Neisseria spp. by 
limiting the access of the cationic peptides to the outer membrane (Jones et al., 
2009). Expression of the factor H binding protein also contributes to the 
neutralisation of the LL-37 anti-microbial effect, probably due to the electrostatic 
interaction between these two molecules (Seib et al., 2009). Furthermore, the 
study by Tzeng et al. revealed that mutations in the operon encoding the efflux 
pump genes MtrC-MtrD-MtrE are associated with higher susceptibility to killing 
by LL-37 and other cationic antimicrobials, specifically polymyxin B and 
protegrin-1 (Tzeng et al., 2005). This indicates that the efflux pump is important 
for sustaining antimicrobial killing mechanisms. It has also been shown that 
Neisseria spp. withstands the AMP challenge more effectively when attached to 
nasopharyngeal epithelial cells. The activation of the CDC42 and Rho cell 
signalling cascade in the host by meningococci, by a cytoskeleton-independent 
process, is believed to have a protective effect, although the mechanism is 
unclear (Geörg et al., 2013).  
1.2.4 Evasion of the oxidative stress 
Role of professional phagocytes in generating oxidative stress 
The mucosal surfaces, epithelium and blood stream contain an abundance of 
professional phagocytes that are involved in the clearance of the invading 
pathogens. Macrophages, monocytes and neutrophils differentiate from myeloid 
progenitor cells through a maturation process. Macrophages kill meningococci 
after activation through the classical complement cascade. As described before, 
meningococci are very proficient in circumventing the recognition and activation 
of the killing cascade. Neutrophils are the major cellular components of the 
immune system responsible for clearance of meningococci. Neutrophils use 
three characteristic killing strategies: 1. Intracellular killing via phagocytosis; 2. 
extracellular killing by the release of granules containing antimicrobial peptides 
and reactive oxygen and nitrite species that cause oxidative stress; 3. secretion 
of neutrophil extracellular traps (NETs) that are formed by secreted DNA, AMPs 
and ROS/RNS. The role of these NETs is to trap the pathogen and deprive it of 
essential nutrients and kill it (Criss and Seifert, 2012).  
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Neutrophils and macrophages both produce ROS (Reactive Oxygen Species) 
and RNS (Reactive Nitrogen Species) to destroy invading microorganisms. 
ROS/RNS target the bacteria in the phagolysosomes, and in the extracellular 
environment when released with the bactericidal granules. The enzyme 
responsible for the production of ROS is NADPH oxidase. This multiunit 
enzyme assembles on the phagocyte’s plasma membrane in response to 
phagocyte activation, where it generates the production of hydroxyl free 
radicals, superoxide anions, and hydrogen peroxide (Roos et al., 2003). In 
addition, NADPH oxidase is present in the granules of neutrophils alongside 
myeloperoxidase, which uses hydrogen peroxide to produce hypochlorous acid. 
This adds to the broad anti-microbial repertoire of neutrophil granules (Fang, 
2004). RNS include nitric oxide produced by nitric oxide synthase (iNOS) and 
peroxynitrate. Apart from professional phagocytes, RNS is constitutively 
produced by epithelial cells of the respiratory tract as a cellular or intracellular 
signalling molecule. RNS regulate smooth muscle tone, ciliary function, 
electrolyte transport and protection from invading pathogens (Bove and van der 
Vliet, 2006). 
Effect of ROS and RNS on pathogens 
ROS/RNS are highly reactive and can penetrate the microbial envelope through 
anion channels (Pacher et al., 2007). ROS/RNS react with thiols, 
metalloproteins and DNA. Oxidative damage of DNA is caused mainly by ROS, 
whereas RNS interferes with respiratory processes and DNA replication by 
oxidising metal ions (Fe, Mn) required by key enzymes involved in these 
processes (Fang, 2004). Bacteria appear to have evolved many mechanisms to 
evade killing by ROS and NOS. These are considered below. 
Neutralisation of ROS by meningococci 
The first line of defence from ROS in meningococci is the enzymatic 
neutralisation of ROS by superoxide dismutases and catalases (Criss and 
Seifert, 2012). Highly unstable superoxide anions are converted to hydrogen 
peroxide by superoxide dismutase. The catalases neutralise hydrogen peroxide 
to producing water and oxygen (Eason and Fan, 2014). Meningococci express 
two types of superoxide dismutases: cytopolasmic SodB and periplasmic SodC 
(Wilks et al., 1998). SodC is also involved in the neutralisation of ROS released 
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by activated macrophages, and protects opsonised meningococci from 
phagocytosis (Dunn et al., 2003). Another mechanism of protection from 
oxidative stress is the uptake of L-glutamate via the L-glutamate transporter 
(GltT), and converting it into glutathione. As a result, the redox environment in 
the cytoplasm of the pathogen helps to reduce the damage by ROS (Talà et al., 
2011).  
Neutralisation of RNS by meningococci 
Meningocci are adapted to microaerobic growth by utilising nitrate produced by 
two enzymes from the denitrification pathway: nitrate reductase (AniA), and 
nitric oxide reductase (NorB). AniA catalyses the conversion of nitrate into nitric 
oxide, whilst NorB reduces NO to the more stable nitrous oxide (Rock and Moir, 
2005). These enzymes help Neisseria spp. to detoxify RNS with help  from 
cytochrome C’, the product of the cycP gene (Anjum et al., 2002). Expression of 
NorB and cytochrome C’ has been shown to increase the survival of 
meningococci in the nasopharyngeal mucosa and in macrophages by different 
mechanisms (Stevanin et al., 2005). Depletion of NO, which is an important 
signalling molecule, has been attributed to the modulation of the inflammatory 
response exerted by monocyte derived macrophages by changing the levels of 
cytokines and chemokines (Stevanin et al., 2007). It also promotes intracellular 
survival of phagocytised meningococci by inhibiting macrophage apoptosis 
(Stevanin et al., 2005). According to the study by Laver et al., this phenomenon 
can be explained by the reduction in NO, which decreases the level of S-
nitrosylation of the host cells (Laver et al., 2010). S-nitrosylation is an important 
post-translational modification of proteins, and is implicated in the control of 
intracellular cell signalling, apoptosis, neurotransmission and gene expression. 
Therefore, by metabolising NO, the main substrate for S-nitrosylation, 
meningococci are able to modulate many cellular and inflammatory processes 
in the host for its own advantage.  
DNA repair 
Damage of DNA caused by oxidative stress can, if unrepaired, lead to abnormal 
cell function, genome instability during replication, and accumulation of 
mutations which can affect pathogen survival (Friedberg EC, 2006). The 
primary mechanism of DNA repair after oxidative stress in cells is the base 
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excision pathway (BER) (Bjelland and Seeberg, 2003). Meningococci have a 
lower number of BER enzymes compared with E. coli, and do not possess an 
SOS repair system (Black et al., 1998; Davidsen and Tønjum, 2006). However, 
their repair network is efficient enough for withstanding oxidative damage. Two 
key enzymes of the BER system in meningococci are the bi-functional 
glycosylases Nth and MutM (also known as Fpg), which are involved in the 
removal of damaged nucleobases and incision of the DNA-backbone by two 
different mechanisms (Nagorska et al., 2012). In addition, MutY, a mono-
functional glycosylase, has an anti-mutagenic role by removing adenines paired 
with 8-oxoG, a common product of oxidative damage (Davidsen et al., 2005).  
The abasic nucleotides are further fixed by AP endonucleases or exonucleases 
by BER (Carpenter et al., 2007; Davidsen et al., 2007). Deletion of both Nth and 
MutM genes greatly decreases the survival rate of N. meningitidis that are 
subjected to oxidative stress (Nagorska et al., 2012).  
1.2.5 Evasion of the adaptive immune system 
Most people are likely to be a carrier of Neisseria meningitidis at some stage of 
their lives, but only a small proportion of individuals develop meningococcal 
disease. Protection against N. meningitidis is exerted by the presence of the 
anti-meningococcal antibodies in healthy patients, which is quite common in the 
general population (Goldschneider et al., 1969). Anti-meningococcal antibodies 
can clear the pathogen by three different mechanisms: 1. Bactericidal 
mechanism by the activation of the classical complement pathway and the 
insertion of the membrane attack complex (Goldschneider et al., 1969); 2. 
Opsonophagocytosis, where antibodies bound to the pathogen surface promote 
its uptake by neutrophils (DeVoe, 1976); 3. Antibody-dependent cellular toxicity 
in sites with low levels of complement (Lowell et al., 1979). Immunity against 
meningococcal infection can be acquired naturally by exposure to non-
neisserial organisms (i.e. E. coli), through carriage of commensal N. lactamica 
or asymptomatic carriage and disease associated with N. meningitidis. Carriage 
of N. lactamica has been shown to generate cross-reactive antibodies that are 
protective against N. meningitidis colonisation. However, they have been shown 
to promote opsonophagocytosis rather than a bactericidal effect (Evans et al., 
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2011). Carriage of meningococci or past history of meningococcal disease elicit 
the production of anti-meningococcal IgA and IgG antibodies, which protect the 
host from both colonisation of the nasopharynx and invasion of the blood 
stream. Vaccination is another way of acquiring immunity against pathogenic N. 
meningitidis. 
Although naturally acquired immunity seems to be quite efficient in the control of 
meningococcal invasion, there are still meningococcal strains which can evade 
recognition by the host’s adaptive immune system. In most of the serogroups, 
vaccination has proved to be efficient in preventing infection. However, 
neisserial genomic fluidity and rapid genomic changes in concert with antigenic 
pressure activated through the vaccination process leads to the selection of 
strains which are no longer sensitive to the vaccine elicited bactericidal killing.  
Antigenic variability of the major neisserial virulence factors is a huge problem 
in the development of cross-reactive neisserial vaccine. Neisseria spp. have the 
largest number of genes that undergo phase variation in all pathogenic bacteria 
(Saunders et al., 2000). Phase variation, alongside other mechanisms 
promoting genomic rearrangements (which were described in Section 1.2), 
contributes to the huge repertoire of genes and rapid changes which lead to the 
loss of vaccine induced immunity. 
Serogroup B uses another strategy to evade recognition by the immune 
response named molecular mimicry. The capsule and LPS of this serogroup is 
chemically modified so that it resembles structures present on the host cells. 
The capsule of serogroup B contains a homopolymer of α2-8 sialic acid, which 
is also present on the NCAM-1 antigen on host neural cells (Finne et al., 1983). 
The LPS molecules contain a lacto-N-neotetraose epitope (L-NNT), which is 
also present on the surface of human red blood cells (Lo et al., 2009; Moran et 
al., 1996). 
As a consequence, the capsule and LPS of serogroup B are characterised by 
low immunogenicity. In addition, their inclusion in the vaccine formulation could 
result in eliciting auto-immune antibodies.  
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1.2.6 Defence against host nutritional immunity - iron acquisition by 
Neisseria spp. 
Iron is an essential nutrient for almost all living organisms. To date, the few 
exceptions reported are microorganisms such as Lactobacillum plantarum and 
Borrelia burgdorferi who use manganese or cobalt in place of iron (Posey and 
Gherardini, 2000; Weinberg, 1997). Iron is available in two oxidation forms: as 
ferrous (Fe2+) and ferric (Fe3+) ions. Changes in the redox state of iron are 
utilised by many enzymes involved in cellular functions. However, by-products 
of cellular oxidative reactions in the presence of iron are converted into reactive 
oxygen species, which are highly toxic to the cells. Free radicals can damage 
lipids, DNA and proteins. Thus, iron levels, and its subcellular localisation, are 
tightly regulated.  
In the human host, the majority of free iron is stored within cells as haem, iron-
sulphur clusters in various proteins or in ferritin, which contains 15-20% of total 
body iron (Clarke et al., 2001; Jordan and Saunders, 2009). The main source of 
intracellular haem is haemoglobin (Hb) which constitutes 67% of the total haem, 
and is normally contained within erythrocytes (Runyen-Janecky, 2013). Other 
intracellular sources of haem are myoglobins, cytochromes and the recently 
described cytoglobin and neuroglobin (Liu et al., 2012b; Watanabe et al., 2012). 
Extracellular iron in the host is usually found in complex with iron-binding 
proteins including transferrin (Tf) and lactoferrin (Lf). Each of the iron-binding 
proteins has a specific niche in the human body i.e. transferrin is predominantly 
found in serum, but is also present in CSF, whilst lactoferrin is in secreted fluids 
such as tears, milk and bile (Jordan and Saunders, 2009). Spontaneous 
haemolysis causes the release of Hb in the serum, but free Hb is captured by 
the serum haptoglobin (Jordan and Saunders, 2009). Free haem in the serum 
released by turnover of haem-binding proteins is captured by haemopexin, 
which has the highest known affinity to haem (Tolosano and Altruda, 2002), with 
a Kd in the subpicomolar range (Hrkal et al., 1974). 
Sequestration of iron and haem within host proteins not only protects the 
organism from the toxic effects of these molecules, but it is also believed to play 
an important role in non-specific protection from infections known as “nutritional 
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immunity” (Weinberg, 1975). Iron availability is an important limiting factor for 
neisserial invasion, as free iron concentration in the host (10-9 – 10-18 M) 1012-
fold lower than that required for microbial growth (Cassat and Skaar, 2013; 
Weinberg, 1978). Levels of free iron in the host can be lowered even more 
dramatically in response to infection by the release of the liver hormone 
hepcidin, which is responsible for iron homeostasis (De Domenico et al., 2010; 
Rossi, 2005). Hepcidin is also released locally at the site of infection by 
neutrophils and macrophages, thus limiting iron availability (Peyssonnaux et al., 
2006). Other inflammatory cytokines, such as interferon-gamma, TNF-alpha, IL-
1 and IL-6, can also induce hypoferremia in a hepcidin-independent manner by 
modulating local iron metabolism (Nairz et al., 2010; Weiss, 2005). In addition to 
these mechanisms, neutrophils at the site of infection release secondary 
granules which contain lactoferrin. Lactoferrin has a higher affinity for iron 
compared to other iron binding proteins in the acidic environment characteristic 
of sites of infection, and can contribute to local hyperferremia (Baker and Baker, 
2012). Another mechanism of iron sequestration is the secretion of lipocalin-2, 
also known as siderocalin or neutrophil gelatinase-associated protein (NGAP), 
by neutrophils, macrophages and other cell types in response to the 
inflammation. Lipocalin-2 can bind directly to certain siderophores, like 
enterobactin (Bachman et al., 2009; Smith and Wilks, 2012). Also, phagocytes 
mobilised at infection sites are believed to limit iron availability by 
overexpressing the NRAMP1 intracellular iron transporter. NRAMP1 is 
responsible for a reduction in the amount of divalent ions in the endosomes, 
which can have implications for the intracellular survival of pathogens (Jabado 
et al., 2000; Vidal et al., 1995).  
Pathogens seem to have evolved a number of strategies to overcome host iron-
sequestering defences. The mechanisms of iron acquisition depend on the 
pathogen niche (for example mucosal surfaces, blood stream or cerebrospinal 
fluid - CSF), localisation (intra- or extracellular)and preferred iron source (for 
example haemoglobin, transferrin, lactoferrin, haem). Pathogens modulate the 
expression of proteins involved in iron acquisition according to the availability 
and the source of iron. This review will cover iron acquisition strategies of gram 
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negative bacteria, with the focus being on the neisserial iron acquisition system 
(summarised in Figure 1.11). 
1.2.6.1 Siderophores 
Siderophores are low molecular weight molecules secreted by Gram-positive 
and Gram-negative bacteria to chelate free iron from precipitates or host iron-
binding proteins in the extracellular milieu (Krewulak and Vogel, 2008). 
Although very diverse in structure, they can be divided into three groups based 
on the functional groups that are involved in iron coordination: 
hydroxycarboxylate, catecholate or hydroxymate (Boukhalfa and Crumbliss, 
2002). Siderophores can bind iron tightly, with a dissociation constant that 
exceeds 10-50 M (Cassat and Skaar, 2013). This allows them to compete with 
transferrin. Ferric iron–siderophore complexes bind to designated outer 
membrane receptors, and are transferred inside cells by TonB-dependent 
transporters, which will be discussed in more detail in section 1.2.6.3. Once 
inside the cell, ferric iron is stripped from the siderophore, which is then either 
degraded, or recycled and secreted back into the extracellular environment. 
Although in Neisseria spp. no siderophores were yet identified, it has been 
shown that N. gonorrhoeae is able to bind siderophores produced by other 
pathogenic bacteria (Carson et al., 1999). 
1.2.6.2 Haemophores 
Functions of haemophores are similar to siderophores. However, unlike 
siderophores, haemophores are proteinacious in nature and acquire Fe-haem 
complexes from host haem-transporter proteins. Hemophores are either 
secreted, or are loosely associated with the outer membrane. They act by either 
outcompeting the host proteins (like HasA from Serratia mercescens), or by 
inducing conformational changes in the host proteins, resulting in the release of 
haem from the complexes (for example HxuA from H. influenzae). 
Haemophores loaded with haem interact with the appropriate TonB-dependent 
outer membrane receptor and either release haem, which is transferred to the 
cytoplasm, or the haemophores remain associated with the outer membrane 
and function as haem storage proteins (Wandersman and Delepelaire, 2012). 
The best characterised haemophore expressed by Gram-negative bacteria is 
HasA from Serratia marcescens, which has sequence homologs in 
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Pseudomonas aeruginosa and Yersinia pestis (Létoffé et al., 1998; Rossi et al., 
2001). HasA acquires haem from haemoglobin, haemopexin, leghaemoglobin 
and myoglobin (Wandersman and Delepelaire, 2012). Upon haem binding, 
HasA undergoes a conformational change. It has been shown that HasA can 
form dimers by domain swapping. The HasA dimers bind haem with lower 
affinity than the monomers. However, the dimers are not able to bind to HasR, 
indicating that this might be a mechanism of haem storage and sequestration to 
limit availability of this molecule from other, competing microorganisms (Czjzek 
et al., 2007). The structure of the HasA-HasR-Haem complex is shown in Figure 
1.4. 
In many cases, haemophores aid haem acquisition from host binding proteins, 
but are not essential for the function of outer membrane receptors. In the 
neisserial HpuAB bipartial transporter, both components of the haemoglobin-
haptoglobin receptor are indispensable for the extraction of haem from the host 
haem-complexes. HpuA is a lipoprotein anchored in the outer membrane, like 
many bacterial haemophores, however, when expressed alone, HpuA is unable 
to bind either haemoglobin or haemoglobin-haptoglobin complexes. The outer-
membrane receptor HpuB, when expressed alone, showed detectable binding 
of the Hb and Hb-Hp complexes, but this phenotype was unable to utilise 
haemin from the bound complexes. This indicates that HpuA does not function 
as a haemophore per se, but is an essential component for substrate 
recognition and transport across the outer membrane (Rohde and Dyer, 2004). 
No other haemophore proteins have been identified in Neisseria spp. to date. 
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Figure 1.4 Representation of structures of haem receptor HasAR proteins of 
Serratia marcescens.  
A. Ribbon representation of the structure of apo-HasA in an open conformation (PDB 
file: 1YBJ) B. Structure of holo-HasA (PDB file: 1B2V). The haem molecule is shown 
in purple, as a space-filling representation. Residues involved in haem binding (haem-
32 and Tyr-75) are represented as yellow sticks. The loop containing His-32 closes on 
haem upon its binding. C. Structure of HasR, a TonB dependent haem transporter, in 
complex with haem and HasA (PDB file 3CSL). HasR forms a 22-β-strand barrel 
structure (shown in green) with the plug domain occluding the pore of the receptor 
(represented in red) – a structure typical for TonB-dependent receptors. Binding of 
holo-HasA to HasR triggers a conformation change, with the protein returning to its 
open conformation, which allows the release of haem. D. HasR residues within 5 Å of 
the bound haem molecule are shown in stick representation. His-189 is a residue in the 
loop of the plug domain, whereas His-603 is a highly conserved residue in many of the 
bacterial haem receptors (as shown in Fig. 1.8). Images were generated and rendered in 
Pymol. 
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1.2.6.3 TonB-dependent transporters (TBDTs) 
The outer membrane of Gram-negative bacteria constitutes an impermeable 
barrier for siderophores, haem and iron complexes. Only free iron can utilise the 
outer membrane porins to cross this barrier. However, this transport system is 
extremely inefficient due to the low levels of iron in the extracellular milieu. 
Bacteria overcome this hurdle by expressing outer membrane receptors, which 
either directly transfer siderophores and haem across the membrane into 
periplasm, or are involved in the extraction of iron or haem from host transport 
proteins or from their own haemophores. The energy for transport is provided 
from the proton motive force of the inner membrane by the TonB/ExbB/ExbD 
complex. The TonB-dependent transporters can either bind directly to the 
ligand, extract iron or haem and transport it across the membrane (single 
component TBDTs) or, in addition to the membrane receptor, utilise another 
component in the form of lipoproteins in iron acquisition (bipartite TBDTs). FetA 
is an example of single component neisserial receptor for xenosiderophores.   
Structure of TBDTs 
In 2010 Noinaj and coworkers published a comprehensive structural analysis of 
the twelve solved TBDT structures available at that time (Noinaj et al., 2010). 
Recently reported structures of transferrin binding proteins A and B with bound 
transferrin were analysed by negative electron stain microscopy. The analysis 
of tripartite structure consisting of TbpA, TbpB and human holo-transferrin 
greatly enhanced the understanding of structure and function of the iron outer 
membrane transporters in Gram-negative bacteria (Calmettes et al., 2012; 
Noinaj et al., 2012b). 
All TBDT structures that have been solved share similar topology despite the 
limited sequence homology and different ligands. All these proteins consist of a 
22-stranded β-strand barrel with an enclosed N-terminal plug-domain that 
occludes the pore to prevent the entry of substances harmful to the bacteria. In 
some structures, the plug domain is buried inside the β-barrel structure, 
whereas in others it protrudes into the periplasm. The N-terminus of the plug 
domain consists of a TonB box, which is a consensus sequence responsible for 
interaction with the TonB-ExbB-ExbD complex, and transduction of energy from 
the inner membrane. Plug domains are highly solvated indicating possible 
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conformational changes that allow the transport of ligands through the pore. 
Plug domain loops can protrude into the extracellular space and be involved in 
the binding of ferric or haem-complexes (Noinaj et al., 2010).  
The transmembrane β-sheets are connected to the periplasmic site by 10 short 
loops consisting of 2 to 10 residues. The extracellular receptor site consists of 
11 long loops, labelled from L1 to L11, with sizes ranging from 2 to 37 residues. 
These extracellular loops are not only responsible for interacting with the ligand, 
but they can also form flaps occluding the light of the pore (Krewulak and Vogel, 
2008; Noinaj et al., 2010). Extracellular loops show highest sequence diversity 
even between close homologs. This will be as a result of evolutionary 
divergence in response to different ligands and antigenic variation.  
Iron transporters – TbpAB and LbpAB 
To utilise iron from the host proteins lactoferrin and transferrin, Neisseria spp. 
uses bipartite TonB-dependent transporters: LbpAB and TbpAB respectively. 
The transmembrane proteins LbpA and TbpA show a typical topology for TonB-
dependent transporters. They share 43% sequence identity, with the highest 
level of diversity found in the external loops. Some unique features were 
identified in the TpbA structure, including the presence of a helix finger in loop 3 
that is involved in iron extraction, extremely long loops that are involved in 
transferrin binding (loop 4 and 5), and a long loop in the plug domain that 
contains the conserved iron binding motif EIEYE. Additionally, loop 8 appears to 
be necessary for iron internalisation from transferrin (Noinaj et al., 2012b) (Fig. 
1.5. B).  
Despite different ligands and low sequence identity (below 30%), the 
lipoproteins LbpB and TbpB do have similar structures (Fig 1.5 A.). The 
structures of these proteins are characterised by the presence of two domains 
known as lobes (N- and C-terminal lobe). Each lobe consists of a barrel formed 
by 8 β-strands, which is flanked by a handle domain rich in β-strands. 
Additionally, the N-terminal lobes contain an α-helical fragment. Both lobes are 
connected by a linker region, which is longer than the LbpB protein. The main 
feature that distinguishes between LbpB and TbpB is the presence of a 
negatively charged region in the C-lobe of LbpB, which is believed to be 
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involved in protection from the cationic antimicrobial peptide lactoferricin 
(Morgenthau et al., 2012). Also, TbpB remains attached to the outer membrane 
via a C-terminal anchor peptide, which is required for interaction with TbpA 
(Yang et al., 2011). In contrast LpbB is subjected to cleavage by the NalP 
membrane protease, and can be released into the extracellular environment. 
One hypothesis states that LbpB function can be modulated via NalP activity. In 
the blood, where NalP is overexpressed, more LbpB is released in response to 
a more hostile environment, whereas on mucosal surfaces, more LbpB remains 
surface associated due to the limited activity of NalP, and is involved in 
lactoferrin binding (Morgenthau et al., 2014).  
 
Figure 1.5 Crystal structures of TbpB and TbpA in complex with human 
transferrin.  
A. A cartoon representation of TbpB in complex with holo-human transferrin with iron 
depicted as a red sphere. TbpB binds iron-loaded human transferrin and stabilises  its 
closed conformation. B. A cartoon representation of TbpA in complex with human apo-
transferrin. TbpB is a typical TonB-dependent transporter consisting of 22 anti-parallel 
β-strands that form a pore in the outer membrane (green) with a plug domain that 
occludes the light of the channel (red). TbpA consists of an L3 alpha-helix finger, which 
is involved in iron release from transferrin. Images were generated using Pymol using 
with PDB files: 3VE1 and 3V8X. 
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Neither lipoprotein is essential for the survival of bacteria when functional outer 
membrane receptors are present, but their presence increases the efficiency of 
iron acquisition. TbpB shows a preference for the iron-loaded forms of 
transferrin, whereas TbpA binds both forms, apo- and holo-Tf, with similar 
affinity. It has been speculated that surface exposure of the lipoprotein through 
the anchor peptide, and preference for the holo-form of Tf, allows more efficient 
and unrestricted capturing of the iron-loaded ligand in the environment with 
lower iron availability (Silva et al., 2012). Other proposed functions of the 
lipoproteins include participation in iron extraction after binding to the outer 
membrane receptor, and facilitating the dissociation of the ligand from the 
membrane receptor after iron is removed (Noinaj et al., 2012a).  
Mechanism of iron utilisation from transferrin by TbpAB transporter 
Analysis of recently solved crystal structures of transferrin binding proteins has 
allowed an increased understanding of the iron extraction process from the host 
proteins, and transport of the iron through the outer membrane receptor. The 
TbpB N-lobe has been shown to be a binding site for the C-lobe of holo-
transferrin. The interactions between these two proteins cause conformational 
changes in the transferrin, resulting in the stabilisation of the iron-loaded form of 
the protein. The binding promotes the conformational changes in the anchor 
domain of TbpB, and allows a closer interaction with TbpA.  
It is not exactly clear how the transferrin is passed from TbpB to TbpA, and 
whether it involves the simultaneous binding of transferrin by those two 
proteins. Two studies have produced contradictory models. According to Noinaj 
and colleagues (Noinaj et al., 2012a) the transferrin has non-overlapping 
binding sites recognised by TbpA and TbpB, allowing formation of the transient 
tri-partite complex (Fig. 1.7), whereas another study claims that the binding 
sites overlap, preventing simultaneous binding by those two proteins (Silva et 
al., 2012). No direct interaction between TpbA and TpbB has been observed 
when TbpB is in the apo-form. Upon binding to TbpA, transferrin changes its 
conformation to an open state, which allows iron extraction. This process is 
probably dependent on the energy derived from TonB. It has been shown that a 
single lysine residue in the helix finger of loop 3 plays an important role in this 
process. Furthermore, transport of iron through the TbpA pore is coordinated by 
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changes in the entire plug domain. Transferrin dissociates from TpbA, aided by 
TpbB, which shows a much lower affinity to apo-transferrin (Noinaj et al., 
2012b). A schematic representation of the iron acquisition process from human 
transferrin by the neisserial TbpAB transport system is shown in Figure 1.6. 
 
 
Figure 1.6 Model of iron transport by TbpAB receptor.  
1. Holo-human transferrin (hTF) is captured by TbpB, with the docking peptide in the 
fully extended conformation. 2. Upon binding of hTf, the docking peptide undergoes a 
confirmation change bringing hTF closer to the TbpA. 3. The two models of transfer of 
hTF from TbpB to TbpA: 3a. Interaction of TbpA with the anchor peptide of TbpB 
results in the release of hTF that can be readily captured by TbpA. Simultaneous 
binding of hTF by TbpA and TbpB is prevented by steric and allosteric factors. (Silva et 
al., 2012). 3b. TbpB transfers hTF to TbpA with the formation of a transient tri-partite 
complex, as proposed by Noinaj et al. (Noinaj et al., 2012a). In both models, energy 
from the TonB system is required for the dissociation of TbpB from hTf. 4. Iron is 
released from hTF and transported through the pore of TbpA in the periplasm, where it 
is captured by FbpA docked to the periplasmic loop of TbpA. 5. Apo-hTf and holo-
FbpA dissociate from TbpA. Figure based on (Noinaj et al., 2012a; Silva et al., 2012) 
  
50 
 
 
Figure 1.7 Model of the structure of the tri-partite complex of TbpA and TbpB 
with human transferrin.  
A. A view from the site of the complex, showing simultaneous binding of the transferrin 
C-lobe by TbpA and TbpB. B. An overhead view from the top of the tri-partite 
complex. The model is based on the structures PDB ID: 3V8X and 3VE1, and is 
proposed by Noinaj and colleagues and supported by the data from the negative stain 
electron microscopy (Noinaj et al., 2012b). Both panels were drawn and rendered in 
Pymol. The cartoon representation with the transparent surface shows TbpA coloured in 
green, with the L3-loop finger in magenta, TbpB is shown in cyan, the transferrin C-
lobe in purple, and the N-lobe in pink. A ferric ion is shown as a red sphere. 
 
Unlike HpuAB, transferrin and lactoferrin transporters in Neisseria spp. show 
species selectivity with regards to the binding ligand. This is because the region 
of transferrin that interacts with the TbpAB receptor is highly variable in other 
species (Noinaj et al., 2012a). 
The Role of the TonB-complex in iron transport 
Transport through the outer membrane via TonB-dependent transporters 
requires energy. As the periplasm is devoid of ATP, and the outer membrane 
has no electrochemical potential to generate energy, TonB-dependent 
transporters utilise proton motive force from the inner membrane delivered by 
the TonB/ExbB/ExD complex. The TonB protein is anchored in the inner 
membrane via its N-terminal domain. It contains a proline-rich central domain 
which spans the periplasm. Its C-terminal domain is responsible for the 
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interaction with the outer membrane receptor by its TonB-box. ExbB and ExbD 
are localised in the inner membrane and support TonB. The ExbB protein has 
three transmembrane helical domains that interact with TonB. ExbD in turn 
stabilises the ExbB structure. ExbB and ExbD harvest energy from the 
transmembrane electrochemical potential and transfer it to TonB. Upon ligand 
binding, the outer membrane receptor undergoes a conformational change, 
allowing the interaction of TonB with the N-terminal TonB-box. The energy 
delivered by TonB causes unfolding, or pulling, of the plug domain of the 
membrane receptor, facilitating transport of the ligand by an unknown 
mechanism. In many cases, energy is also needed for dissociation of the apo-
haemophore or apo-siderophore from the receptor. The loss of either TonB or 
the proton motive force in the transferrin receptor causes irreversible binding of 
the transferrin, and greatly impairs dissociation of haemoglobin from the HpuAB 
receptor (Rohde and Dyer, 2004). 
TonB is also believed to interact with periplasmic binding proteins, which are 
located at the periplasmic site of the beta-barrel and are involved in periplasmic 
passage to the inner membrane permease. The hypothesis is based on the 
observations that the E. coli siderophore binding protein FhuD can form 
complexes with TonB (Carter et al., 2006), as well as BtuF, the periplasmic 
binding protein for vitamin B12 (James et al., 2009). 
Haem transporters in Neisseria – HmbR and HpuAB 
In Neisseria spp., two haemoglobin receptors have been previously 
characterised in some detail. HmbR is a single component TonB-dependent 
transporter which is involved in haem acquisition from haemoglobin. Expression 
of this gene is associated with the invasive phenotype of Neisseria meningitidis, 
emphasising its role in iron acquisition in the blood stream (Harrison et al., 
2009). In gonorrhoeae, hmbR is present usually as a pseudogene, and no 
expression is observed (Stojiljkovic et al., 1996). HpuAB is a bipartite receptor 
for both haemoglobin and haemoglobin-haptoglobin, and is expressed in 
pathogenic and commensal Neisseria spp. Despite low sequence homology 
between HmbR and HpuB (28% identity), and other characterised haem 
transporters, they share a typical structural topology for TonB dependent 
transporters. In addition, loop 7 in most haem/haemoglobin receptors contains 
52 
 
two highly conserved motifs, FRAP and an NPNL box, and a conserved 
histidine residue (Fig. 1.8). This region has been shown to be essential for 
haemoglobin binding and/or extraction of haem from the haemoglobin (Bracken 
et al., 1999; Fusco et al., 2013; Liu et al., 2006). Deleting this region in the 
HmbR receptor did not affect haemoglobin binding to the receptor, but affected 
utilisation of haem from the haemoglobin, whereas growth supported by haem 
as a sole iron source was unaffected. This indicates that the region is important 
for haem extraction from its proteinacious complexes. 
 
hmbR  AAQL-NQAWRVGYDITSGYRVPNASEVYF-TYNHGSGN---------WLPNPNLKAERST 
hpuB  DWRF-TKHLHLLAKYSTGFRAPTSDETWL-LFPHPDFY---------LKANPNLKAEKAK 
hasR  AVRPGVEWLELYTTYGKSWRPPAITETLTNGSAHSSST---------QYPNPFLQPERSR 
hmuR  ---K-CSHVTNRLSYAEGYRAPSLQEMYF-FFNHGAFF---------IYGNPDLKPEKSR 
hemR  SVTP-TDWLMLFGSYAQAFRAPTMGEMYN-DSKHFSMNIMGNTLTNYWVPNPNLKPETNE 
Figure 1.8 Sequence alignment of fragments from five different TonB-dependent 
haem transporters.  
Five haem TBDTs from various Gram-negative bacteria were analysed by Clustal 
Omega and Boxshade server: HAHmbR (Accession Number: NP_274673.1) and HpuB 
(AAC44893.2) from Neisseria meningitidis, HasR from Serratia marcenscens 
(CAE46936.1), HmuR from Porphyromonas gingivalis (YP_004509477.1) and HemR 
from Yersinia enterocolitica (CAA48250.1). The motifs FRAP and NPNL, and the 
conserved histidine residue are highlighted in red. 
 
Unlike other haemoglobin receptors, HmbR also requires an intact plug domain 
for the utilisation of haem from haemoglobin. However, the histidine in position 
500 which is highly conserved between haem binding receptors (Fig. 1.8) was 
not involved in haem transport in HmbR (Perkins-Balding et al., 2003). In 
addition to loop 7, loop 6 was also shown to be involved in haem utilisation from 
haemoglobin, and showed the lowest sequence diversity when comparing 
numerous neisserial isolates (Evans et al., 2010). Haemoglobin binding sites in 
HmbR were identified as loops 2 and 3, which show a high degree of sequence 
polymorphisms. This can explain the fact that HmbR, despite preference for 
human haemoglobin, can also bind haemoglobin from other sources (Evans et 
al., 2010; Perkins-Balding et al., 2003). Similarly to HmbR, HpuB also shows 
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high sequence conservation in loops 6 and 7 with high sequence divergence in 
the loop that is homologous to loop 2 (Harrison et al., 2013). As mentioned 
before, the lipoprotein HpuA is essential for the utilisation of iron from 
haemoglobin and haemoglobin-haptoglobin complexes, and is probably 
responsible for the interactions with haptoglobin. This would explain the 
presence of an additional lipoprotein for the utilisation of haem from the more 
complex Hb-Hp substrate compared to HmbR, which is unable to utilise it 
(Rohde and Dyer, 2004). 
Another TonB-dependent, single outer membrane zinc receptor, ZnuD 
(previously known as TdfJ), might also be involved in haem acquisition (Stork et 
al., 2010). This receptor is able to support haem-dependent growth when 
expressed in the E. coli haem auxotroph strain. ZnuD is similar to other haem 
receptors in that it has the FRAP/NPNL motifs and the conserved histidine 
residues in the loop 7. The zinc binding site is located in loop 2. It is possible 
that this receptor might be involved in the transport of two different substrates 
depending on the circumstances and substrate availability. This is because  its 
expression is regulated by two regulatory proteins: Zur and Fur (Kumar et al., 
2012).  
Siderophore transporter – FetA 
The ferric-xenosiderophore complexes have been shown to interact with FetA, a 
ferric enterobactin transporter (formerly known as FrpB) found in N. 
gonorrhoeae. This indicates that FetA may be involved in hijacking iron from 
exogenous iron complexes (Carson et al., 1999). Other ligands for this receptor 
have been identified, and include salmochelin and dihydroxybenzoylserin 
(DHBS). This indicates broader ligand specificity (Hollander et al., 2011). The 
FetA gene is located upstream to its periplasmic binding protein fetB, which has 
been shown to be indispensable for iron utilisation from siderophores. 
Downstream of the fetB gene is a designated ABC transporter FetCDEF 
(Carson et al., 1999). FetA undergoes phase variation and is subject to iron fur-
mediated regulation. The presence of a 91% identical FetA homolog in N. 
meningitidis suggests that these bacteria can also acquire iron in a similar way 
(Pettersson et al., 1995). 
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1.2.6.4 Other uncharacterised iron transporters in Neisseria 
Bioinformatic analysis of the genomes of Neisseria spp. resulted in the 
identification of several genes that display features typical for the TonB 
dependent transporter family (Tdfs) (Hagen and Cornelissen, 2006; Turner et 
al., 2001). Further analysis of homology based on the consensus sequences 
revealed high homology of one of them, TdfF, to the siderophore receptor FpvA 
from E. coli. Two other genes,TdfG and TdfH, showed high homology to the 
haem TonB-dependent transporter HasR from Serratia marcescens (Turner et 
al., 2001).  
TdfF has been shown to be essential for intracellular iron acquisition by 
Neisseria spp., because a mutant with a defective TdfF protein was unable to 
survive within epithelial cells. The addition of excess free iron restored the 
intracellular survival of the mutant (Hagen and Cornelissen, 2006). Another 
argument that supports TdfF involvement in iron acquisition is the presence of 
the putative periplamic binding protein gene, with high similarity to fetB, 
upstream of the tdfF gene. TdfF expression is believed to be regulated in an 
iron-independent manner, as no studies have reported protein expression in 
conditions with different iron availability (Cornelissen and Hollander, 2011), and 
expression in gonococci was only observed when grown in the presence of 
serum (Hagen and Cornelissen, 2006). The involvement of another regulatory 
protein, MpeR (which belongs to the AraC family of proteins), in the regulation 
of expression is also speculated (Cornelissen and Hollander, 2011). This gene 
is also associated with virulence in Neisseria spp., as the presence of the 
operon associated with this gene is unique to the pathogenic species. 
TdfG and TdfH encode large proteins (>100 kDa) with features typical for TonB 
dependent haem transporters. However, mutants that expressed inactivated 
TdfG or TdfH retained the ability to grow on haem as a sole iron source, leaving 
the question about their function unanswered (Turner et al., 2001).  
1.2.6.5 TonB independent transport across the outer membrane 
Although most iron and iron complexes are transported across the outer 
membrane via TonB-dependent receptors, N. gonorrhoeae can utilise iron from 
some siderophores or haem in a TonB-independent manner. Mutants lacking 
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the expression of tonB and fetA genes were still able to grow in the presence of 
xenosiderophores. This suggests that other structures in the outer membrane 
might be involved in siderophore or haem transport across the outer membrane 
(Strange et al., 2011). One hypothesis mentions a possible role for PilQ in the 
passive transport of haem. PilQ is a component of the TypeIV secretion system 
that is responsible for the secretion of pili subunits across the outer membrane. 
A study performed by Chen et al. demonstrated that PilQ allows the passive 
passage of free haem, and some other compounds, in the periplasm. A 
phenotype with a single point mutation results in the increased leakage of low 
molecular weight compounds through the pore formed by PilQ (Chen et al., 
2004). However, studies performed by Strange at al. showed that TonB-
independent transport of some xenosiderophores is still observed in mutants 
that lack the PilQ and Mtr proteins (protein forming a pore in the efflux pump) 
(Strange et al., 2011). This indicates that some outer membrane porins might 
allow some passive transport through the outer membrane, or that there is an 
additional mechanism of transport which needs to be characterised.  
1.2.6.6 Periplasmic transport of iron 
Following passage through TbpA, free ferric iron is captured by the FbpA 
protein, which is attached to the periplasmic face of TbpA. It has been shown 
that TbpA shows higher affinity for the apo-FbpA than for the holo-FbpA, 
allowing dissociation of the protein after binding of iron. This higher affinity for 
iron seen in FbpA compared to TbpA is important for the unidirectional transport 
of iron from the outer membrane receptor into the periplasm (Siburt et al., 
2009). 
FbpA is also known as a bacterial transferrin due to its structural and functional 
similarities to human transferrin. The ferric iron binding site in FbpA consists of 
four amino acids in a similar conformation as that seen in transferrin, and they 
both require the presence of an exogenous anion for tight iron binding. 
Additional similarities include the presence of a bilobial structure and similar 
mechanisms of ligand binding described as a Venus Fly Trap or Pac-Man 
motion, where two large lobes of the protein close around bound ligand.  
(Parker Siburt et al., 2012).  
56 
 
FbpA is expressed from the fbpABC operon, which also encodes an inner 
membrane permease involved in the transport of iron in the cytoplasm (FbpB), 
and an ATP-binding protein that provides energy for translocation through the 
cytoplasmic membrane (FbpC). This operon was demonstrated to be essential 
for the utilisation of iron from other iron sources, like lactoferrin and some 
bacterial xenosiderophores. Bacteria without an FbpABC transport system were 
unable to survive when iron, in the form of lactoferrin, transferrin or 
siderophores, was used as the only iron source, but the growth was unaffected 
in the presence of haem. This indicates that haem transport across the inner 
membrane utilises an additional transport system yet to be identified (Strange et 
al., 2011).  
1.2.6.7 Haem metabolism in the cytoplasm 
The key component in cytoplasmic haem metabolism in Neisseria is haem 
oxygenase (HO). Mutants of N. meningitidis and N. gonorrhoeae with an 
inactive haem oxygenase gene were unable to grow when haem or haem 
complexes were the sole iron source (Zhu et al., 2000a). Haem oxyganase 
proteins are 95-98% identical in Neisseria spp., with the residues that are 
involved in catalytic function being totally conserved. It also shares 
approximately 20% sequence identity with the human haem oxygase 1 (HO-1), 
with the highest homology in the sites important for HO function. The hemO 
gene is located upstream of the hmbR gene that encodes a haemoglobin 
receptor. Although both genes have their own promoters, which are regulated 
by the presence of an individual fur region, transcriptional coupling of both 
genes has been observed (Zhao et al., 2010). 
Haem oxygenase requires NADPH and O2 for its activity. The end products of 
the reaction are: free reduced iron (Fe2+), biliverdin and CO. Free reduced iron 
in the cytoplasm is then incorporated into different enzymes, or stored in the 
cytoplasm in the form of bacterioferritin. It is not clear how Neisseria spp. 
utilises either biliverdin or CO (Zhu et al., 2000b). 
1.2.6.8 Regulation of the gene expression involved in iron acquisition  
A study by Grifantini identified 233 genes in the neisserial genome that are 
differentially expressed in iron-replete and iron-deplete conditions. Almost half 
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of them were predicted in silico to contain a Fur box in the promoter region. In 
Neisseria spp., the Fur box consists of the consensus region 
nATwATnATwATnATwATn. The binding of the Fur protein to the promoter 
region has been experimentally confirmed for most of these predicted genes 
(Grifantini et al., 2003).  
Fur protein is highly conserved in Neisseria, with a sequence identity of over 
90%. Between different species of Gram-negative bacteria there is quite a high 
sequence diversity; however, they do share some common features. The N-
terminus contains an alpha-helical rich region that is involved in DNA binding, 
whereas the C-terminus is responsible for metal binding through its conserved 
histidine rich region, and forms the dimerization interface (Fillat, 2014).  
The mechanism of Fur-mediated repression of gene expression has been 
widely studied, and it is characteristic for most of the iron receptors in Neisseria 
spp. In iron-replete conditions, binding of iron to Fur monomers triggers a 
conformational change in the proteins, which allows the formation of a dimer. 
An iron-loaded dimer binds to the Fur box in the promoter region and prevents 
binding of RNA polymerase, thus repressing protein expression. In contrast, in 
low iron conditions, Fur is prevalent in its monomeric form, which does not bind 
to DNA, so protein expression is unrestricted (Fig. 1.9.A.) (Escolar et al., 1997). 
Studies by Delany and coworkers identified 83 genes regulated by Fur, of which 
only 44 genes were repressed. Surprisingly, 39 genes were activated, indicating 
a more versatile mechanism of gene regulation by Fur (Delany et al., 2006). In 
the last few years, many studies have demonstrated that Fur-modulated protein 
expression by iron-independent mechanisms also required  the involvement of 
other regulatory proteins and sRNAs (Yu and Genco, 2012).  
Some bacteria are able to adapt the expression of their iron receptors in 
response to the presence of host-iron binding proteins or siderophores via the 
extracytoplasmic sigma factor (ECF). The HasR haemoglobin receptor from 
Serratia marcenscens is involved in signal transduction to the ECF sigma factor 
upon binding of its haemophore HasA. This results in the expression of HasR.  
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Figure 1.9 Regulation of gene expression in Neisseria spp. in response to the 
environmental factors.  
A. Fur-mediated repression of genes involved in iron uptake and transport in iron-
replete conditions. In the presence of iron, Fur forms a dimer which is able to bind to 
the Fur cassette in the promoter region, preventing attachment of the RNA Polymerase, 
and gene expression. In the absence of iron, Fur is present as a monomer which is 
unable to bind to FUR cassette, thus gene expression is unaffected (Figure adapted from 
Yu and and Genco with permission (Yu and Genco, 2012). B. The MisR/S two 
component system regulation of hmbR and hemO as a control mechanism is 
independent of Fur. MisS is a membrane-bound histidine kinase which undergoes auto-
phospharylation in response to environmental signals. The phosphoryl group is then 
transferred to the cytoplasmic gene expression regulator MisR, which is a DNA binding 
protein. MisR has been shown to bind to the promoter regions of hemO and hmbR 
genes, thus increasing their expression levels. Figure based on (Tzeng et al., 2006; Zhao 
et al., 2010). 
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A study by Jordan and Saunders that compares the transcription profiles of 
Nesseria meningitidis when grown on different iron-binding host proteins 
(haemoglobin, transferrin and lactoferrin) revealed differences in the response 
and gene expression. These differences were not limited to the genes involved 
in the iron metabolism. Phenotypes grown on lactoferrin were associated with 
the up-regulation of genes involved in carriage, including genes involved in cell 
adhesion and oxidative stress, which are required for mucosal colonisation. 
Growth on transferrin resulted in the upregulation of the fewest number of 
genes, with the TbpA gene being up-regulated the most. The transcriptome of 
N. meningitidis grown on transferrin is similar to the expression profile of 
bacteria grown in iron-replete conditions. Responses to haemoglobin showed 
the up-regulation of genes that are typical of iron-replete conditions, and genes 
associated with an invasive phenotype and increased resistance to the host 
immune defence in the blood stream. The differential expression of the genes in 
response to different host iron-binding proteins is a mechanism of adaptation to 
different niches (Jordan and Saunders, 2009). It is not clear how bacteria are 
able to recognise changes in the extracellular environment and how the signals 
form the environment are translated into differential gene expression. The 
results of the study suggest that Neisseria may employ an unknown mechanism 
similar to the ECF sigma factor that is employed by iron host protein binding 
protein receptors. 
Neisserial outer membrane receptors and other proteins involved in iron 
metabolism are regulated by iron-dependent fur-mediated mechanisms. Only 
TdfH expression is independent of the iron levels, and ZnuD is activated by iron 
(Cornelissen and Hollander, 2011).  
An additional mechanism for the expression of the Hmbr receptor was 
described that involves the two-component MisR/S system. MisR/S is believed 
to be responsible for sensing of environmental stimuli and the transduction of 
the signal inside the cells. This allows the pathogen to adapt protein expression 
to the changing environment, for example adhesion to the host epithelial cell, 
intracellular survival (Jamet et al., 2009; Tzeng et al., 2006). The hmbR gene is 
located downstream of the hemO gene, and both genes have their own 
promoters and sequences typical for a Fur box, although they seem to be 
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transcriptionally linked. MisR/S is believed to activate expression, as mutants 
that do not express the MisR/S genes showed reduced levels of expressed 
hmbR and hemO genes, even in the iron-depleted conditions (Fig. 1.9.B.). 
Expression was then restored following complementation with MisR/S (Zhao et 
al., 2010). MisR/S regulation seems to be independent of iron regulation, and 
might be an additional mechanism for controlling protein expression to allow 
adaptations to the changing environment. The HpuAB gene was also shown to 
be regulated by MisR/S, unlike the transferrin and lactoferrin receptors, which 
indicates that this regulation might be linked to haemoglobin utilisation.  
 
1.2.6.9  Phase variation as a mechanism of regulating gene expression    
In addition to regulating gene expression in response to environmental stimuli, 
Neisseria spp. modulates expression of many genes by stochastic changes in 
the gene sequence. This mechanism is believed to allow quick adaptation to the 
changing environment and immunogenic pressure before the microorganisms 
are subjected to selective stimuli. The genes subjected to phase variation are 
either in the ON or OFF state, where the protein is either expressed or not; or 
the level of protein expression is modulated by changes in the promoter region 
(Lovett, 2004). Genes undergoing phase variation are characterised by the 
presence of simple sequence repeats (SSR), which are composed of either 
poly(G) or poly(C), or with coding repeats (CR) which are fragments of four or 
more nucleotides. The SSR are prone to errors during DNA replication via 
slipped-strand mispairing. This results in frame-shift mutations, which in turn 
can prevent protein expression. The presence of SSR is also associated with 
translational frame-shifting (Alamro et al., 2014) (Fig. 1.10).  
Three of the outer membrane iron transporters (HmbR, HpuAB and FetA) were 
shown to be subjected to phase variation. HmbR and HpuAB genes contain 
poly(G) regions, and changes in the number of guanidine residues results in 
gene expression being in either an ON or OFF state (Lewis et al., 1999). FetA 
phase variation occurs by targeting the poly(C)-rich region in the promoter 
region, resulting in changes in the protein expression between low and high 
levels (Fig. 1.10) (Carson et al., 2000). TbpA does not undergo phase variation 
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as TbpA expression is necessary for neisserial survival within the host, and 
transferrin is the preferred iron source of the Neisseria spp. No evidence of 
phase variation of LbpAB was observed; however, the gene associated with the 
proteolytic cleavage of LpbA, NalP, undergoes phase variation. Thus, the 
function of LbpA can be modulated and contribute to immune system evasion 
via stochastic regulation of gene expression through NalP. 
 
 
Figure 1.10 Schematic representation of the mechanisms of phase variation in 
Neisseria.  
Changes in the length of simple sequence repeats (SSR) within the gene lead to 
ON/OFF switching of gene expression (for example hmbR and hpuAB, which contain 
poly-G tracts). However if these changes are in the promoter region, the length of the 
SSR determines levels of transcription (For example the fetA promoter, which contains 
poly-C tracts). Insertion or excision of mobile DNA fragments such as IS1106A3 can 
also result in ON/OFF switching by the  introduction of pre-term Stop codons, as shown 
in hpuA (Tauseef et al., 2011) Adapted from Lo et al. with permission (Lo et al., 2009). 
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Phase variation of the outer membrane antigens favouring either OFF or low 
expression status has been reported in persistent carriage was strains, and is a 
result of the constant selective pressure from the host immune system (Alamro 
et al., 2014). Differences in the prevalence of haemoglobin receptors HmbR and 
HpuAB that are in an ON state between carriage and invasive isolates has also 
been observed. The 91% of invasive isolates express either one or both 
haemoglobin receptors, with an overrepresentation of HmbR, in contrast to 71% 
of carriage isolates, which display preferential expression of HpuAB. Expression 
of either receptors or HmbR only seems to facilitate the invasion of Neisseria 
spp., and can have an implication in immune evasion (Tauseef et al., 2011). 
Phase variation is a form of adaptation to the different niches, with different 
availability of iron host proteins. This is because, during carriage, N. 
meningitidis resides in the nasopharynx where haemoglobin is scarce, whereas 
invasive isolates disseminate in the blood stream where levels of haemoglobin 
are higher, especially in later stages of infection. 
 
In summary, Neisseria spp. have the ability to withstand host nutritional 
immunity when requires adaptation to different ecological niches during 
colonisation and invasion of the host. At each stage of neisserial infection the 
availability and source of iron can differ drastically. Therefore, Neisseria spp. 
has  evolved a very sophisticated iron acquisition system which is tightly 
regulated during neisserial pathogenesis. An overview of all characterised up to 
date proteins involved in iron transport in Neisseria spp. is illustrated in Figure 
1.11. 
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Figure 1.11 Overview of iron acquisition system in Neisseria meningitidis.  
Iron in the host is sequestered by the host binding proteins transferrin (Tf) and 
lactoferrin (Lf), or it is bound to xenosiderophores produced by co-colonising bacteria. 
Most of the iron is available as haem complexes with host proteins, specifically 
haemoglobin (Hb), haptoglobin (Hp) and haemopoexin. Iron, in all forms, is transported 
through the outer membrane via TonB-dependent transporters (TBDT).The TBDTs 
either directly bind the ligand and transport iron or haem in the periplasm (single 
component TBDT) or require additional lipoprotein or haemophore for binding of the 
ligand (bipartite TBDT). To the single-component TBDTs belong: HmbR (haemoglobin 
receptor), FetA (siderophore receptor) Tdf transporters (transport of iron, siderophores 
and haem), ZnuD –zinc and haem transporter. The bipartite TBDTs are– HpuAB 
(haemoglobin-haptoglobin receptor), TbpAB – transferrin binding protein, LbpAB – 
lactoferrin binding protein or HpuAB – haemoglobin-haptoglobin binding protein. 
Periplasmic binding proteins (for example FbpA, FetA or an uncharacterised receptor) 
transport Fe, siderophores or haem respectively to the cytoplasmic membrane. Inner 
membrane translocators, specifically permease, which is responsible for both the 
removal iron from haem or siderophores and its translocation into the cytoplasm, and 
ATPase, which provides energy for transport. Iron in the cytoplasm is incorporated into 
the bacterial proteins, or it is stored as bacterioferritin. Haem, after iron removal, is 
metabolised by haem oxygenase to billiverdin and CO. Figure adapted from (Perkins-
Balding et al., 2004) (Kumar et al., 2012) and Sathyamurthy (2011). 
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1.3 Introduction to study 
1.3.1.1 Gly1ORF1 – a potential virulence factor of Neisseria spp. 
A gene encoding Gly1ORF1 protein was discovered as a result of a search for 
potential cytotoxins produced by Neisseria gonorrhoeae (Arvidson et al., 1999). 
In the study by Arvidson et al., an E. coli library containing chromosomal 
fragments of N. gonorrhoeae strain MS11A was screened for clones with 
haemolytic activity, a property that often correlates with toxicity to other cell 
types (Bernheimer, 1988). The study resulted in the selection of one haemolytic 
clone with an insert referred to as gonolysin 1 (Gly1). The insert contained two 
open reading frames (ORF1 and ORF2) which were suggested to be co-
transcribed probably generating a bicistronic transcript as the promoter 
sequence was found only upstream of the gly1ORF1 gene. A ribosomal binding 
site was present upstream of each open reading frame (Fig. 1.12) (Arvidson et 
al., 1999).  
 
Figure 1.12 Schematic representation of the gly1 locus.  
The gly1 locus consists of two open reading frames gly1ORF1 and gly1ORF2 separated 
by a short non-coding sequence. No promoter sequence has been detected between the 
ORFs suggesting the two genes are co-transcribed from the promoter upstream the 
ORF1. 
 
Gly1ORF1 encodes a 140 aa protein with a predicted molecular weight of 17.8 
kDa and pI of 9.57. The identified N-terminal signal peptide comprised of 21 
amino acids is processed by the neisserial and E. coli signal peptide membrane 
proteases, resulting in the release of mature Gly1ORF1 product with the 
molecular weight of 15.6 kDa. Gly1ORF1 was predicted to have periplasmic 
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localisation with no obvious motifs indicating its insertion in the outer 
membrane. This was experimentally confirmed, with the data showing that 
Gly1ORF1 is present in the outer membrane of N. gonorrhoeae and E. coli 
constructs as well as in the filtered culture supernatant (Arvidson et al., 1999). 
Initial structural studies indicate that Gly1ORF1 forms dimers in the solution 
(Arvidson et al., 2003). 
 
 
Figure 1.13 Genomic localisation of the gly1ORF1 gene. 
A snapshot of the region of the N. meningitidis MC58 genome (NCBI Reference 
Sequence: NC_003112.2) containing gly1ORF1 gene (NMB0776), which is in close 
proximity to other genes predicted to be involved in haem biosynthesis. Gly1ORF2 
(hemD) is located directly downstream gly1ORF1 and encodes a protein with high 
sequence homology to E. coli uroporphyrinogen III synthase, which is a key enzyme in 
haem biosynthesis. Gly1ORF1. The hemX gene (NMB0778) encodes uroporphyrin-III 
C-methyltransferase, whereas hemE encodes uroporphyrinogen decarboxylase.  
 
 
Gly1ORF2 encodes a slightly acidic protein which is 247 aa long with a 
predicted molecular weight of 31.8 kDa and a pI of 6.25. The region between 
amino acids 86-187 has homology to the hemD gene of E. coli and 
Psuedomonas aeruginosa (27% and 36% identity respectively) encoding the 
enzyme uroporhirynogen III synthase that catalyses synthesis of 
uroporphyrinogen III from hydroxymethylbilane. Uroporphirynogen III is a 
precursor of the components of haem groups that are essential for synthesis of 
bacterial cytochromes and catalases (Granick and Beale, 1978). The genes 
gly1ORF1 and ORF2 were suggested to be co-transcribed (Arvidson et al., 
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1999) (Fig. 1.13). This prompted speculations that Gly1ORF1 is also involved in 
haem metabolism. 
Analysis of the distribution of gly1 in Neisseriae by High Stringency Southern 
Blotting showed that the locus was present in three clinically most important 
species: Neisseria meningitidis, N. gonorrhoeae and N. lactamica (Arvidson et 
al., 1999). Meadows analysed the distribution of gly1ORF1 within a number of 
carriage and invasive strains of N. meningitidis and N. lactamica and 
demonstrated that the gene is widespread in those species irrespectively of 
their invasiveness. The gly1 gene is also conserved in N. meningitidis with over 
90% identity (Meadows, 2004)  
The studies on a gly1ORF1 null mutant of N. gonorrhoeae showed that the 
product of this gene is not essential for the survival of N. gonorrhoeae in 
laboratory conditions. The absence of the Gly1ORF1 gene had no effect on the 
adherence to and invasion of three epithelial cell lines by N. gonorrhoeae, and 
only slightly decreased intracellular survival. However, the gly1 null mutant 
showed increased toxicity to human fallopian tube tissue causing much more 
damage than the wild type strain. Complementation with recombinant 
Gly1ORF1 resulted in a phenotype similar to that of the wild type (Arvidson et 
al., 1999). This prompted a suggestion that Gly1ORF1 could be responsible for 
modulation of cytotoxicity in N. gonorrhoeae.  
Despite the fact that Neisseria spp. are normally non-heamolytic in vivo, the 
overexpression of gly1ORF1 product resulted in the lysis of red blood cells on 
sheep or horse blood agar (Arvidson et al., 1999). The haemolysis could be a 
result of the disturbance of the membrane integrity and subsequent leakage of 
some host proteins, i.e. lipases and proteases. The interaction of recombinant 
Gly1ORF1 with erythrocytes was also demonstrated by FACS analysis of 
RBC’s incubated with fluorescently labelled recombinant Gly1ORF1 (B. Chen, 
M.Sc. Thesis, University of Sheffield) and by light microscopy showing that red 
blood cells incubated with Gly1ORF1 formed aggregates and drastically 
changed their typical morphology from a discoid to an irregular shape with lots 
of protrusion and blebs (Sathyamurthy, 2011). 
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Furthermore, the screening of a human cDNA library with Gly1ORF1 in a yeast 
two-hybrid system revealed that Gly1ORF1 interacts with erythrocyte 
membrane protein 4.2 (EBP42), a major component of the RBC cytoskeleton 
(Meadows, 2004)). The interaction of Gly1ORF1 with EPB4.2 was further 
confirmed by Sathyamurthy by fluorescent microscopy. He demonstrated that 
fluorescently labelled Gly1ORF1 was binding to mammalian cells expressing 
recombinant EPB4.2 as opposed to cells containing an empty expression vector 
(Sathyamurthy, 2011). 
The ability of Gly1ORF1 to interact with RBCs, together with the genetic 
localisation with genes involved in haem metabolism, pointed towards a 
possible role of Gly1ORF1 in haem acquisition. Following this lead, 
Sathyamurthy investigated the ability of Gly1ORF1 to bind haem. The results 
confirmed that Gly1ORF1 was indeed selectively sequestered from the solution 
and was binding to haemin-agarose beads. Also, when incubated with free 
haemin in solution Gly1ORF1 caused a spectrophotometric shift in the 
maximum absorbance wavelength of haem (Sathyamurthy, 2011). 
In order to study Gly1ORF1’s role in iron acquisition in vivo, a Gly1ORF1 
isogenic mutant, N. meningitidis MC58, was generated. The growth rates of the 
wild-type (WT) and Gly1ORF1-null- mutant MC58 were measured in chemically 
defined minimal liquid media containing FeSO4, haemin and haemoglobin as 
sole iron sources. The results showed that the Gly1ORF1 knock-out mutant is 
unable to grow in media with haem or haemoglobin as the sole iron source, 
whereas no difference in the growth rate of the WT and Gly1ORF1 knock-out 
was observed in the presence of FeSO4. The growth of the ΔGly1ORF1 MC58 
in haem- and haemoglobin-containing media was partially restored after 
complementation with recombinant Gly1ORF1. This indicates that Gly1ORF1 is 
involved in the acquisition of iron from haem or haemoglobin. The findings were 
further confirmed using a disc-diffusion growth assay, which also demonstrated 
limited growth of the Gly1ORF1 knock-out with haem and haemoglobin as the 
only iron source (Sathyamurthy, 2011).  
Although the role of Gly1ORF1 in haem acquisition seems to be undisputable, 
the significance of this protein in neisserial pathogenesis is unclear. As 
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previously mentioned, the protein does not seem to be necessary for neisserial 
invasion and adherence ((Arvidson et al., 1999). Also, it does not affect the 
intracellular survival of meningococci (Sathyamurthy, 2011). Unlike other 
proteins involved in iron acquisition, the expression of the protein is not 
regulated by iron levels in the Fur-dependent manner (Grifantini et al., 2003). 
Gly1ORF1 upregulation is mentioned only in the study by Deghmane and 
colleagues which investigated the changes of protein expression upon contact 
with epithelial cells (Deghmane et al., 2003).  
However, the fact that Gly1ORF1 is involved in iron acquisition and that the 
gly1ORF1 gene is present in all tested invasive isolates and the majority of 
commensal isolates (Meadows, 2004) indicates that it might be an important 
virulence factor and needs further characterisation. 
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1.4 Project aims and hypothesis 
 
Following hypotheses were proposed and explored in this study: 
1. Gly1ORF1 is implicated in the haem acquisition in Neisseria through the 
interaction with host proteins and neisserial iron transporters. 
2. Gly1ORF1 is able to elicit protective bactericidal response. 
3. The newly identified Gly1ORF1 homologs protein family are a novel 
group of bacterial virulence factors with similar structure and functions. 
 
The aims of the project: 
1. To solve the crystal structure of Gly1ORF1 and identify the haem binding 
site. 
2. To study Gly1ORF1 interaction with haem. 
3. To further investigate Gly1ORF1 interaction with the red blood cell 
protein EPB4.2. 
4. To investigate the interaction of Gly1ORF1 with neisserial proteins 
involved in iron acquisition. 
5. To explore the Gly1ORF1 immunogenic properties and ability to elicit 
protective bactericidal response. 
6. To characterise Gly1ORF1 homologs’ and paralogs’ structure and 
function. 
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CHAPTER 2 CHARACTERISATION AND 
CRYSTALLISATION OF GLY1ORF1 
VARIANTS 
2.1 Introduction 
Although the gly1ORF1 gene is highly conserved in Neisseria spp. and present 
in most of sequenced clinical isolates, the role of the protein in neisserial 
pathogenesis is not clear. Recent advances in the characterisation of the 
protein pointed towards the role of the protein in iron acquisition. As described 
in the introduction to the study, Gly1ORF1 has been shown to interact with red 
blood cells specifically targeting its major cytoskeleton protein EPB4.2 and bind 
haem.  
The crystal structure of recombinant Gly1ORF1 of N. gonorrhoeae strain MS11 
has been solved by Dennis Arvidson (Michigan State University, unpublished). 
The quaternary structure revealed the presence of a groove at the dimer 
interface which was suggested as a haem binding site according to molecular 
docking analysis performed by Prof. Jon Sayers. Although the groove seems to 
be a potential haem-binding site, several mutations introduced in this region by 
Sathyamurthy (Sathyamurthy, 2011) did not alter haemin binding in vitro as 
monitored spectrophotometrically. Also, no difference in the stoichiometry of 
binding was observed, as all mutated proteins demonstrated a 2:1 protein to 
haemin ratio. The results might indicate that the groove is not a binding site or 
the mutation did not cause sufficient steric hindrance to prevent haem binding.  
This chapter describes studies on several new mutant versions of Gly1ORF1 of 
N. meningitidis MC58 that includes investigating binding of the haem and ability 
to oligomerise, as well as measuring haem binding affinity. The main aim of this 
chapter was to identify the haem binding site of Gly1ORF1 and includes 
attempts to crystallise Gly1ORF1 in the presence and absence of haemin. 
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2.2 Results and Discussion 
2.2.1 Site Directed mutagenesis using the phosphorothioate approach 
The wild type gly1ORF1 gene, cloned into M13mp18 phage DNA, was 
subjected to site directed mutagenesis. This resulted in the creation of 7 single 
amino acid mutant genes, as described in the Materials and Methods Section 
7.4.1. The aim of the mutagenesis described in this chapter was to identify the 
haem binding site of Gly1ORF1. Two possible binding sites were investigated: a 
groove at the dimer interface and the site between two β-sheets of a Gly1ORF1 
monomer. Mutations of Glycine-47 to Arginine and Arginine-48 to Glycine were 
predicted to cause electrostatic and steric changes preventing formation of a 
dimer and no haem binding should be observed if the interface is a putative 
binding site (Fig. 2.1). The assumption that the haem binding site might be 
located between two β-sheets of a Gly1ORF1 monomer was based on the 
multiple sequence alignment of Gly1ORF1 homologs, which is described in 
Chapter 6 (Fig. 6.4 and Fig 6.5). The majority of the conserved residues 
(Phenylalanine-4, Lysine-12, Tyrosine-26, Phenylalanine-28, Glutamic Acid-35, 
Aspargine-67, and Tyrosine-72) are located in this position. Therefore, those 
residues were subjected to mutagenesis. Methionine-63 was selected due to its 
hydrophobic character and localisation (Fig. 2.2).  
 
 
Figure 2.1 Gly1ORF1 
residues at the 
predicted dimer’s 
interface subjected to 
site directed 
mutagenesis. 
Cartoon representation 
of the unpublished 
Gly1ORF1 structure of 
N. gonorrhoeae strain 
MS11 with the residues 
subjected to mutagenesis 
(Arginine-48 in magenta and Glycine-47 in yellow) shown as sticks. The image is 
rendered using Pymol. 
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Figure 2.2 Residues subjected to site directed mutagenesis localised between two β-
sheets of the Gly1ORF1 monomer. 
Cartoon representation of the unpublished Gly1ORF1 structure of N. gonorrhoeae strain 
MS11 with the residues subjected to mutagenesis shown as sticks. Mutations were 
introduced using the phosphoraothioate and PCR based mothods described in the text. 
The image was rendered using Pymol. 
 
Single-stranded circular phage DNA containing the gly1ORF1 gene was 
annealed with oligonucleotides designed to introduce the required mutation. A 
polymerisation reaction with the addition of dCTPαS resulted in the formation of 
three circular forms of DNA: double stranded DNA (RFIV), with one wild type 
strand and one mutated strand, nicked double stranded DNA (RF II), and 
single-stranded DNA (Fig 2.4, Lane 1). Treatment with the T5 endonuclease 
targeted only the nicked and single stranded DNA, leaving the completely 
polymerised dsDNA intact (Fig. 2.4, Lane 2). Digestion using the restriction 
enzyme AvaI created a nick in a wild-type strand only as the mutated strand is 
resistant to AvaI activity due to the presence of phosphorothioate in the 
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cleavage position (Sayers et al., 1992) (Fig. 2.4, Lane 3). The nicked wild type 
strand was removed by treating it with the T7 gene 6 exonuclease (Fig. 2.4, 
Lane 4). This left the mutated strand intact. After polymerisation with normal 
dNTPs, double-stranded DNA with the appropriate mutations on both strands 
was obtained (Fig. 2.4, Lane 5), and the mutated gly1ORF1 gene was sub-
cloned into the pJONEX4 C-histidine tagged expression vector, using the EcoRI 
and BamHI restriction enzymes. Sequencing results of the double-stranded 
M13mp18 phage DNA were obtained for all mutagenesis reactions, and 
confirmed the successful mutagenesis for all the mutants. Fragments were 
successfully sub-cloned into the pJONEX4 C-histidine tagged vector, and 
transformed into CaCl2-competent M72 E. coli cells. The schematic 
representation of the site directed mutagenesis steps is shown in Figure 2.3.  
 
Figure 2.3 Schematic representation of the site directed mutagenesis using the 
phosphorothioate approach.  
RFIV – circular double-stranded DNA; RFII – nicked circular double-stranded DNA; 
ssDNA – single stranded DNA. Arrows indicate an introduced mutation. Figure adapted 
from Sayers et. al., 1992 (Sayers et al., 1992), with permission. 
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Figure 2.4 Successful mutation of R48 to G in Gly1ORF1 using phosphorothioate 
approach.  
Site directed mutagenesis was performed according to the method illustrated in Fig. 2.3. 
Aliquots of the reaction at step A (Lane 1), step B (Lane 2), step C (Lane 3), step D 
(Lane 4) step E (Lane 5) and reference lanes with double-stranded (Lane 6) and single-
stranded M13mp18Gly1 DNA (Lane 7) were applied to 1% agarose gel containing 
DTT next to DNA marker (Lane M) with sizes shown in kilobases. Negative control 
(Lane 8) contains a polymerisation sample without the addition of an oligonucleotide 
after treatment with T5 FEN endonuclease. 
 
2.2.2 Small scale expression experiments of the genes encoding mutated 
Gly1ORF1. 
Small scale heat induction of all Gly1ORF1 mutants was performed according 
to the protocol described in Materials and Methods Section 7.5.1. The heat 
induction was successful, with variable levels of relative expression (Fig. 2.5).  
 
Figure 2.5 SDS-PAGE 
analysis of small scale 
expression of the Gly1 C-
histidine tagged mutants by 
heat induction in M72 E. coli 
cells (Panel A) and 
supernatant (Panel B).  
Samples before induction 
(Lane U) and after heat 
induction (Lane I) were 
separated on 13% SDS-PAGE 
gel and stained with Coomasie. 
Arrows indicate bands 
corresponding to Gly1ORF1 C-
histidine tagged mutants.  
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Gly1ORF1 G47R and R48G expression was not visible on the SDS-PAGE gel 
(data not shown). However, western blot with anti-Gly1ORF1 rabbit polyclonal 
antibodies confirmed the presence of the protein in culture supernatants of 
tested clones (Fig. 2.6). The Gly1ORF1 protein in the cell pellet was mostly 
insoluble (data not shown). However, attempts to refold this could have resulted 
in purifying a protein that still contained a signal peptide. It was decided that 
only the secreted protein would be purified. Thus, a large-scale purification was 
performed using the culture supernatants from induced cells. 
 
 
Figure 2.6 Western blot analysis of small scale heat induction.of Gly1ORF mutants 
G47R and R48G showing presence of the protein in the culture supernatants.  
Three clones for each mutant were tested in parallel (Lanes 1-3 and 4-6)). Proteins 
were detected using rabbit anti-Gly1ORF1 polyclonal antibodies. 
 
2.2.3 PCR based Site Directed Mutagenesis 
Four more mutants were produced using a PCR based method (see Materials 
and Methods Section 7.4.2), where the whole plasmid (pJONEX4-Gly1ORF1 C-
histidine tagged) was amplified using mutagenic primers. This resulted in 
multiple copies of the linear mutated DNA (Fig. 2.7, Fig. 2.8, Panel A). The 
linearised, mutated plasmid was treated with T4 polynucleotide kinase to 
phosphorylate the 5 ends, and the template DNA was removed using DpnI, a 
restriction enzyme which cleaves only methylated DNA. Constructs were then 
circularised by ligation with T4 ligase (Fig. 2.6, Panel B.), and transformed into 
CaCl2 - competent M72 E.coli cells. The schematic representation of the 
principle of this method is shown in Figure 2.7. 
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Figure 2.7 Schematic representation of the single step PCR based method.  
A. Principle of primer design for different mutations. B. Steps of the mutagenesis. Grey 
circles illustrate template DNA plasmid. Black and red lines and circles are amplified 
mutagenized DNA in linear and circularised form respectively. See further explanation 
in the text (Picture adapted from the NEB website with permission). 
 
 
Figure 2.8 Agarose gel analysis of the site-directed mutagenesis by a single-step 
PCR method. showing PCR products of the linearised pJONEX4 C-histidine – 
Gly1ORF1 (Panel A) and ligated mutagenized plasmids (Panel B) 
Panel A: Lane M – 1 kb DNA ladder, Lane 1- PCR product of the pJONEX4 C-
histidine tag vector with the Gly1F4A mutant, Lane 2 – Gly1K12A, Lane 3 – Gly1 
M63A, Lane 4 – Gly1dSTOP, Lane 5 – negative control of PCR reaction with no 
template and K12A primers. Panel B: Ligation of the linear mutagenized plasmids. 
Lane 1- 4 – constructs in the same order as in panel A., Lane 5 - negative control: 
construct Gly1 K12A without T4 ligase.  
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After successful transformation (Materials and Methods Section 7.3.5), DNA 
from three colonies for each construct were sequenced to confirm the presence 
of the appropriate mutation. All clones were tested for the ability to produce the 
mutated protein in 5 ml cultures (Fig. 2.9).  
 
Figure 2.9 Detection of mutant Gly1ORF1 proteins production in cell pellets 
(Panel A) and culture supernatants (Panel B) using SDS-PAGE and western blot 
respectively.  
Three clones (Lanes 1-3) of each mutant Gly1ORF1 (F4A, K12A, dSTOP, M63A) 
were heat induced in 5 ml cultures. The Gly1ORF1 mutant proteins in supernatants 
were detected using anti-Gly1ORF1 polyclonal antibodies. The un-induced Gly1ORF1 
C-histidine tag cultures are shown in Lane U. Purified Gly1ORF1 C-histidine tag 
protein (Lane 4) was used as a positive control for western blot. Clones selected for 
large scale induction are marked with red circles. 
 
There was no detectable protein production of the Gly1F4A protein in either cell 
pellets or culture supernatant in any of the three clones when tested by SDS-
PAGE and western blot (Fig. 2.9). This occurred even though the sequencing 
results confirmed the correct sequence and presence of the mutation. It is 
probable that selected Gly1F4A clones contained mutation within the plasmid 
78 
 
DNA sequence that affected successful expression of the gene. Sequencing 
results confirmed the presence of the expected mutation in two of the three 
Gly1K12A clones. The production of the Gly1K12A-1 protein was higher than in 
the other K12A clones (Fig. 2.9, Panel B). Sequencing of the Gly1 dSTOP 
clones showed the correct sequence for two out of the three clones, but the 
clone 1 had a spontaneous mutation (resulting in a valine 19 being replaced by 
methionine), which resulted in a lack of protein production (Fig. 2.9). A frame-
shift mutation was present in the Gly1M63A - clone 1, which explains the lack of 
expression of this construct (Fig 2.9, Panel B) 
In summary, the single step PCR mutagenesis method is a quick and 
uncomplicated method to obtain a desired mutation. However, the KAPA 
Biosystems HiFi Hot Start polymerase, which was used in the PCR, has a low 
proofreading activity, which resulted in many spontaneous mutations. The 
mutations in the insert region were easily detected by sequencing, and incorrect 
clones were discarded. However, it is not common practice to sequence the 
whole cloning vector. Mutations in the vector sequence itself could affect 
expression of an insert or the antibiotic resistance selection genes. For large 
scale protein production, the following clones were selected: Gly1K12A 1, 
Gly1dSTOP 2 and Gly1M63A 1 (Fig. 2.9). 
 
2.2.4 Large scale production of the WT Gly1ORF1 C-histidine tagged 
protein and the Ni-affinity purification of the protein 
The large scale production of the proteins was carried out according to the 
protocol described in the Materials and Methods Section 7.5.2. Levels of 
produced Gly1 C-histidine tagged protein in the 3 litre fermenter differed from 
batch to batch. The induced supernatant, after overnight incubation, showed 
great variability in Gly1ORF1 concentration, and contamination with other 
proteins. In the picture shown below (Fig. 2.10) the Gly1 C-histidine tagged 
protein was readily detected in the supernatant; however the presence of many 
contaminating proteins indicated partial cell lysis.  
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Figure 2.10 Large scale 
protein production of WT 
Gly1ORF1 C-histidine in 3 l 
culture with 4YT media.  
Lane U – sample before 
induction; Lane 3h – sample 3 
hours after induction; Lane 
o/n -– sample after overnight 
incubation. 
 
 
2.2.5 Purification of Gly1ORF1 on Ni-affinity column 
Batch to batch variation was also observed when purifying the Gly1ORF1 C-
histidine tagged protein on a Ni-affinity column (see Materials and Methods 
Section 7.6.1). Some purification attempts resulted in high yields of purified 
protein with little or no protein observed in the flow-through from the column. 
Other purification attempts, however, resulted in only partial binding of the 
protein to the Ni-affinity column, which resulted in very low yields of the protein. 
On other occasions the culture supernatant passed through the Ni-affinity 
column and removed the nickel ions from agarose beads, and no binding was 
observed.  
It was hypothesised that the culture supernatants contained metal scavenging 
proteins or molecules which were removing nickel ions from the Ni-chelate 
resin, thus reducing the capacity of the column. The effect of addition of NiCl2 to 
the culture supernatant on the yields of recovered protein was tested. Adding 
NiCl2 before loading the culture supernatant on the column enhanced binding of 
the Gly1 C-histidine tagged protein to the matrix. After addition of NiCl2 to the 
final concentration of 2.5 mM most of the Gly1ORF1 C-histidine tagged protein 
was bound to the column (Fig. 2.11, Panel A). Increasing NiCl2 concentration up 
to 10 mM did not increase yields of recovered protein, as presumably at this 
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concentration it competes with the immobilized nickel on the column for the 
tagged protein (Fig. 2.11, Panel B). 
 
 
Figure 2.11 The addition of NiCl2 to the culture supernatant aids the recovery rate 
of the Gly1 C-histidine tagged protein from the Ni--affinity column.  
Supernatants containing secreted Gly1 C-histidine tagged protein (Panel. A., Lane L) 
were supplemented with increasing concentrations of NiCl2 and loaded on the 
equilibrated Ni-affinity column. A. Flow-through samples analysed using SDS-PAGE, 
show almost complete binding of the tagged protein to the column at 2.5 mM NiCl2. B. 
The Gly1 C-histidine tagged protein was eluted from the column using 500 mM 
imidazole, and the eluted fractions were analysed by SDS-PAGE.  
 
Gly1ORF1, in the presence of NiCl2, was purified on a larger scale using 1 litre 
of supernatant. Protein samples were dialysed into 25 mM NaOAc, pH 4; 50 
mM NaCl. In low pH conditions Gly1ORF1 remains soluble even at the 
concentration up to 25 mg/ml (Fig. 2.12). 
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Figure 2.12 Purification of the 
C-histidine tagged Gly1ORF1 
protein on a Ni--affinity 
column from the supernatant. 
Lane L – sample before loading 
on to the column, Lane – F, 
Sample after passing through the 
column, Lane W – wash of the 
column with low imidazole 
concentration (25 mM), Lanes 1 
– 6 – eluted fractions. 
 
Adding NiCl2 to the supernatants was also effective for the purification of some 
of the mutant versions of the protein, specifically K12A and Y72F. These were 
purified from the supernatants at high yields (over 10 mg of protein per 1 litre of 
supernatant). However, the majority of the Gly1ORF1 mutant proteins did not 
bind to the Ni-resin despite the presence of NiCl2. The proteins were only 
recovered from the supernatants after ammonium sulphate precipitation. One 
possible explanation is that the proteins were incorporated into outer membrane 
vesicles that were released by E. coli during protein induction. The histidine-tag 
would then be inaccessible, and unable to interact with the Ni-resin, which 
resulted in low binding to the Ni-affinity column.  
 
2.2.6 Determining the size and distribution of the Gly1ORF1 C-histidine 
tagged multimeric forms using Dynamic Light Scattering 
Dynamic light scattering methods enable the measurement of the size of 
molecules in a solution or suspension, as well their size distribution. In this 
method, the protein solution is exposed to light from a laser. The constant 
movement of the molecule causes the dispersion of light in different directions, 
which results in fluctuations in the absorbed light. The smaller the particles, the 
higher the fluctuations of absorbed light intensity are observed. From the 
intensity of these fluctuations, it is possible to calculate the velocity of the 
Brownian motion which, by using Stokes-Einstein relationship, enables the 
determination of the size of the molecule. 
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The WT Gly1ORF1 (0.5 mg/ml) was analysed using Dynamic Light Scattering 
(DLS) (see Materials and Methods Section 7.8.4). To disrupt the monomeric 
form, DTT was added to a final concentration of 10 mM, and the sample was 
measured by DLS to investigate changes in the oligomerisation state. The 
results identified three populations of peaks, with average sizes which are 
shown in Table 2.1. 
Table 2.1 Results of the DLS analysis of Gly1ORF1 size in non-reducing and 
reducing conditions* 
 Gly1ORF1 Gly1ORF1 + 10 mM DTT 
Peak 1 6.82 nm ± 0.92 6.90 nm ± 0.81 
Peak 2 30.95 nm ± 2.93 31.03 nm ± 2.58 
Peak 3 180.83 nm ± 15.86 261.57 nm ± 26.42 
*Results of three independent measurements with SEM using protein samples from the 
same preparation  
 
There was no difference in the first two peaks, which correspond to the protein 
monomer and probably a dimer, between the non-reducing and reducing 
conditions. The largest oligomer showed a significant increase in size when in 
reducing conditions (Fig. 2.13).  
These results indicate that the oligomeric forms of Gly1 are quite stable, and the 
presence of DTT did not disrupt the smaller oligomers. However, the largest 
oligomer expanded in size when in reducing conditions, which can be explained 
by the relaxation of the structure due to the loss of disulphide bonds.  
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Figure 2.13 Analysis of the 
size and distribution of 
multimers of Gly1ORF1 by 
DLS.  
A. Distribution of the size 
intensity of Gly1ORF1 in 
non-reducing (blue) and 
reducing conditions (pink). 
This shows the presence of 
three populations of proteins, 
with similar sizes for the two 
peaks of smaller size, and a 
slight increase in the size of 
the largest oligomer in 
reducing conditions.  
B. Comparison of the sizes of 
the three populations of 
Gly1ORF1 multimers in non-
reducing (blue) and reducing 
conditions (red) 
demonstrating a significant 
difference (p=0.002) in the 
size of the largest oligomer. 
The student t-test was used for 
statistical analysis.  
C. Comparison of the 
percentage intensity of the 
peaks corresponding to each 
multimeric form. The 
percentage distribution of 
each multimeric form is 
similar between non-reducing 
and reducing conditions. In 
both cases, bars corresponding 
to the monomers are less abundant then the multimers, with similar distribution for the 
two larger oligomers. 
 
 
With the monomers of Gly1ORF1 in a globular form, it would be expected that 
the dimers should be double the size of the monomer. However, in this 
experiment, a second peak that probably corresponds to a dimer is almost five 
times bigger than that of the monomer. Similarly, the third peak is also 
approximately five times the size of the second peak. Therefore, it was 
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suggested that Gly1ORF1 can form multimers at different interface than the one 
shown in Gly1ORF1 crystal structure. For example, it is possible that Gly1ORF1 
can undergo a domain swap, leading to the formation of a chain of Gly1ORF1 
monomers where the N-proximal β-sheet of one protein interacts with the C-
proximal β-sheet of a second, and is stabilised by an intra-molecular disulphide 
bond. As a consequence, the size of the molecules measured by DLS would be 
much bigger as the method determines the diameter of the rotating molecule.  
 
2.2.7 Haemin binding by the Gly1ORF1 mutant proteins 
The Gly1ORF1 mutant proteins were produced and purified by Ni--affinity 
chromatography, similarly to the wild-type protein. In order to establish if the 
introduced mutations prevented haemin binding by the protein, a haemin-
agarose pull-down was performed as described in the Materials and Methods 
Section (7.8.1).  
All mutants examined retained the ability to bind to the immobilised haemin, 
with a visible enrichment of protein on the beads Fig. 2.14, Lane B), and a 
reduction in the amount of protein in the supernatant after incubation (Fig 2.14, 
Lane S). No such effect was observed for BSA, which was used in the assay as 
a negative control and to increase the solubility of Gly1ORF1 at neutral pH. 
Only faint bands corresponding to BSA were observed in the fractions 
containing proteins bound to the haemin beads (Fig. 2.14, Lane B). This is 
probably the result of non-specific interactions with the haemin. It is not clear 
whether the introduced mutations are located away from the actual haemin 
binding site, or if a single amino-acid mutation is not capable of causing 
sufficient steric hindrance to prevent the interaction. As this assay is only 
qualitative, no information is available about whether the mutated protein’s 
affinity for haemin was altered.  
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Figure 2.14 Selective binding of the mutated Gly1ORF1 proteins to haemin-
agarose beads in the pull down assay. 
Samples containing mutant and wild type (WT) Gly1ORF1 proteins and bovine serum 
albumin BSA (Lanes L) were incubated with haemin agarose beads. BSA served as a 
stabilising agent and a negative control for the assay. The haemin beads with bound 
proteins were centrifuged down and supernatant containing unbound proteins was 
removed (Lanes S) The beads were washed with PBS containing 0.5 M NaCl (Lanes 
W) to reduce nonspecific interactions with the beads. The proteins were eluted from the 
beads by boiling in SDS-PAGE loading buffer and added to SDS-PAGE gel (Lanes B). 
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2.2.8  Analysis of the oligomerisation of Gly1ORF1 by glutaraldehyde 
cross-linking 
It was previously demonstrated that Gly1ORF1 is able to oligomerise by the 
formation of intramolecular disulphide bonds, as treating the protein with a 
reducing agent, such as DTT, disrupted the oligomeric forms back to monomers 
(Meadows, 2004). The data from the DLS experiment shown in section 2.2.6 
also confirm this observation. Trapping of oligomers can be achieved by the 
addition of a cross-linking agent, such as glutaraldehyde. This amine-reactive 
homo-bifunctional cross-linker forms covalent cross-links between lysine side-
chains that are in close proximity.  
In order to examine if the introduced mutations caused any disruptions to the 
oligomerisation of the proteins, all purified mutants were treated with 
glutaraldehyde as described in Materials and Methods Section 7.8.5. The 
proteins were then separated using SDS-PAGE and visualized by western blot. 
The low solubility of the proteins at neutral pH, which is optimal for the reaction, 
precluded testing the proteins at higher concentrations. On the initial western 
blots, using standard transfer conditions, no proteins corresponding to the 
Gly1ORF1 oligomers were observed (data not shown). However, almost 
complete loss of the Gly1ORF1 monomers was observed for all tested proteins 
with increasing concentration of glutaraldehyde (data not shown). These results 
indicated that the Gly1ORF1 oligomeric forms were either too large to be 
separated by SDS-PAGE, or the transfer of the separated protein was 
ineffective. Reducing the concentration of the SDS-PAGE gel to 7.5% and 
increasing the transfer time allowed the detection of the multimeric forms for all 
the Gly1ORF1 mutants and the wild-type protein (Fig.2.15). All Gly1ORF1 
mutants were able to form oligomeric forms. A quantitative comparison of the 
proteins was not possible due to the formation of aggregates that did not enter 
the gel, which is shown in the third blot, where the stacking gel was left intact 
(Fig. 2.15). 
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Figure 2.15 Western blots showing the oligomerisation of the Gly1ORF mutant 
proteins and the wild-type, after treatment with glutaraldehyde. 
Glutaraldehyde was used at a final concentration of 0.1% (v/v) and 0.05% (v/v). The 
aliquots of the reactions were loaded onto 7.5% (v/v) SDS-PAGE gel next to the control 
with no added glutaraldehyde. The semi-dry transfer was extended to 90 minutes. 
Proteins were detected using rabbit anti-Gly1ORF1 polyclonal antibodies. 
 
2.2.9 Spectrophotometric analysis of Gly1ORF1 interactions with haem. 
Previous work in the Sayers’ laboratory demonstrated that Gly1ORF1 forms an 
insoluble precipitate upon binding haem. The precipitation of Gly1ORF1-haem 
complexes was the main obstacle in co-crystallisation trials. Two of the 
generated mutants: Gly1K12A and Gly1M63A, demonstrated much higher 
solubility compared to the wild type protein, with no precipitant observed when 
up to 15 µM of protein was incubated with 5 µM haemin (Fig. 2.16). 
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Figure 2.16 Haemin spectra 
upon binding, with the WT 
Gly1ORF1 and two mutants 
demonstrating precipitation.  
Increasing concentrations of the 
WT Gly1ORF1 protein showed 
increasing levels of precipitation. 
In the absorbance spectra the 
precipitant causes a significant 
increase in the absorbance 
without changing the maximum 
absorbance. The Gly1M63A 
mutant showed some levels of 
precipitation which was 
manifested as some distortion in 
the spectra. The Gly1K12A 
complexes with haem 
demonstrated the highest 
solubility, with the spectra 
appearing similar for all the 
tested protein concentrations.  
 
 
 
 
 
Change in the maximum absorbance of haemin is often indicative of the protein-
haemin interaction. There was no shift in the maximum absorbance for any of 
the tested proteins, however when comparing the spectra of the K12A mutant at 
the lowest (2.5 µM) and the highest (15 µM) protein concentrations, there was a 
detectable change in the shape of the curve at the longer wavelengths (Fig. 
2.17). This indicates a possible protein–haem interaction, which was observed 
in the haemin-pull down assay. It is possible that the haem concentration used 
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was too low to cause a shift; however, low yields of the protein and limited 
solubility of haem at neutral pH were limiting factors in the experimental design. 
The remaining mutants were not tested at such high concentrations due to the 
low yields of purified proteins; however, initial experiments showed the 
formation of precipitate in the presence of haem (data not shown). 
 
 
Figure 2.17 Differences in the 
haemin spectra in the 
presence of the Gly1ORF1 
K12A protein.  
The protein was present at two 
concentrations; 2.5 and 15 µM. 
Haem, at a concentration of 5 
µM, was used. 
 
 
2.2.10 Gly1ORF1 K12A crystallisation trials  
The Gly1ORF K12A mutant was selected for crystal trials due to a much higher 
solubility than the wild-type protein in the presence and absence of haemin. 
This mutant still bound haemin when tested by the haemin-agarose pull-down 
assay (See Section 2.1.8). Crystal trials were performed by Jason Wilson, from 
the Department of Molecular Biology and Biotechnology, University of Sheffield. 
The Gly1ORF1 K12A mutant was purified from the culture supernatant as 
previously described (Materials and Methods, Section 7.6.1), dialysed against a 
low pH buffer (25 mM NaOAc, pH 4; 50 mM NaCl) and concentrated. The 
crystals of apo-Gly1ORF1 K12A were grown in 0.2 M NaBr, 0.1 M Bis-Tris 
propane pH 6.5, and 20% (w/v) PEG3350 using the drop-sitting method, at a 
protein concentration of 10 mg/ml (Fig. 2.18, Panel A.). The holo-Gly1ORF1 
K12A was prepared by incubating the purified protein with haemin solution. The 
unbound haemin was removed from the solution by small scale gel exclusion 
chromatography using Zeba Spin Columns (Thermo Scientific).  
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Figure 2.18 Crystals of the Gly1ORF1 K12A mutant. 
Protein crystallised without the addition of haemin (A) and with haemin (B). Pictures 
kindly provided by Jason Wilson, Department of Molecular Biology and 
Biotechnology, University of Sheffield. 
 
Figure 2.19. Results of haem soaking of the Gly1ORF1 K12A crystals. 
A. Crystals of Gly1ORF1 K12A crystals with no haemin; B. Crystals after haemin-
soaking. Solid haemin was added to the drop containing protein crystals. A change in 
the colour of crystals to red was observed after several weeks of incubation. Pictures 
kindly provided by Jason Wilson. 
The holo-Gly1ORF1 K12A crystallised in 0.1 M MIB buffer pH 8 and 25% 
PEG1500 at 2-3 mg/ml (Fig. 2.18, Panel B.). In parallel, crystals of the apo-
Gly1ORF1 K12A that crystallised in 0.2 M ammonium acetate, 0.1 M Bis-Tris 
pH 5.5 and 17% (w/w) PEG 10000 were subjected to crystal soaks. Solid haem 
crystals were added to the drops containing crystals of the apo-Gly1ORF1 and 
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incubated for two weeks (Fig. 2.19). Crystals from both the co-crystallisation 
and crystal soak trials were coloured red, indicating the successful incorporation 
of haemin into the protein crystals.  
The crystal structure of the apo-Gly1ORF1 K12A protein was solved at a 
resolution of 2.7 Å by Jason Wilson, Department of Molecular Biology & 
Biotechnology, at The University of Sheffield. The X-ray diffraction for the 
crystals of the holo-Gly1ORF1 K12A from the haem co-crystallisation trials 
generated data at a low resolution, which was not sufficient for solving the 
structure. However, the signal collected by the multichannel analyser (MCA) 
during data acquisition showed the presence of a peak corresponding to iron, 
confirming that the co-crystallisation with haemin was successful (Fig. 2.20).  
 
 
Figure 2.20 A screen shot of the MCA scan of the holo-Gly1ORF1 K12A crystal 
from the co-crystallisation trial. 
 
2.2.11 Structural analysis of the Gly1ORF1 K12A protein 
The crystal structure of the mature recombinant Gly1ORF1 K12A in the apo-
form was solved by Jason Wilson (University of Sheffield). The protein, as 
described previously is present as a dimer in the asymmetric unit (Arvidson et 
al., 2003). Each monomer consists of two sets of four anti-parallel β-strand 
sheets arranged orthogonally to each other, and connected by a single α-helix 
domain (Fig. 2.21).  
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Figure 2.21 A cartoon representation of the Gly1ORF1 K12A structure in two 
orientations.  
The β-strands are shown in magenta, unstructured loops in pink, and α-helices in cyan. 
The cysteine residues 6 and 103 that form a disulphide bond are represented as yellow 
sticks. Picture generated in Pymol. 
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The crystal structure is almost identical to the unpublished structure of the 
recombinant Gly1ORF1 from N. gonorrhoeae MS11, which was solved by 
Ardvison, and provided to the Sayers laboratory. The replacement of the lysine 
at position 12 did not cause any obvious changes in the structure that could 
explain the higher solubility observed for the mutant (data not shown). 
The search for structural cavities that could accommodate a haem molecule 
using the MetaPocket Finder bioinformatics tool (Huang, 2009) revealed the 
presence of a large pocket at the dimer interface, with the highest Z score 
16.02. Several pockets were also identified at different sites; however, with 
much lower prediction scores (Fig. 2.22). 
 
 
Figure 2.22 
Identification of 
potential haem binding 
sites in the Gly1ORF1 
K12A using the 
MetaPocket Finder 
server. 
The pocket with the 
highest score is located 
in the cavity at the dimer 
interface, and is depicted 
as small, purple spheres. 
Two additional pockets 
where identified that had 
a lower score, and are 
represented as light pink 
spheres. Images  
generated and rendered in Pymol. 
 
In order to identify potential haem binding sites on the protein, the docking of 
haem to the protein was performed using several bioinformatic tools including 
SwissDock (Grosdidier et al., 2011a, b), Patchdock  (Schneidman-Duhovny et 
al., 2005; Schneidman-Duhovny et al., 2003) and Hex (Macindoe et al., 2010). 
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The majority of the hits located haem in the largest pocket that was identified by 
the MetaPocket Finder. The result with the highest prediction score from the 
haem docking with PatchDock server (Schneidman-Duhovny et al., 2005; 
Schneidman-Duhovny et al., 2003) is shown in Figure 2.23. 
 
Figure 2.23 Surface 
representation of the 
prediction of Gly1ORF1 
K12A haem binding site. 
The molecular haem docking 
was done using PatchDock 
prediction. Haem is 
represented by red spheres. 
The image was rendered in 
Pymol. 
Some residues in the Gly1ORF1 K12A structure that are located within 5 Å from 
the haem molecule in the predicted model (Fig. 2.22) were previously subjected 
to site directed mutagenesis by Sathyamurthy (Sathyamurthy, 2011). Single 
amino acid substitutions of aspartic acid 50, lysine 64 and glutamic acid did not 
inhibit haem binding. In this study, the mutation of arginine 48 to glycine also 
had no effect on haemin binding and oligomerisation. This may indicate that the 
changes to the structure or electrostatic potential in Gly1ORF1 were insufficient 
to disrupt Gly1ORF1 haem interactions. Possibly, mutation of a bigger fragment 
would result in more dramatic changes in the protein structure and inhibit haem 
binding. In future studies mutation of the residues 48-50 (shown as yellow sticks 
in Figure 2.22) could have more prominent effect on the haem binding. These 
three residues seem to stabilise the haem docking in the cavity at the 
Gly1ORF1 dimer’s interface in the predicted haem binding site.  
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Figure 2.24 Representation of the predicted haem binding site in GlyORF1 K12A 
structure.  
The haem docking was done using PatchDock prediction server (Kelley and Sternberg, 
2009). Gly1ORF1 K12A residues within 5 Å of the haem molecule are shown in stick 
representation. The pink and yellow representation of the residues differentiates the 
residues from two monomers of Gly1ORF1. Structure of Gly1ORF1 is shown in 
transparent carton representation. The haem binding site was predicted by MetaPocket 
finder (Schneidman-Duhovny et al., 2005; Schneidman-Duhovny et al., 2003). The 
image was generated and rendered in Pymol. 
 
Some residues in the Gly1ORF1 K12A structure that are located within 5 Å from 
the haem molecule in the predicted model (Fig. 2.24) were previously subjected 
to site directed mutagenesis by Sathyamurthy (Sathyamurthy, 2011). Single 
amino acid substitutions of aspartic acid 50, lysine 64 and glutamic acid did not 
inhibit haem binding. In this study, the mutation of arginine 48 to glycine also 
had no effect on haemin binding and oligomerisation. This may indicate that the 
changes to the structure or electrostatic potential in Gly1ORF1 were insufficient 
to disrupt Gly1ORF1 haem interactions. Possibly, mutation of a bigger fragment 
would result in more dramatic changes in the protein structure and inhibit haem 
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binding. In future studies mutation of the residues 48-50 (shown as yellow sticks 
in Figure 2.24) could have more prominent effect on the haem binding. Those 
three residues seem to stabilise the haem docking in the cavity at the 
Gly1ORF1 dimer’s interface in the predicted haem binding site.  
 
2.2.12 Binding studies of the Gly1ORF1–haem interaction using 
microscale thermophoresis 
Microscale thermophoresis (MST) is a technique that allows quantitative 
analysis of protein-ligand interactions. An infrared laser pulse generates a 
microscale temperature gradient within a small glass capillary. This causes 
movement of the molecules (thermophoresis), which can be detected by 
fluorescence. Any changes in the hydration shell, charge or size of the molecule 
upon binding of a ligand also alters the molecule’s thermophoresis. Changes in 
the thermophoresis or the temperature increase as a function of the ligand 
concentration, allowing the determination of the dissociation constant (Kd) of the 
interactions. 
 
Figure 2.25 Changes in the Gly1ORF1 fluorescence in the presence of haemin. 
A. Capillary scan with serial dilutions of haemin, ranging from 50 µM (Capillary 1) to 
0.181 µM (Capillary 12). This shows a dose-dependent reduction in the fluorescence of 
Gly1ORF1 G47R upon the addition of increasing haemin concentrations. The 
measurements were performed on the Monolith NT.115 Series, at 20% LED power, 
using the red filter. B. The SDS-test: fluorescence scan of denatured Gly1ORF1, with 
the two highest and two lowest dilutions of haemin (Lane 1 – 0.302 µM, Lane 2 – 0.181 
µM, Lane 3 – 50 µM, Lane 4 – 30 µM).  
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For studying Gly1ORF1 interactions with haemin, affinity purified proteins were 
fluorescently labelled with Monolith NTTM Protein labelling Kit Red-NHS, 
according to the manufacturer’s instructions. The protein concentration was 
constant at 200 nM in all tested samples, with the serial dilutions of haemin 
ranging from 50 µM to 0.181 µM (3:2 serial dilutions). The hydrophilic capillaries 
were optimal for performing the measurement. The protocol was described in 
Materials and Methods Section 7.8.3. The experiments were performed on at 
least two separate occasions with freshly labelled protein. 
The determination of the Kd using microscale thermophoresis requires constant 
concentration of the fluorescently labelled protein in all tested samples. The 
results of the capillary scan of Gly1ORF1 with serial dilutions of haemin show a 
dose-dependent reduction in the fluorescence with increasing concentrations of 
the ligand (Fig. 2.25, Panel A.). In order to determine if the reduction in 
fluorescence with increased concentration of haemin was a result of protein–
haem interaction, or the loss of the protein due to aggregation and precipitation, 
the SDS test was performed. Mixtures containing a constant concentration of 
protein and serial dilutions of haemin were prepared as before. The samples 
with the two highest and two lowest dilutions of the ligand were mixed at a ratio 
of 1:1 with 2xSD buffer containing 4% (w/v) SDS and 40 mM DTT, and boiled 
for 5 minutes. The scan showed that upon denaturation, the fluorescence was 
almost completely restored. This indicates that the reduction in fluorescence 
with increasing amount of haemin was a result of haemin binding (Fig. 2.25, 
Panel B.). Therefore, changes of the fluorescence, not the thermophoresis data 
were used for determining the Kd and EC50 for three Gly1ORF1 mutants: G47R, 
Y72F and M63A. The remaining Gly1ORF1 mutants could not be tested due to 
the loss of protein during the labelling step and/or problems with aggregation. 
Analysis of the dissociation constant and plotting the binding curve was 
performed using the NTAnalysis Software 1.4.27 (Nanotemper Technologies 
GmbH). Binding curves for Gly1ORF1 G47R mutant are shown in Fig. 2.26). 
The data indicate that the protein concentration used for the assay was in the 
optimal range, as the Kd and EC50 values are very similar (Table 2.2). The 
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concentration of the ligand could not be tested at higher concentrations due to 
the solubility issue. 
 
 
Figure 2.26 Results of the MST analysis of haem binding by Gly1ORF1 G47R.  
Haemin was titrated into a constant concentration (0.2 µM) of the labelled protein. Both 
graphs represent the same data. The graphs represent curves fitted using: A. the 
equation for the Kd determination; B. the Hill equation. Error bars show standard 
deviation of n=3. Results for the Gly1ORF1 variants M63A and Y72F are shown in 
Table 2.2.  
 
Table 2.2 Affinity haem binding for Gly1ORF1 mutants. 
Gly1ORF1 variant Kd [µM] EC50 [µM] 
G47R 1.16 ± 0.056  1.3 ± 0.027 
M63A 1.07 ± 0.102 1.38 ± 0.019 
Y72F 0.577 ± 0.037 0.892 ± 0.055 
 
The results obtained for the G47R and M63A mutants are very similar. 
However, the Y72F variant shows almost twice the affinity for haemin compared 
to the other Gly1ORF1 variants tested. Unfortunately, the affinity of the 
interaction could not be determined for the wild-type version due to the loss of 
protein during the labelling step caused by aggregation. It is therefore 
impossible to say whether Y72F has comparable affinity to the WT and two 
other mutations caused a reduction in haemin binding, or the opposite: G47R 
and M63A are comparable to the wild-type, and mutating tyrosine72 resulted in 
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tighter binding of haem. To answer this question, the haem binding affinity for 
the wild type Gly1ORF1 must be determined.  
 
2.2.13 Expression of the native Gly1ORF1 using the pET21 expression 
vector 
Although the crystal structure of the Gly1ORF1 K12A with a C-terminal 
histidine-tag was solved in this study, there is a possibility that the native 
Gly1ORF1 protein could exhibit different properties by forming dimers with the 
different interface. Also, having an untagged version of the protein enriches the 
repertoire of methods that can be used for studying Gly1ORF1 interactions with 
other recombinant proteins that are expressed with a histidine-tag. Previous 
attempts to express and purify large amounts of the native protein were 
unsuccessful. Expression of the native Gly1ORF1 protein in pJONEX4 was very 
low, and on many occasions was detectable only by western blot (data not 
shown). This made purification of the native protein extremely difficult. 
 
 
Figure 2.27 Comparing expression of native Gly1ORF1 in pET21 expression 
vector with (Panel A.) and without (Panel B) the signal peptide.  
A. Expression of the full length, native Gly1ORF1 in 1 l auto-induction media. Samples 
were taken 16, 24 and 48 hours after inoculating. Two 1 litre flasks were inoculated in 
parallel. Lane M – protein marker, Lane UN – sample of the inoculum before adding to 
the auto-induction media; Lanes 1, 2 – parallel cultures. B. Auto-induction of the 
Gly1ΔSP construct in the pET21 vector. Lane 1 – sample used as an inoculum, Lane 2 
– sample taken after 24 hours post inoculum. C. Cell lysis and sodium deoxycholate 
wash of inclusion bodies from the 1 litre auto-induction culture. Lane 1 – Total cell 
lysate of Gly1ΔSP, Lane 2 – soluble fraction after centrifugation of the cell lysate, 
Lane 3 – inclusion bodies after the sodium deoxycholate wash.  
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An attempt to produce large quantities of the native protein was performed 
using the T7-expression system. Sub-cloning the gly1 gene into the pET21 
vector increased the expression levels, but protein yield was still relatively low 
compared to other Gly1ORF1 variants expressed in this system (Fig. 2.27, 
Panel A.). To avoid problems with unprocessed signal peptide which could later 
interfere with the assays, the DNA fragment encoding the signal peptide 
sequence was removed from the pET21-Gly1ORF1 construct with a single-step 
PCR method; described in the Material and Methods Section 7.4.2. The 
expression was tested in 5 ml auto-inducing media. The auto-inducing media 
contain lactose and glucose as a carbon source. At low cell density, 
concentration of glucose in the media is higher than lactose and genes under 
control of lac operon are repressed. During bacterial growth, the concentration 
of glucose in the media decreases. Reduction of glucose concentration below 
levels of lactose induces expression of those genes. 
The expression was successful, and the protein yield was much higher when 
compared to the culture of the full length gly1ORF1 gene (Fig 2.27, Panel B.). A 
large scale auto-induction (see Materials and Methods Section 7.5.4) resulted in 
even higher yields than the small scale culture. Analysis of the fractions after 
cell lysis showed that the Gly1ΔSP protein (which lacks the signal peptide) is 
totally insoluble (Fig. 2.27, Panel C, Lanes 1-2), so a sodium deoxycholate 
wash of the insoluble fraction was performed as described in Materials and 
Methods Section 7.6.3.1. The purified inclusion bodies yielded relatively pure 
protein, and were used for refolding trials (Fig. 2.27, Panel C, Lane 3).  
Analysis of the culture supernatants by SDS-PAGE gel failed to detect the 
presence of Gly1ΔSP and the full-length Gly1ORF1... 
2.2.14  Refolding of native Gly1ORF1ΔSP 
The use of the Thermo Scientific Pierce Protein Refolding kit allowed the 
screening of numerous conditions for Gly1ΔSP refolding (see Materials and 
Methods Section 7.6.3.1). The primary screen with low and high protein 
concentrations tested the effect of different concentrations of guanidine 
hydrochloride and L-arginine, as well as a reducing environment (GSH:GSSG) 
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on protein refolding. After protein refolding in the tested conditions, protein 
aggregation was measured spectrophotometrically at 450 nm.  
Table 2.3 Results of refolding of the native Gly1ΔSP protein using Pierce Protein 
Refolding Kit.* 
Trial/Base 
Refolding 
Buffer 
Guanidine 
Hydrochloride 
[M] 
L-
Arginine 
[M] 
Redox Environment Protein 
precipitation 
1 0.4 0 2 mM GSH : 0.2 mM GSSG Yes – high 
2 0.4 0.4 2 mM GSH: 0.4 mM GSSG No 
3 0.4 0.8 1 mM GSH : 1 mM GSSG No 
4 0.9 0 2 mM GSH : 0.4 mM GSSG Yes - low 
5 0.9 0.4 1 mM GSH: 1 mM GSSG No 
6 0.9 0.8 2 mM GSH : 0.2 mM GSSG No 
7 1.4 0 1 mM GSH : 1 mM GSSG No 
8 1.4 0.4 2 mM GSH : 0.2 mM GSSG No 
9 1.4 0.8 2 mM GSH : 0.4 mM GSSG No 
*Final protein concentration – approximately 1 mg/ml 
 
Refolding of low concentrations of Gly1ΔSP (final concentration of 
approximately 100 µg/ml) in all the tested conditions resulted in no protein 
aggregation. In trials with high protein concentration (with final concentrations of 
protein at approximately 1 mg/ml), aggregates were observed in samples with 
no arginine and low concentrations of guanidine hydrochloride (Table 2.3, Trial 
1 and 4), which indicated that the presence of arginine is crucial for Gly1ΔSP 
refolding. Arginine is known for its ability to supress protein aggregation, 
although the mechanism remains uncharacterised (Tsumoto et al., 2004). The 
presence of a reducing environment did not seem to have an effect on 
aggregation. The composition of each screening condition and the results of 
aggregation for the high concentration of protein are shown in Table 2.3.  
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Figure 2.28 Haemin agarose pull down of native Gly1ΔSP after refolding trials. 
Aliquots of refolded and dialysed in PBS Gly1ΔSP protein containing BSA as a 
negative control (Lane L) were incubated with haemin agarose beads The beads were 
centrifuged down and supernatant containing unbound protein was removed (Lane S); 
beads were washed with PBS containing 0.5 M NaCl (Lane W) and proteins were 
eluted from the beads by boiling in SDS-PAGE loading buffer (Lane B). 
 
To test whether the protein had correctly refolded, a haemin agarose pull-down 
assay was performed. Trials 2, 3 were tested separately, whilst trials 5 and 8 
were pooled together due to the same concentration of L-arginine. Trials 6 and 
9 were pooled together for the same reason. Samples with no arginine in the 
refolding buffer were not considered for further assays. As the results show, all 
the tested samples were able to selectively bind to haemin agarose beads (Fig. 
2.28). 
Size exclusion chromatography (SEC) separated the protein of interest from 
contaminants that differed in molecular weight. SEC can also be employed as 
an analytical tool for determining protein size, and for multimerisation studies. In 
the native Gly1ΔSP refolding and purification process, SEC can help monitor 
the state of the refolded protein. Correctly refolded protein should give sharp 
elution peaks. However, if the protein is not properly refolded it elutes at a 
higher molecular weight as a result of aggregation, or, if the peaks are broad 
and distorted, the protein has refolded incorrectly. 
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2.2.14.1 Large scale refolding and size exclusion chromatography of 
native Gly1ΔSP 
Approximately 60 mg of purified inclusion bodies of Gly1ΔSP was refolded in 
refolding buffer number 3 from the Pierce protein refolding kit, and samples 
after concentration were loaded onto the size exclusion column (see Materials 
and Methods Section 7.6.3.1). The elution profile is shown in Fig 2.29. 
 
 
Figure 2.29 Refolded Gly1ΔSP elution from the size exclusion column.  
The sample (0.5 ml), at a concentration of approximately 30 mg/ml, was loaded on to a 
GE Healthcare Superose 6 10/300 GL column and eluted in 0.5 ml fractions. The UV 
traces of the eluted protein are shown as the blue line, the brown line shows changes in 
conductivity, and the green line shows the pressure. 
 
Increasing the amount of protein in the refolding conditions did not trigger 
aggregation on the column, which confirms the choice of refolding buffer. 
However, some precipitation was observed in fraction C12, which contains the 
highest concentration of protein (according to the UV-Vis traces). This indicates 
that the solubility of the protein at very high concentrations must be limited in 
this buffer. 
Three peaks were observed during elution from the SEC column. Fractions 
corresponding to each peak were pooled together and concentrated ten-fold 
using the Viva-spin columns and analysed using SDS-PAGE in both non-
reducing and reducing conditions. When analysing pooled fractions from the 
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first peak (A13-B3) by SDS-PAGE, a faint band at the size corresponding to the 
monomeric Gly1 was visible only in the reducing conditions (Fig. 2.30, Peak 1).  
 
Figure 2.30 Analysis by SDS PAGE of the 
pooled and concentrated fractions of 
Gly1ΔSP collected from SEC 
Refolded Gly1ΔSP was separated on the GE 
Healthcare Superose 6 10/300 GL column. 
Collected samples were analysed by SDS-
PAGE in both non-reducing and reducing 
conditions. Peak 1 – pooled and 
concentrated fractions A13 to B4, Peak 2 – 
fractions B13-C8, Peak 3 – fractions C14 to 
D3, which correspond to the highest peak on 
the UV-Vis elution profile. 
 
Fractions corresponding to the second peak should contain the dimeric form of 
Gly1ΔSP. Analysis of the fractions in both reducing and non-reducing conditions 
did not show any obvious protein at the dimer size; however, there was a 
difference in band intensity, showing a higher concentration of monomeric 
Gly1ΔSP in reducing conditions compared to samples run without DTT. Peak 3 
corresponds to monomeric Gly1ΔSP and shows that this form is prevalent 
under these conditions. The presence of an extra band just above the Gly1ΔSP 
monomer in the non-reducing conditions might indicate that some proportion of 
the protein was not properly refolded, which affected migration in the SDS 
PAGE gel (Fig. 2.30). 
Changing the buffer to PBS or to a 50 mM Tris-HCl, 100 mM NaCl buffer 
resulted in precipitation of the protein, indicating that L-arginine is necessary for 
maintaining protein solubility.  
In summary, the Gly1ORF1 protein posed several challenges in the 
experimental design. Gly1ORF1 is characterised by low solubility in neutral 
conditions (not exceeding 10 µM) without the addition of stabilising reagents, 
such as BSA. The protein can be stored at higher concentrations only at low 
pH, which is far from the physiological conditions. The acidic conditions are also 
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not compatible for studying protein-haem interactions, as haem solubility is 
greatly reduced in these conditions. In addition, the protein tends to form large 
insoluble aggregates upon haem binding, which also limits the number of 
experimental methods available for studying the protein-ligand interaction. In 
this study, the introduction of the point mutation (K12A) significantly increased 
the solubility of the Gly1ORF1 protein. The protein retained its haem binding 
activity without the formation of insoluble aggregates. This enabled the 
successful crystallisation of the protein, which allowed the crystal structure of 
the haem-free protein to be determined. Co-crystallisation trials with haemin 
also gave promising results. However, the data collected for the crystals of the 
holo-Gly1ORF1 K12A were too low resolution to be solved. Therefore, the 
conditions for co-crystallisation of Gly1ORF1 K12A with haemin must be further 
optimised.  
Another problem encountered in this project was inconsistent expression of the 
protein in the heat-inducible expression system. The yields of the protein 
present in the cell pellets were low, and the protein was unprocessed and 
insoluble. However, the protein was also secreted in the culture supernatants. 
The yields and purity of the protein differed from batch to batch. In this study, a 
gene encoding the Gly1ORF1 native protein without a signal peptide (Gly1ΔSP) 
was cloned into T7-expression vector. This resulted in a significant increase in 
protein yields in the cell pellets. However, the protein was present in inclusion 
bodies. Nevertheless, the levels of protein expression in the T7-inducible 
system proved to be reproducible and easily controlled when compared to the 
heat-inducible system. For future experiments requiring high yields of protein, 
mutated gly1ORF1 genes could be sub-cloned into the same T7-expression 
system without the signal peptide.  
Problems in purifying some Gly1ORF1 mutants from the culture supernatants 
by IMAC (Ion-Metal Affinity Chromatography) were partially resolved by 
enriching the media with NiCl2, or by ammonium sulphate precipitation. 
However, it required handling large volumes of supernatant, and the yields 
depended also on the efficiency of protein secretion, which was not 
reproducible and varied between mutant proteins. Therefore, producing the 
protein as inclusion bodies at high yields, and refolding it in the conditions 
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optimised in this study seems to be a better alternative. However, there is 
always a risk that even a single point mutation could have an impact on the 
refolding process, and each mutant would require separate optimisation of the 
refolding conditions. This would be time consuming. 
There is still a need for optimising the buffer conditions for protein storage at 
high concentrations, in neutral conditions without the use of interfering 
additives. The use of agents, including L-arginine, which seems to increase the 
protein solubility at pH 7-8, does interfere with labelling reactions. BSA, which 
stabilises the protein, is also able to bind haem, and therefore cannot be used in 
haem binding experiments. There is an increasing number of commercial kits 
that allow screening of a wide range of buffer conditions in order to optimise a 
particular protein’s solubility. It is possible that the addition of a low 
concentration of detergent or inert solvent, such as DMSO could be beneficial 
for protein stability and preventing aggregation.  Such measures would greatly 
facilitate studies on the Gly1ORF1 protein. 
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CHAPTER 3 STUDIES ON GLY1ORF1 
INTERACTIONS  
3.1 Introduction 
Gly1ORF1 was first identified as a protein that confers a weak haemolytic 
activity when expressed in E. coli (Arvidson et al., 1999). Further experiments in 
our laboratory demonstrated that Gly1ORF1 is able to bind to red blood cells 
when analysed by FACS and causes morphological changes of red blood cells 
characterised by clumping and loss of the discoid shape (Sathyamurthy, 2011). 
The yeast two-hybrid experiments by Meadows showed that Gly1ORF1 
specifically binds membrane protein EPB4.2 – one of the main components of 
the red blood cell cytoskeleton (Meadows, 2004), which was further confirmed 
by Sathyamurthy. The experimental data showed interactions with mammalian 
cell lines expressing recombinant EPB4.2 protein (Sathyamurthy, 2011). The 
fact that EPB4.2 is not expressed on the surface of the cells, but is present on 
the cytoplasmic face of the membrane prompts the question of how Gly1ORF1 
enters the cells to allow the interactions with its identified binding partner. It was 
hypothesised that Gly1ORF1 might have a membrane receptor on the surface 
of the red blood cells allowing it to be translocated across the cell membrane. In 
this chapter the aim was to investigate whether Gly1ORF1 interacts with other 
proteins on the red blood cell membrane that could be potential receptors using 
a cross-linking approach. It was also investigated whether Gly1ORF1 binding to 
red blood cells is reversible by performing subsequent washes and analysing 
the amount of the protein that was bound to red blood cells.  
Also, the experiments in this chapter describe cloning and expression of 
EPB4.2 in E. coli and purification of the protein. The aim was to co-crystallise 
EPB4.2 and Gly1ORF1 protein and study the interactions between the proteins 
using the biolayer interferometry approach.  
Gly1ORF1 protein has been shown to bind haemin in vitro and the data by 
Sathyamurthy demonstrated that the Gly1ORF1 knock-out mutant is not able to 
grow on haem or haemoglobin as the sole iron source (Sathyamurthy, 2011). 
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This suggested that Gly1ORF1 might be involved in iron acquisition in 
Neisseria. Two haem receptors were identified in Neisseria: HmbR and HpuAB, 
which were described in Section 1.2.6.3. It was hypothesised that Gly1ORF1 
might play a role of a haemophore for the neisserial outer membrane receptors 
by capturing haem from the extracellular environment and transporting it to the 
outer membrane receptors. Similar haemophores were described in many 
bacteria, e.g. HasA in Serratia marcescens (Czjzek et al., 2007). 
A further aim of this chapter was to clone and express neisserial haem 
receptors and investigate if Gly1ORF1 is able of interact with them. 
 
3.2 Results and Discussion 
3.2.1 Interactions with red blood cells 
3.2.1.1 Reversibility of binding to red blood cells 
This experiment aimed to investigate whether the interactions of Gly1ORF1 with 
red blood cells are reversible. Human red blood cells from a healthy volunteer 
were first incubated with Gly1ORF1 and then washed sequentially with PBS for 
15 minutes each time by gentle mixing (see Materials and Methods Section 
7.9.4). Samples of the red blood cell suspension were taken for SDS-PAGE 
followed by western blot with anti-Gly1ORF1 antibodies. The immunoblot 
showed that the amount of Gly1ORF1 bound to red blood cells was significantly 
reduced after first two washes with no further reduction after the third wash (Fig. 
3.1). It is not clear whether the bound Gly1ORF1 traversed the membrane and 
was captured inside red blood cells or if there is strong interaction with 
membrane proteins that were not disrupted after sequential washes. Gly1ORF1 
tends to precipitate in the presence of haemin and it might also be possible that 
some lysis occurred during incubation and free haem interacted with Gly1ORF1 
causing precipitation. Gly1ORF1 could then be pelleted during centrifugation 
together with intact red blood cells and was not removed after aspiration of the 
wash buffer.  
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It is quite interesting that even after addition of DTT in the loading buffer 
Gly1ORF1 is still present in multimeric forms. It is possible that upon binding to 
the target protein on the red blood cells, complexes are very stable and can 
have limited accessibility for the reducing reagent or that components of the red 
blood cells such as haemoglobin could partially interfere with the DTT reaction 
as previously reported (Netto and Stadtman, 1996). 
 
Figure 3.1 Immunoblot showing 
reversible binding of Gly1ORF1 to 
human red blood cells.  
Red blood cells (RBCs) were incubated 
with Gly1ORF1. The RBCs were 
centrifuged down and supernatant (S/N) 
with unbound protein was removed. RBCs 
were subsequently washed with PBS. A 10 
µl aliquot of red blood cell suspension was 
taken after each wash. The aliquots of red 
blood cells with bound proteins after each 
wash were analysed by western blot with 
anti-Gly1ORF1 antibodies.  
 
3.2.1.2 Cross-linking of Gly1ORF1 with red blood cells 
It is still not clear whether Gly1ORF1 has a receptor in the membrane of red 
blood cells allowing translocation of the protein inside the cells and interaction 
with protein EPB4.2. To try to identify potential receptor in red blood cells, 
Gly1ORF1 was incubated with red blood cell suspension and two reversible 
cross-linkers were added (see Materials and Methods Section 7.9.3). DTSSP 
(3,3’-dithiobis[sulfosuccinimidylproprionate]) is reversible cross-linker that is not 
membrane-permeable and can cross-link only cell surface proteins, whereas 
DTBP (dimethyl 3,3’-dithiobispropionimidate) is able to cross the cell membrane 
and target proteins inside the cells. The advantage of using those cross-linkers 
is reversibility of the reaction. Addition of DTT to the sample cleaves the spacer 
arms in coupled proteins. Red blood cells after cross-linking were lysed and 
analysed by western blot with anti-Gly1ORF1 antibodies in both non-reducing 
and reducing environments. The results of the cross-linking with both reagents 
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did not show any obvious proteins at high molecular weight indicating 
interactions of Gly1ORF1 with RBC membrane proteins (Figure 3.2). Although 
interactions with EPB4.2 were previously shown in our lab, no bands 
corresponding to the complex of EPB4.2 with Gly1ORF1 size (approximately 88 
kDa) were detected. Interestingly, some extra bands running at a lower 
molecular weight than Gly1ORF1 monomer and dimer were detected in non-
reducing gels which were not present in the reducing conditions. The band just 
below 30 kDa could be Gly1ORF1 cross-linked to some other small protein. It 
could be also a more compact form of a Gly1ORF1 dimer that migrates faster in 
the SDS-PAGE gel, which needs to be further investigated. 
 
Figure 3.2 Immunoblot of Gly1ORF1 cross-linking with red blood cells.  
Gly1ORF1 was incubated with red blood cells or ghosts in suspension and subjected to 
reversible cross-linking with DTSSP and DTBP. Gly1ORF1 with no added cells or 
membranes was used as a control. After cross-linking, red blood cells and ghosts were 
centrifuged down, lysed and run on SDS PAGE and analysed by western blot with anti-
Gly1ORF1 antibody. Samples were run in non-reducing (-DTT) and reducing 
conditions (+DTT). The Gly1ORF1 was detected using anti-Gly1ORF1 polyclonal 
antibodies. 
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It is not clear why a monomer of Gly1ORF1 after treatment with both cross-
linkers showed a different gel migration pattern in the presence of red blood 
cells compared to Gly1ORF1 incubated with ghosts or without red blood cells 
and membranes. One of the explanations is conformational changes in the 
Gly1ORF1 structure such as domain swapping triggered by the presence of red 
blood cells and fixed by the presence of cross-linkers. If the changes were 
triggered by the presence of the red blood cell membranes, samples subjected 
to cross-linking with ghosts would be expected to show similar pattern. One of 
the explanations of such changes could be the presence of haem. A question of 
how Gly1ORF1 gets inside red blood cells remains unanswered.  
3.2.2 Gly1ORF1 interactions with recombinant EPB4.2 
3.2.2.1 Sub-cloning and expression of membrane protein EPB4.2 
EPB4.2 was codon optimised for expression in E. coli and the gene was 
synthesized by Eurofins with a sequence encoding the N-terminal histidine tag. 
The gene was then subcloned from the pUC57 vector into the pET21 vector 
using NdeI and HindIII restriction sites. The construct was propagated in E. coli 
XL1Blue and expressed in E. coli BL21DE3 cells by induction with 0.1 mM IPTG 
(see Materials and Methods Section 7.5.3), 
Analysis of induced cell lysates by SDS-PAGE analysis showed a detectable 
band at approximately 72 kDa in the induced samples (Fig. 3.3, Panel A). The 
expression levels of EPB4.2 were much lower than the positive control with N-
biotin tag Gly1ORF1 (Fig. 3.3, Panel A, Lane cntr). Western blot analysis of the 
induced samples showed some protein degradation after 4 hour-induction, 
indicating that the protein is unstable (Fig. 3.3, Panel B). Thus, for large scale 
expression, the protein induction was limited to two hours. An attempt to purify 
the protein by Ni--affinity chromatography under native conditions was 
unsuccessful due to protein degradation even after adding EDTA-free protease 
inhibitors cocktail (Roche) to solutions used for purification. This indicates that 
the protein might be susceptible to proteases that are not inhibited by the 
EDTA-free reagent. However, EDTA is not compatible with the Ni--affinity 
column and had to be avoided. Therefore, the protein was purified in denaturing 
conditions using guanidine hydrochloride (see Materials and Methods Section 
112 
 
7.6.3). Protein was bound to the column in the presence of 3 M guanidine 
hydrochloride and was refolded on the column. Fractions containing N-histidine 
tag EPB4.2 were concentrated, buffer exchanged into PBS and used for 
studying protein-protein interactions (Fig. 3.4, Panel A.). The western blot 
analysis with the mouse monoclonal anti-EPB4.2 confirmed that the purified 
protein is EPB4.2 (Fig. 3.4, Panel B). 
 
Figure 3.3 Analysis of expression of N-histidine tag EPB4.2 in BL21DE3. 
Analysis performed: by SDS-PAGE (Panel A) and by western blot (Panel B). Mid-log 
phase duplicate cultures were induced with 0.1 mM IPTG and samples 2 and 4 hours 
were run on the SDS-PAGE gel and subjected to western blot with anti-histidine tag 
mouse mAbs. The presence of a faint band at approximately 72 kDa size was detected 
by SDS-PAGE (indicated with arrows). Western blot analysis showed an extra band of 
approximately 22 kDa which is a degradation product of the expressed protein. Culture 
of Bl21DE3-pET21(N-biotin-Gly1ORF1) was used as a positive control for the 
induction conditions (Lane cntr).  
 
Figure 3.4 EPB4.2 purification on Ni-
affinity column under denaturing 
conditions.  
A. SDS-PAGE gel showing ten times 
concentrated fractions (3-5) (Lanes 1 to 
3) collected from Ni-affinity column in 
linear gradient of imidazole. Samples of 
5 µl from each fraction were loaded in 
each lane. The band corresponding to the 
degradation product at 22 kDa is marked 
with an arrow. B. Western blot analysis of the purified recombinant protein with the 
mouse monoclonal anti-EPB4.2 antibody (Abcam). Lane 1 – purified recombinant N-
histidine tagged EPB4.2; Lane 2 – positive control for the antibody – isolated red blood 
cells membranes (2 µg in the lane).  
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The yields of the purified protein were low (less than 0.3 mg from 12 g of 
induced cells); however, the amount was sufficient to perform an initial test for 
detection of the interaction with Gly1ORF1. In order to study whether the 
recombinant N-histidine tag EPB4.2 can bind to Gly1ORF1 in vitro, a biolayer 
interferometry approach was used. A BLITz machine (ForteBio) was used for 
the study. The method involves measuring changes of the white light 
interference reflected from the biosensor surface with reference to the internal 
layer. Binding of the molecules to the surface of the biosensor causes changes 
in the interference pattern that can be measured in real time. For studying 
protein-protein interactions one of the binding partners is immobilised on the 
surface of the biosensor and is incubated with different concentrations of the 
second partner. The method allows quantitative measurement of the 
association and dissociation of a ligand from the biosensor, thus allowing 
determination of binding kinetics of two molecules.  
For detecting the interactions between EPB4.2 and Gly1ORF1, N-histidine tag 
EPB4.2 was first immobilised covalently on AR2G biosensors (Amine-reactive 
2nd Generation biosensors) according to the manufacturer’s instructions and 
incubated with the Gly1ORF1 C-histidine tag solution. However, the AR2G 
sensors do not allow a directional immobilisation of proteins with high numbers 
of lysine residues. Therefore, a Gly1ORF1 binding site in the large proportion of 
immobilised EPB4.2 protein molecules might be inaccessible. An alternative - 
Ni-NTA sensors enable immobilisation of N-histidine tag EPB4.2 in a similar 
way as the protein is anchored to the red blood cell membrane via N-terminal 
mirystyl-group (Das et al., 1994). Unfortunately, this approach could not initially 
be used. The binding partner also contained a histidine-tag and would interact 
with the sensor. Only at the later stage of the project, success in the purification 
and refolding of the non-tagged Gly1ORF1 allowed the use of Ni-NTA 
biosensors. The N-histidine tagged EPB4.2 coupled to Ni-NTA biosensors via 
its N-histidine tag was incubated with the native Gly1ORF1 to analyse protein-
protein interactions. 
In both cases no interaction between the proteins was detected (Fig. 3.5). The 
main reason for that might be improper refolding of the EPB4.2 protein on the 
Ni-affinity column. The instability of the protein which could be observed even 
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during protein expression in E. coli dictated the choice of the denaturing 
purification conditions. Possibly, the addition of a protease inhibitor to the cell 
culture shortly after induction and before harvesting the cells might prevent or 
decrease the degradation and allow purification in the native conditions. 
Another approach could include a choice of a different Ni-affinity resin that 
would tolerate the presence of EDTA in the purification buffers and thus ensure 
inactivation of the metalloproteases.  
 
Figure 3.5 EPB4.2 interactions with Gly1ORF1 analysed by biolayer 
interferometry (Blitz). 
EPB4.2 was first immobilised on an AR2G biosensor. After setting up a baseline, the 
biosensor was incubated with Gly1ORF1 C-histidine tag protein. Controls included a 
baseline with no protein immobilised incubated with buffer and Gly1ORF1 solution at 
100 µg/ml and a biosensor with immobilised EPB4.2 incubated with buffer only. No 
obvious binding of Gly1ORF1 was observed. 
 
Possibly eukaryotic proteins expressed in E. coli might have limited function due 
to the lack of post-translational modifications. EPB4.2 undergoes myristoylation 
at the N-terminus to allow the attachment of the protein to the red blood cell 
membrane. Presence of the N-histidine tag in the recombinant EPB4.2 protein 
plays an analogous role – it allows attachment to a surface, the biosensor, so it 
was thought very unlikely that this would affect protein-protein interactions. 
However it cannot be ruled out that other post-translation modifications are 
important for the interaction of EPB4.2 with Gly1ORF1. 
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Other approaches to study in vitro Gly1ORF1 and EPB4.2 interactions were 
tested. Purification of the protein from human and porcine erythrocyte 
membranes using the protocol described by Malik and co-workers (Malik et al., 
1993) was unsuccessful, also probably due to the protein degradation during 
purification process. Cross-linking experiments and pull-down assays with the 
detergent treated ghost membranes and C-histidine tagged Gly1ORF1 did not 
show any obvious interactions (data not shown). Finally, collaboration was set 
up with Dr Scott Garforth from the Albert Einstein College of Medicine in New 
York to obtain a purified EPB4.2 expressed in murine cell culture for further 
experiments and co-crystallisation trials. Unfortunately, although the purification 
of small quantities of the protein was successful, again, the protein showed a 
high degree of degradation and was not suitable for further analysis.  
3.2.3 Studying interactions of Gly1ORF1 with haemoglobin receptors  
3.2.3.1 Cloning and expression of haemoglobin receptors 
Oligonucleotides for amplification of the hmbR gene were designed based on 
the N. meningitidis MC58 genomic sequence (Accession number: 
gi77358697:1740259-1742643), whereas oligonucleotides for cloning of hpuA 
and hpuB genes were based on sequence of haemoglobin-haptoglobin 
utilisation operon of N. meningitidis (Accession number: 
gbIU73112.2INMU73112:129-3686). Oligonucleotide sequences and PCR 
conditions are summarised in Table 7.1 in Materials and Methods Section 7.3.2. 
A 2376 bp gene encoding hmbR was successfully amplified from NM MC58 
genomic DNA (Fig. 3.6). However, no DNA fragments corresponding to hpuA 
and hpuB genes were obtained even after several attempts of optimisation. No 
hmbR products were observed for N. gonorrhoeae MS11 or N. lactamica Y92-
1009, which agrees with the results of sequence analysis of genomes of those 
strains and data available in the literature. The PCR product of hpuB gene was 
successfully amplified from N. lactamica Y92-1009 genomic DNA. Although this 
gene was not identified in the available genome of NL Y92-1009, this genomic 
sequence is not complete and is probably missing the hpuAB operon region as 
well as the region encoding gly1ORF1, which was also amplified with the 
positive control primer. Surprisingly, the positive control with primers for the 
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amplification of gly1ORF1 using genomic DNA of NG MS11 as a template gave 
a faint band corresponding to the expected 1.3 kbp – long fragment. In addition, 
a more intense DNA fragment of a larger fragment (approximately 1.8 kbp) was 
observed on the gel. It is possible that through several passages NG MS11 
started to undergo phase variation, which could result in the presence of those 
two products. It was reported in the literature that Neisseria spp. can undergo 
those changes even after relatively few passages (Tauseef et al., 2013). 
 
Figure 3.6 Amplificiation of haemoglobin receptors genes from genomic DNA of 
three strains of Neisseria spp. 
Genomic DNA of N. meningitidis MC58, N. gonorrhoeae MS11 and N. lactamica Y92-
1009 were used as template for PCR of the hmbr, hpuA and hpuB DNA fragments. 
Positive control contains amplified gly1ORF1 DNA fragment (Lane +ve cntr). Lane –
ve cntr - negative control; Lane M – size marker;  
 
HpuB cloning was unsuccessful. The hmbR gene of MC58 was cloned into the 
pET21 vector and successfully expressed in BL21Star(DE3) cells. Expression 
was confirmed by SDS-PAGE gel of induced samples stained with standard 
Coomassie blue stain (Fig. 3.7, Panel B). A protein of the expected size of 
approximately 90 kDa was readily visible on the gel. To ensure the produced 
protein was the haemoglobin receptor, induced cell lysates were subjected to 
SDS-PAGE separation and incubated in TBG buffer without SDS, allowing 
partial in situ refolding of the proteins (see Materials and Methods section 
7.10.2). The gels were then incubated with Congo red or haemin solutions in 
TBG buffer (Fig. 3.7, Panel A. and 3.7, Panel C). Congo red has been 
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previously used to identify haem binding protein in bacteria (Daskaleros and 
Payne, 1987; Smalley et al., 1995; Stugard et al., 1989). It has been used as an 
alternative to haem due to its higher solubility in water. 
Overexpressed recombinant HmbR bound both Congo red and haemin similarly 
to the Gly1ORF1 used as a control for staining.  
 
Figure 3.7 Analysis of small scale induction of HmbR protein in E. coli BL21Star 
(DE3) 
A. SDS-PAGE gel red after incubation in TBG buffer stained with Congo red. B. 
Standard SDS-PAGE gel stained with Coomassie blue stain C. SDS-PAGE gel red after 
incubation in TBG buffer stained with haemin. Results confirm binding of Congo red 
and haemin by expressed recombinant HmbR after in-gel refolding. Lane M – size 
marker; Lane 1 – negative control with a non-inducing HmbR clone, Lane 2 and 3 – 
clones with wild-type hmbR gene, Lane 4 – GlyORF1 C-histidine tag as a positive 
control of staining. 
 
 
To check whether HmbR is expressed on the surface of the recombinant cells, 
freshly transformed BL21Star(DE3) grown for two hours in non-inducing liquid 
medium were streaked out on inducing plates containing selection antibiotic, 
lactose and Congo red (see Materials and Methods Section 7.10.1). Bacteria 
harbouring the pET21 vector containing the hmbR gene grew as red colonies 
indicating selective binding of Congo red and confirming expression of the 
membrane bound receptor. In contrast, colonies of BL21Star(DE3) with an 
empty pET21 vector were pink with red dye present only in the centre of the 
colonies. Presence of the halo around the colonies expressing HmbR indicates 
selective binding of the dye (Fig. 3.8). 
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It was also tested whether bacteria with expressed HmbR can bind haemin and 
haemoglobin in solution (see Materials and Methods Section 7.10.3). Bacteria 
grown in liquid medium and induced with IPTG were tested for the ability to 
sequester haemin or haemoglobin from the solution. Samples were taken at 30 
minute time-points post-induction, the optical density (OD600 nm) of the bacterial 
suspension was adjusted to 1 and the bacterial suspension in PBS was 
incubated with haemin or bovine haemoglobin. The percentage of bound 
haemin and haemoglobin in the samples was determined 
spectrophotometrically by measuring the reduction in absorbance of the 
supernatants after pelleting the cells. Samples with haem or haemoglobin only 
were used as a reference (Fig. 3.9).  
 
 
Figure 3.8 Congo red binding of E. coli cells expressing HmbR grown on Congo 
red inducing plates. 
Cells were streaked out on BHI plates supplemented with lactose (0.05% w/v), 
ampicillin (100 µg/ml) and Congo red (0.005% w/v). A. BL21Star (DE3) cells with 
pET21-HmbR construct; B. BL21Star(DE3) with an empty pET21 vector. 
 
Cells expressing hmbR gene reduced the concentration of haemin in the 
solution by up to 80%, whereas cells with an empty vector showed negligible 
binding. The highest level of haemin binding was observed up to 60 minutes 
post-induction and the ability of bacteria to bind haemin slowly decreased after 
extended induction. Previous observation of Congo red plates with bacteria 
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streaked after induction showed a drastically decreased number of colony 
forming units after induction indicating a toxic effect of hmbR expression on the 
cells. Moreover, there was a mixture of pink and red colonies indicating a loss of 
ability to express the gene by some bacteria. Those bacteria probably started to 
overgrow bacteria expressing the hmbR gene, hence the reduction of binding 
after extended induction. E. coli expressing hmbR did not show obvious binding 
of haemoglobin. A similar experiment performed by Simpson and co-workers 
(Simpson et al., 2000) with overexpressed hmuR receptor from Porphyromonas 
gingivalis showed some level of haemoglobin binding (around 15%). However, 
the cell strain used for overexpression BL21(DE3)pLysE allowed a slower 
induction rate which could be more efficient for incorporation of the produced 
receptor in the membrane. This could result in more effective binding of 
haemoglobin to the cells.  
 
 
Figure 3.9 Binding of haemin and haemoglobin by E. coli expressing hmbR 
 
BL21Star(DE3) cells with an empty pET21 vector and duplicate cultures expressing 
hmbR (pET21-Hmbr1 and pET21-Hmbr2) were taken at 30 minutes intervals post-
induction and incubated with haemin or haemoglobin at final concentrations of 5 µM 
and 10 µM respectively. 
 
 
 
3.2.3.2 HmbR interactions with Gly1ORF1 
Gly1ORF1 interactions with recombinant HmbR were examined by a whole cell 
binding assay using E. coli BL21Star(DE3) producing HmbR as described in 
Materials and Methods Section 7.10.4. Western blot analysis of cell pellets and 
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supernatants after incubation with Gly1ORF1 showed reduction of Gly1ORF1 
concentration in the supernatants incubated with cells expressing hmbR. No 
obvious reduction in the Gly1ORF1 concentration in the supernatant was 
observed for cells with an empty pET21 vector (Fig. 3.10 and 3.11 Panel A.). In 
the samples with cells harbouring pET21-HmbR construct there was a lower 
amount of Gly1ORF1 in the first 60 minutes post induction. After 90 minutes 
post-induction the amount of Gly1ORF1 in the supernatants was comparable to 
the samples with an empty vector. The statistical analysis shows that at 60 
minutes post induction, the difference between samples with an empty pET21 
and pET21-HmbR vector in depletion of Gly1ORF1 from the supernatants is 
statistically relevant (Fig. 3.11). The highest depletion of Gly1ORF1 in the 
supernatant observed 60 minutes post-induction corresponds with the results 
for haemin binding (Fig. 3.9, Panel A). This is probably an optimal induction 
time for the hmbR expression as extended inductions leads to the selection of 
cells that lose the ability to express hmbr gene, which was mentioned earlier in 
this chapter. 
 
Figure 3.10 Binding of Gly1ORF1 by E. coli expressing hmbR.  
E. coli cells with an empty pET21 vector and the pET21-HmbR construct were grown 
to a mid-log phase and induced with 0.1 mM IPTG. Samples at a final volume of 1 ml 
were incubated with Gly1ORF1 for the times indicated at the final concentration of 2.5 
µM for 1 hour at 37°C. After incubation cells were centrifuged down and supernatants 
were removed and cell pellets were resuspended in 100 µl of TE buffer containing 1% 
(w/v) SDS and boiled for 5 min. Supernatants and cell lysates were analysed by western 
blot with the anti-Gly1ORF1 rabbit antibody. This figure is representation of three 
independent experiments. 
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The analysis of the cell lysates after incubation of Gly1ORF1 shows higher 
binding of Gly1ORF1 to the cells expressing hmbR at 30 minutes post 
induction. The differences can be explained by the fact, that analysis of the 
western blot images is only a semi-quantitative method and is affected by the 
quality of the transfer and detection with the antibodies. However, the data 
clearly show a difference in the binding between the cells expressing hmbR and 
cells with an empty vector (Fig. 3.11).  
 
 
Figure 3.11 Gly1ORF1 binding 
by the E. coli cells expressing 
hmbR.  
A semi-quantitative analysis of 
western blot images with ImageJ 
software. A. Analysis of 
depletion of Gly1ORF1 in the 
supernatants after incubation 
with induced E. coli cells 
containing an empty pET21 
vector and pET21-HmbR 
construct. The percentage of 
Gly1ORF1 in the supernatant 
was calculated using a negative 
control (Gly1ORF1 solution with 
no cells added) as a 100% 
reference. B. Analysis of 
Gly1ORF1 binding to E. coli 
cells at the time points after 
induction. Samples taken before 
induction were used as a 0% 
reference. The graph shows results of 3 independent experiments with error bars 
showing SEM. The results with an asterix were statistically significant when analysed 
using the student t-test. 
 
In summary, in this subsection hmbR was successfully cloned and expressed in 
E. coli BL21Star(DE3) cells and the haem binding and Congo red binding 
assays show that the receptor is functional. The data of the experiments with 
Gly1ORF1 binding to the whole E. coli cells expressing hmbR shows some level 
of Gly1ORF1 binding compared to the cells with an empty vector. This opens a 
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possibility of further studies on Gly1ORF1 being involved in the iron acquisition 
in Neisseria spp.  
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CHAPTER 4 IMMUNOLOGICAL STUDIES 
ON GLY1ORF1 
4.3 Introduction  
After many years of research, in January 2013 a new MenB vaccine – 4CMenB 
was licensed by the European Commission for children older than 2 months. 
The vaccine is a result of a novel approach in vaccine design, called reverse 
vaccinology. The vaccine candidates were selected after in silico search for 
surface exposed and potentially immunogenic antigens with a high degree of 
sequence similarity within the genome of the MC58 strain. The aim was to find 
the surface exposed antigens that would confer broad strain coverage.  
According to the study by Vogel and co-workers, the 4CMenB vaccine could 
protect only against 78% percent of MenB strains in Europe (Vogel et al., 2013). 
The data show clearly that there is still a need for the development of a more 
effective vaccine, with higher strain coverage and ideally, with cross-protective 
activity also to other serotypes that would enable eliciting herd-immunity 
similarly to widely used MenC vaccine. The search for surface-exposed 
antigens that are highly conserved in Neisseria spp. and are able to induce a 
long-term antibody response still continues. There are many genes in the 
neisserial genome that could meet the criteria but remain largely 
uncharacterised. 
One such protein is Gly1ORF1 which is a subject of this study. Gly1ORF1 is a 
small, positively charged protein. According to the experiments performed in our 
lab, the protein expressed in E. coli is secreted in the culture supernatant and 
present in outer membrane vesicles (Meadows, 2004; Sathyamurthy, 2011). 
Arvidson et al reported that the protein was also present in outer membrane 
preparations from N. gonorrhoeae (Arvidson et al., 1999). The analysis of 
neisserial isolates for the presence of Gly1ORF1 genes performed by Meadows 
showed that 96.7% of the tested isolates had the gly1ORF1 gene. The 
sequencing results revealed a high level of sequence conservation with many 
strains showing 100% sequence identity (Meadows, 2004).  
124 
 
In addition, an analysis of the gene prevalence in the neisserial genome 
database confirmed presence of the gene in sequences of over 200 clinical 
isolates with a high degree of sequence homology (Sayers, unpublished data).  
The initial experiments done by Sathyamurthy showed that antibodies raised 
against Gly1ORF1 have detectable bactericidal activity against the MC58 strain 
of N. meningitidis (Sathyamurthy, 2011). The results encouraged further studies 
on Gly1ORF1 immunogenic properties.  
Results from our laboratory suggested that Gly1ORF1 is immunogenic as the 
generation of anti-Gly1ORF1 sera resulted in a high antigenic response in 
rabbit. This chapter focuses on testing if high antibody levels against Gly1ORF1 
could be detected in sera of patients diagnosed with meningococcal infection 
and if the incidence of the invasive disease resulted in the increase in anti-
Gly1ORF1 antibody levels after a month long convalescence. Also, the study 
tried to establish if a carriage state could result in increased antibody levels to 
Gly1ORF1. In order to test that, sera of 96 patients with no suspected 
meningococcal infection were screened for an increased response to 
Gly1ORF1.  
To test if antibodies raised against-Gly1ORF1 can confer a protective 
bactericidal activity, a serum bactericidal assay was performed with Gly1ORF1 
anti-sera and affinity purified antibodies. This method is a gold standard for 
evaluation of potential vaccine candidates (Borrow et al., 2005b). The principle 
of the method is to test if antibodies against the target antigen can kill bacteria 
in presence of the exogenous complement source.  
In order to activate complement mediated killing via the classical pathway, an 
antigen must be surface exposed to allow the recognition by the protective 
antibodies. To evaluate if Gly1ORF1 meets this criterium, several approaches 
were undertaken to detect expression of the protein in several neisserial 
isolates including western blot analysis of outer membrane vesicles and whole 
cell lysates, Whole Cell ELISA and FACS analysis. 
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4.4 Results and Discussion 
4.4.1 Levels of anti-Gly1ORF1 antibodies in sera of septic patients and 
volunteers with no suspected meningococcal infection 
Sera from 6 patients (aged 22-43 years) with acute meningococcal septicaemia 
taken on admission to hospital and one month after infection were screened by 
enzyme-linked immune-absorbent assay (ELISA) for the presence of antibodies 
raised against Gly1ORF1 and NM MC58 outer membrane vesicles (OMVs) 
which served as a positive control for the assay (see Materials and Methods 
Section 7.11.2). The aim of the experiment was to establish whether exposure 
to meningococcal infection is associated with increased levels of antibodies to 
Gly1ORF1 during and after the infection. 
Serum of one of 6 patients (Fig. 4.1; Patient 2) showed a response to 
Gly1ORF1 comparable to the response against OMVs. There was no obvious 
difference between samples taken during acute infection and one month post-
infection. There was some increased response against Gly1ORF1 in Patient 4. 
Sera from those two patients were tested at higher dilutions to determine the 
antibody titres against Gly1ORF1 alongside a serum sample from a healthy 
volunteer with no history of meningococcal infection which was used as a 
control (Fig. 4.2). 
Patient 2 showed a positive response to Gly1ORF1 and OMVs for serum 
dilutions up to 1:160. An antibody titre against Gly1ORF1 in patient 4 was 
determined to be 1:80 compared to the MC58 OMVs titre which was 1:320. The 
healthy volunteer exhibited a titre against OMVs higher than 1:500, whereas 
some response to Gly1ORF1 was observed only up to a 1:20 dilution. This 
finding was similar to the response of remaining septic patient samples tested in 
the initial screen. The presence of antibodies to Gly1ORF1 was detected in two 
out of 6 septic patients indicating that Gly1ORF1 is able to induce immunogenic 
response in some cases. No information was available about the strains 
causing the meningococcal infection in tested patients. It is possible that levels 
of expression of Gly1ORF1 vary from strain to strain and can be also influenced 
by the host-pathogen interactions, hence the low response to Gly1ORF1 was 
observed in the remaining patients. 
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Figure 4.1 Results of initial ELISA screen for antibody response to Gly1ORF1in 
sera from 6 patients with acute septicaemia  
Sera were taken on admission to hospital (PRE) and one month after infection 
(POST).Test performed in triplicate at each serum dilution. The anibody response to 
Gly1ORF1 (5 µg/ml) and NM MC58 outer membrane vesicles (OMV – 1 µg/ml) was 
measured in triplicate. The error bars indicate SEM.  
127 
 
 
Figure 4.2 Results for ELISA antibody titres against Gly1ORF1 and MC58 OMV 
in human sera. 
Sera from two septic patients and one healthy volunteer were tested in serial two-fold 
dilution in triplicate. Error bars indicate SEM. 
 
In order to determine what is the prevalence of increased antibody response to 
Gly1ORF1 in the healthy population, sera of 96 patients with no suspected 
meningococcal infection were initially screened at 1:20 dilution to select 
samples with highest response for further analysis. The mean and standard 
deviation were calculated for the population of 96 serum samples. Samples with 
response to Gly1ORF1 higher than one standard deviation were tested at 
higher dilutions to determine antibody titres against Gly1ORF1. Outer 
membrane vesicles of NM MC58 were used as a positive control for the assay. 
The tested samples were obtained from individuals at the age of 18-50. The 
report by Health Protection Agency shows that mean antibody titres against 
OMV from serogroup B meningococci vary between different age groups. The 
anti-OMV IgG reach a maximum level in individuals at the age of 19 (geometric 
mean titre over 70) and remain fairly high in older age groups (geometric mean 
titres varying from 50-75) (Trotter et al., 2007a). The antibody titres vary from 45 
to 75. It was expected that in the population of the tested samples there would 
be a high response to outer membrane vesicles. 
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Figure 4.3 Analysis of presence of Gly1ORF1 antibodies in cohort of 96 patients 
with no suspected meningococcal infection. 
A. An initial ELISA screen for samples with highest response to Gly1ORF1. MC58 
OMV served as positive control. Sera were tested at 1:20 dilution. The graph shows 
means of three repeats and error bars show one standard deviation. B. Comparison of 
response to OMV and Gly1ORF1 in positive samples. C. ELISA: anti-Gly1ORF1 titre 
measurement in selected samples. The graph shows the means of three repeats with 
error bars showing SEM 
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In the initial screen, 7 out of 96 non-septic patients (7.3%) showed higher than 
one standard deviation response to Gly1ORF1. All selected samples had higher 
response to Gly1ORF1 than to control MC58 OMV apart from sample number 4 
which was just on the border line of standard deviation (Fig. 4.3, Panel B.). 
Additional ELISA confirmed high anti-Gly1ORF1 antibody titres for 5 out of 7 of 
the selected samples, where 3 of them showed a response up to a serum 
dilution of 1:320 and 2 of them at a dilution of 1:160 (Fig. 4.3, Panel C.). It is 
possible that two of the samples which in the initial screen gave positive result 
were sensitive to freeze-thaw cycle and lost the ability to interact with 
Gly1ORF1.  
In summary, 5 out of 96 samples (5.21%) showed higher than one standard 
deviation response to Gly1ORF1. Results from this screen showed that 
Gly1ORF1 antibody levels can be increased even in people who were never 
diagnosed with meningococcal infection. It is possible that positive samples 
came from individuals with previous episodes of N. meningitidis carriage. This 
indicates that exposure to Gly1ORF1 expressed in N. meningitidis can induce 
human antibody response. 
 
4.4.2 Evaluation of serum bactericidal activity of anti-Gly1ORF1 
antibodies 
One of the essential properties of a vaccine candidate is its ability to induce 
production of protective antibodies against the target organisms. This can be 
assessed by a serum bactericidal assay (SBA). This gold standard method tests 
the ability of antibodies raised against a target molecule to induce complement 
mediated killing of the pathogenic bacteria.  
Initial experiments in our lab showed that rabbit anti-Gly1ORF1 affinity-purified 
antibodies are able to induce serum bactericidal activity (Sathyamurthy, 2011). 
The aim of this study was to determine the SBA titres for the Gly1ORF1 
antisera and test whether there is a difference in the antibody titres in control 
sera from mice injected with PBS. For the purpose of this experiment 6 mice 
were immunised with Gly1ORF1. Three control mice were immunised with PBS 
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(see Materials and Methods Section 7.11.1). Purification of the antigen for 
immunisation and initial screen of mouse anti-sera were performed by Dr 
Rachel Walton. Immunisation and mouse blood collection was performed at 
BioServe UK Ltd at the University of Sheffield.  
The antibody titres of pooled sera against Gly1ORF1 from 6 immunised mice 
were measured by ELISA as described in Materials and Methods Section 
7.11.1. Results showed that mouse Gly1ORF1 anti-sera a showed detectable 
response to the protein even above 104 serum dilution (Fig. 4.4) 
 
Figure 4.4 Antibody titres in mouse sera 
raised against Gly1ORF1. 
Titres were determined by ELISA using 
purified Gly1ORF1 at the concentration of 5 
µg/ml. An average of n=2 was plotted on the 
graph with error bars indicating SEM. 
 
 
According to the Health Protection Agency standards, anti-sera tested with 
human complement that exhibit higher than 50% killing rate at 1:4 dilution or 
higher are considered bactericidal (Borrow et al., 2005a). In order to test if sera 
raised against Gly1ORF1 were able to mediate complement mediated killing, a 
serum bactericidal assay (SBA) was performed as described in Materials and 
Methods Section 7.11.3. The SBA results with mouse anti-sera confirmed that 
Gly1ORF1 antibodies are able to induce complement-mediated killing of NM 
MC58 (Fig. 4.5; Tab. 4.1). De-complemented mouse anti-Gly1ORF1 sera 
showed killing above 50% for serum dilution up to 1:16 when tested with human 
complement. There was statistically significant difference in killing rate between 
anti-Gly1ORF1 and anti-PBS sera for dilutions up to 1:128. All controls with 
bacteria only, bacteria and human complement and anti-sera with heat-
inactivated human complement were done. The results clearly show that anti-
Gly1ORF1 antibodies have bactericidal effect on N. meningitidis.  
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Figure 4.5 Summary of SBA results for mouse anti-Gly1ORF1 and PBS sera 
against wild-type NM MC58 tested with human complement.  
Mean results plotted from 3 to 6 replicates for each dilution with error bars showing 
SEM. Statistical analysis of the results is shown in Table 4.2. 
 
 
Table 4.1 Statistical data analysis of SBA results for mouse sera against Gly1ORF1 
and PBS sera*  
Sidak's multiple comparisons 
test 
Mean 
Diff. 95% CI of diff. Significant? Summary 
Adjusted P 
Value 
Mouse anti-Gly1 serum –  
Mouse PBS serum 
     4 41.65 17.24 to 66.06 Yes **** < 0.0001 
8 43.59 19.18 to 67.99 Yes **** < 0.0001 
16 39.74 15.33 to 64.14 Yes *** 0.0002 
32 26.40 7.104 to 45.69 Yes ** 0.0022 
64 27.29 7.992 to 46.58 Yes ** 0.0015 
128 22.48 3.181 to 41.77 Yes * 0.0132 
256 14.36 -10.05 to 38.76 No ns 0.5929 
512 8.488 -15.92 to 32.89 No ns 0.9685 
1024 4.350 -20.06 to 28.76 No ns 0.9998 
* Data analysed using Two Way Anova test with Sidak’s multiple comparison. 
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Another aim of the experiment was to check if there were differences between 
the wild-type and ΔGly1ORF1 isogenic mutant of NM MC58 in susceptibility to 
bactericidal activity of Gly1ORF1 antibodies. The limited volume of mice anti-
sera available was not sufficient for further experiments, so rabbit anti-sera 
against Gly1ORF1 were tested in the SBA against the wild-type MC58 to 
provide further data. 
 
Figure 4.6 Serum bactericidal assay with rabbit Gly1ORF1 anti-sera.  
A. Colony forming counts (CFUs) from one representative experiment showing controls 
with bacteria only (bugs), bacteria and heat inactivated human complement (HI HC), 
bacteria with human complement (HC) and bacteria with first tested dilution of rabbit 
antisera and heat inactivated human complement (x32 HI HC). B. Summary of 
experiments showing percentage of killed bacteria at serial two-fold dilutions of rabbit 
Gly1ORF1 anti-sera. The percentage of killing was calculated using the sample of 
bacteria with complement only (HC) as a baseline. Each dilution was tested in three to 
six replicates. 
 
Rabbit Gly1ORF1 anti-serum showed very high SBA titres – up to 1:2048 (Fig. 
4.6). The difference in SBA titres of mice and rabbit antisera against the same 
antigen could be caused by the differences in the solubility of the antigen used 
for immunisation. Rabbit anti-sera were raised against an insoluble form of 
Gly1ORF1 which can be more immunogenic (Hermeling et al., 2004). In 
contrast, mice were injected with soluble Gly1ORF1 which could confer lower 
immunogenicity. According to Dr Myron Christodoulides from the University of 
Southampton (verbal communication) rabbit anti-sera can also show high 
background in serum bactericidal assays. Rabbit anti-Gly1ORF1 sera were 
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generated before the experiment was planned and no sample of serum before 
immunisation was available for testing to compare SBA before and after 
immunisation. Thus, it was impossible to check if unimmunised rabbit’s serum 
possessed bactericidal activity that could add to Gly1ORF1 antibodies 
bactericidal effect on Neisseria meningitidis.  
To compare wild-type and Gly1ORF1 knock-out MC58 susceptibility to 
bactericidal effect of Gly1ORF1, rabbit antibodies were affinity purified using 
Gly1ORF1 immobilised on cyanogen-bromide activated agarose beads as 
described in Materials and Methods Section 7.10.3.2). Purified antibodies were 
tested at two-fold serial dilutions starting from 1:20. Results for the assay are 
shown in Figure 4.7 and Table 4.2. 
 
Figure 4.7 Serum bactericidal assay results: comparison of bactericidal activity of 
anti-Gly1ORF1 rabbit affinity purified antibodies against wild-type and 
ΔGly1ORF1 MC58 mutant.  
Results show the means from three individual experiments with error bars showing 
SEM. Results of the statistical analysis of the results is shown in Table 4.2. 
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Table 4.2 Statistical analysis of SBA results for rabbit polyclonal antibodies tested 
against WT and Gly1ORF knock-out*. 
Sidak's multiple  
comparisons test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value 
WT - KO 
     20 24.55 4.382 to 44.71 Yes * 0.0119 
40 20.56 0.3980 to 40.73 Yes * 0.0441 
80 31.58 11.41 to 51.74 Yes ** 0.0011 
160 32.31 12.15 to 52.48 Yes *** 0.0009 
320 28.86 4.169 to 53.56 Yes * 0.0165 
640 30.40 5.705 to 55.10 Yes * 0.0109 
*Data analysed using Two Way Anova test with Sidak’s multiple comparison. 
 
Results of SBA assay showed that the difference in killing between wild-type 
and Gly1ORF1 knock-out MC58 was statistically significant. The wild-type was 
more susceptible to killing than the knock-out MC58. There was some 
background killing of the knock-out in the first tested dilutions. However, as the 
antibodies used for the assay were at high concentration (0.8 mg/ml) they could 
show some hydrophobic interaction with the surface of knock-out bacteria and 
activate complement-mediated killing in a non-specific manner. At 1:80 dilution, 
the antibodies showed no killing of the knock-out and at higher dilutions bacteria 
were not affected by the presence of the antibodies and their number increased 
after incubation, whereas wild-type MC58 numbers at these dilutions were still 
reduced. This was presumably because the knock-out bacteria were able to 
continue to replicate in the course of the assay whereas wild type had been 
killed. Although percentage of killed wild-type NM MC58 is significantly higher 
than killing of Gly1ORF1 knock-out, it did not reach the 50% killing rate and is 
lower than the results previously described by Sathyamurthy. It is possible that 
affinity purification of antibodies in harsh conditions resulted in some level of 
denaturation which can vary from batch to batch. Purified antibodies were still 
detecting Gly1ORF1; however, it could interact less efficiently with the 
complement system and be less effective in inducing killing of MC58. Also, the 
main drawback of the SBA method is low reproducibility due to the differences 
in the antibody levels between complement donors, media used for bacterial 
growth before the assay and length of the incubation. (Andrews and Pollard, 
2014). The main outcome of this experiment is confirmation of the ability of 
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Gly1ORF1 antibodies to induce complement-mediated killing by targeting 
Gly1ORF1. It can be also concluded that Gly1ORF1 is expressed on the 
surface of the cells as the wild-type MC58 was interacting with the anti-
Gly1ORF1 antibodies much more effectively than the Gly1ORF1 knock-out. 
 
4.4.3 Confirmation of surface localisation of Gly1ORF1 in N. meningitidis 
To effectively induce complement mediated killing, an antigen used for 
immunisation must presumably be surface exposed on the pathogen to enable 
activation of the complement cascade. In order to check if Gly1ORF1 can be 
detected on the surface of the bacteria, outer membrane vesicles were purified 
and subjected to western blot with anti-Gly1ORF1 antibodies as well as whole-
cell lysates. Another approach included a whole-cell ELISA with immobilised 
pasteurised neisserial cells and FACS analysis of neisserial cells with 
Gly1ORF1 antibodies and fluorescently labelled secondary antibody. 
 
Figure 4.8 Detection of Gly1ORF1 by western 
blot in outer membrane vesicles of neisserial 
isolates. 
The OMVs were isolated from: wild type NM 
MC58, isogenic Gly1ORF1 mutant (ΔGly1ORF1 
MC58), NM strain H44/76 and N. gonorrhoeae 
MS11. Purified Gly1ORF1 C-histidine tag was 
used as a reference. A 10 µg aliquot of purified 
OMV was loaded in each lane. Arrows indicate 
protein bands at the similar size to Gly1ORF1 
 
 
Analysis of western blots with outer membrane vesicles isolated from different 
strains of Neisseria spp. showed very faint bands corresponding to Gly1ORF1 
size for WT MC58 and NG MS11 (Fig. 4.8). Gly1ORF1 knock-out outer 
membrane vesicle showed proteins at higher molecular weight than Gly1ORF1, 
but no protein at the same size. Outer membrane vesicles of strain H44/76 
showed a band running slightly lower than proteins detected in WT MC58 and 
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NG MS11. Higher molecular weight proteins at approximately 30 kDa were 
observed for all tested strains probably showing some nonspecific interactions. 
The results indicate that Gly1ORF1 is probably expressed at a very low level 
and is not readily detectable by western blot or the antibodies are not sensitive 
enough to detect the antigen under the conditions used to culture the bacteria. 
 
Figure 4.9 Immunoblot of the whole cell lysates of N. meningitidis strains with anti-
Gly1ORF1 antibodies. 
Panel A. contains lysates of laboratory strains: wild type NM MC58 (Lane WT), 
isogenic mutant ΔGly1ORF1 MC58 (Lane KO) and NM strain H44/76. In Panel B, 
Lanes 1-6 represent cell lysates of clinical isolates NM1, 2, 3, 5, 6 and 7 respectively; 
Lane 7 – shows control with purified Gly1ORF1. Protein bands at Gly1ORF1 size are 
indicated with arrows. 
 
Western blot analysis of whole-cell lysates showed a detectable band at 
approximately 17 kDa that was not detected in ΔGly1ORF1 MC58 (Fig. 4.9, 
Panel A, Lane WT and H44/76). It could be unprocessed version of Gly1ORF1. 
Analysis of ten times concentrated liquid culture supernatants did not show 
obvious presence of Gly1ORF1 (data not shown). It was previously described 
that in NG MS11 Gly1ORF1 was only detected in concentrated outer membrane 
vesicles when 20 µg of isolated outer membrane vesicles was loaded in a lane 
(Arvidson et al., 1999). However, due to the high viscosity of outer membrane 
fraction the amount of OMV was limited to 10 µg in this experiment. According 
to the literature, Gly1ORF1 expression could be up-regulated upon contact with 
host cells (Deghmane et al., 2003) so one can conclude that the growth 
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conditions of analysed neisserial strains were not optimal for high levels of 
Gly1ORF1 expression. 
A whole-cell ELISA experiment with immobilised cell suspensions of neisserial 
isolates (see Materials and Methods Section 7.11.4) gave very low signal with 
anti-Gly1ORF1 antibodies (Fig. 4.10). The capsule knock-out version – C13 
gave slightly higher signal than MC58 WT indicating that presence of the 
capsule may mask Gly1ORF1 interactions with antibodies. The whole-cell 
ELISA experiment did not give convincing results for the detection of 
Gly1ORF1.  
 
 
 
Figure 4.10 Detection of Gly1ORF1 on the cell surface by a whole-cell ELISA 
approach.  
Pasteurised cell suspensions of NM MC58, Gly1ORF1 knock-out MC58, NM H44/76, 
capsule deficient mutant-C13 and purified Gly1ORF1 (5 µg/ml) as a positive control for 
the assay were tested with different dilutions of affinity purified anti-Gly1ORF1 
antibody stock at the concentration of 0.8 mg/ml. 
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4.4.4 FACS analysis of neisserial isolates 
Another approach to detect Gly1ORF1 on the surface of the cells was 
undertaken using the method described by Hung and co-workers (Hung et al., 
2013). Neisserial strains were first treated with ethanol to permeabilise the 
capsule and probed with antibodies against the target antigen followed by 
addition of fluorescently labelled secondary antibody as described in Materials 
and Methods Section 7.11.5). In this experiment purified rabbit anti-Gly1ORF1 
antibodies were used. As a positive control for the experiment antibodies 
against alpha protein of IgA1 protease were used. Previous experiments in our 
lab performed by Parsons (Parsons, 2003) demonstrated that the majority of the 
tested neisserial strains showed considerable shifts in fluorescence when 
exposed to anti-alpha affinity purified rabbit antibodies. 
 
 
 
Figure 4.11 FACS analysis of presence of Gly1ORF1 on the cell surface. 
MC58 WT, Gly1ORF1 knock-out and NM H44/76 were exposed to purified rabbit anti-
Gly1ORF1 antibodies and FITC-labelled secondary antibody. Anti-alpha antibodies 
were used as a positive control of the assay.  
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Figure 4.12 Analysis of FACS results with three strains of N. meningitidis.  
A. Comparison of percentage of FITC-positive population after incubation with anti-
Gly1ORF1 or anti-alpha antibodies (positive control) and FITC-labelled secondary 
antibody. B. FACS results with anti-Gly1ORF1 antibodies with results of statistical 
analysis using t-test. Data shows results of three independent experiments with error 
bars showing SEM. 
 
Results of the experiment showed very low levels of fluorescence shift when 
testing neisserial strains with anti-Gly1ORF1 antibodies. Wild-type MC58 
showed comparable level of the shift to Gly1ORF1 knock-out. Another tested 
strain – H44/76 showed higher level of fluorescent shift compared to wild-type 
and knock-out MC58, however the difference was not statistically significant. 
(Fig. 4.11 and 4.12). In contrast, anti-alpha antibodies showed almost complete 
fluorescence shift for all of the strains. 
Six clinical strains were also tested using the FACS method to check if there is 
a difference in levels of detectable Gly1ORF1 in carriage strains and strains 
from systemic blood infection. Isolates NM1 to 5 were associated with carriage 
whereas isolates NM6 and NM7 were invasive strains isolated from blood. All 
clinical strains showed very low (lower to ΔGly1ORF1 MC58) shift in 
fluorescence when probed with anti-Gly1ORF1 antibodies and almost complete 
shift with anti-alpha antibodies (apart from isolate NM7 which show only partial 
shift). A negative control with Streptococcus isolate showed no shift with either 
of the tested antibodies (Fig. 4.13, Fig. 4.14).  
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Figure 4.13 FACS analysis of Gly1ORF1 presence on the surface of neisserial 
clinical isolates.  
The bacterial suspensions were first treated with ice-cold ethanol to permeabilise the 
capsule and then probed with anti-Gly1ORF1 antibody, followed with anti-rabbit FITC 
labelled secondary antibody. The data were collected on FACS LSRII machine at the 
Flow Cytometry Core Facility at the University of Sheffield. The negative control 
contained suspension of Streptococcus spp. treated in the same way as neisserial clinical 
isolates. 
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Figure 4.14 FACS analysis of alpha protein presence on the surface of neisserial 
clinical isolates.  
The bacterial suspensions were also treated with ethanol first, then probed with anti-
Gly1ORF1 antibody, followed with anti-rabbit FITC labelled secondary antibody. The 
data were collected on FACS LSRII machine at the Flow Cytometry Core Facility at the 
University of Sheffield. All isolates apart from NM7 showed complete shift in 
fluorescence. The shift was only partial, which might indicate lower levels of protein 
expression in this isolate. The negative control contained suspension of Streptococcus 
spp. treated in the same way as neisserial clinical isolates. 
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To examine whether gly1ORF1 gene was present in the genomes of the clinical 
isolates, genomic DNA was used as a template for PCR with primers designed 
for gly1ORF1 region: Gly1KOF- 5’-GCCGACGGCAAAACGGTTCA-3’ and 
Gly1KOR-5’-CCAAACCGGCAGGCGCAAA-3’. Analysis of PCR products 
showed presence of the fragment at the same size as in MC58 WT for all 
clinical isolates and H44/76 strain. Gly1ORF1 knock-out, as expected, was at 
higher molecular weight due to the insertion of erythromycin cassette performed 
by Sathyamurthy (Sathyamurthy, 2011) (Fig. 4.15).  
 
 
Figure 4.15 PCR products using genomic DNA of neisserial isolates and primers 
designed for Gly1ORF1 region.  
Genomic DNA was isolated from the neisserial laboratory strains: wild type MC58 
(WT), ΔGly1ORF1 MC58 (KO) and H44/76 and clinical isolates: NM1, NM2, NM3, 
NM5, NM6 and NM7. Lane M contains a DNA size marker.  
 
4.4.5 SBA assay: MC58 WT vs. H44/76 
A higher fluorescence shift of H44/76 with Gly1ORF1 antibodies compared to 
MC58 and western blot analysis of cell lysates and outer membrane fractions 
with detectable bands corresponding to Gly1ORF1 size indicates that the levels 
of gly1ORF1 expression might be higher in this isolate than in MC58 and can 
reach detection level. To investigate whether higher levels of Gly1ORF1 protein 
in H44/76 strain correlates with higher susceptibility to complement mediated 
killing, a serum bactericidal assay with H44/76 and MC58 strain was done as 
described before. 
Although there was a visible difference between MC58 and H44/76 in the 
percentage of killed bacteria at antibody dilutions up to 1:80, an analysis 
showed that the differences are not statistically significant (Fig. 4.16, Tab. 4.3). 
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Figure 4.16 Serum bactericidal assay with anti-Gly1ORF1 antibodies – 
comparison of MC58 and H44/76 strains.  
The data show results from three individual experiments. Anti-Gly1ORF1 antibodies 
stock at 0.8 mg/ml concentration was used. Statistical analysis using Sidak’s multiple 
comparison test showed that the differences in percentage of killing for all antibody 
dilutions are not statistically significant. Error bars show SEM. The results of the 
statistical analysis are shown in Table 4.3. 
 
Table 4.3 Statistical analysis of SBA test for strains MC58 and H44/76* 
Sidak's multiple 
comparisons test 
Mean 
Diff. 95% CI of diff. Significant? Summary 
Adjusted P 
Value 
MC58 - H44/74 
     x10 -18.99 -54.85 to 16.87 No ns 0.5932 
x20 -23.53 -55.61 to 8.543 No ns 0.2423 
x40 -19.22 -51.30 to 12.86 No ns 0.4565 
x80 -9.132 -41.21 to 22.94 No ns 0.9611 
x160 8.327 -23.75 to 40.40 No ns 0.9751 
x320 0.6544 -38.63 to 39.94 No ns > 0.9999 
Data analysed using Two Way Anova test with Sidak’s multiple comparison. 
 
In summary, Gly1ORF1 meets criteria for a vaccine candidate with regards to 
ability to induce antibody response in some individuals during meningococcal 
infection and there is some level of response to Gly1ORF1 in sera from 
population of patients with no meningococcal disease which could be a result of 
carriage. As serum bactericidal activity is regarded as a serological surrogate of 
protection against meningococcal infection (Borrow et al., 2005b), (Frasch et al., 
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2009), it might be indicative that antibodies against Gly1ORF1 might have 
protective effect. The methods used for detecting Gly1ORF1 on the bacterial 
surface gave inconclusive results probably due to the low sensitivity of affinity-
purified antibodies and/or low levels of gly1ORF1 expressed under the 
conditions used to culture the bacteria in the laboratory. The observation that 
WT MC58 is much more susceptible to complement killing upon addition of anti-
Gly1ORF1 antibodies indicates that the antigen is expressed and surface 
exposed in MC58 WT. It can be also concluded that expression of Gly1ORF1 
can be induced in the presence of human serum proteins during SBA assay or 
other host related factors. It would be worth exploring in which conditions the 
synthesis of Gly1ORF1 is up-regulated. An alternative approach for detection of 
gly1ORF1 expression could be a real-time PCR, which in theory is more 
sensitive. Bacteria grown in the optimal conditions for Gly1ORF1 expression 
could be than tested again with methods described in this study. Another 
approach would be generation of monoclonal antibodies with higher affinity to 
Gly1ORF1 which would allow detection of much lower protein levels. The 
project to generate monoclonal antibodies was undertaken in our lab by Dr R. 
Walton with the help of BioServe UK Ltd, however, hybridoma clones generated 
either lost the ability to produce the antibodies or the antibodies were found to 
interact with the histidine tag and linker region of the recombinant protein used 
to immunize mice (data not shown). 
4.4.6 Immunological studies on IgA1 alpha protein 
Antibodies against IgA1 alpha protein were used in this study as a positive 
control for FACS analysis of Gly1ORF1 presence on the surface of the 
neisserial strains. FACS results with anti-alpha antibodies showed in all tested 
neisserial isolates almost complete shift of fluorescence indicating detectable 
levels of protein present on the surface of the cell (Fig. 4.20). These interesting 
results prompted further immunological studies on this protein with similar 
methods used for Gly1ORF1 analysis. Initial analysis included testing human 
sera for presence of anti-alpha antibodies, whole-cell ELISA, western blot 
analysis of cell lysates and outer membrane vesicles as well as ability to induce 
serum bactericidal activity.  
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ELISA with sera from two septic patients and one healthy volunteer showed 
high antibody levels to alpha protein (Fig. 4.17). Two septic patients had 
antibody titres comparable to a response to outer membrane vesicles. 
Surprisingly, the healthy volunteer showed a much higher response to alpha 
protein exceeding a serum dilution of 1:1280. This may indicate that antibody 
production against alpha protein can be induced during carriage. 
 
 
Figure 4.17 ELISA analysis of antibody response against purified NMB alpha 
protein (5 µg/ml) and OMVs (1 µg/ml)  
Sera from two septic patients and one healthy volunteer were tested in serial two-fold 
dilutions.Error bars show SEM. Controls PBS are shown in the graph. Means of two 
replicates are plotted with error bars showing SEM, n=3. 
 
 
It was already demonstrated that alpha protein can be detected with anti-alpha 
antibodies by FACS. The results were also confirmed by the whole-cell ELISA 
method. MC58 WT and H44/76 showed comparable levels of detected alpha 
protein. Higher response was observed for capsule deficient mutant C13. 
Similar effect was observed in the whole-cell ELISA with anti-Gly1ORF1 
antibodies. Surprisingly, Gly1ORF1 knock-out mutant showed much higher 
response to alpha antibodies than other tested strains (Fig. 4.18). Gly1ORF1 
knock-out was cultured on CBA plates containing erythromycin and it is possible 
that although the bacteria had an erythromycin resistance gene, the presence of 
the antibiotic affected bacterial gene expression profile or bacterial surface. 
  
146 
 
 
 
Figure 4.18 Detection of alpha protein on the cell surface by whole cell ELISA 
approach.  
Pasteurised cell suspensions of NM MC58, Gly1ORF1 knock-out MC58, NM H44/76, 
capsule deficient mutant of C13 and positive control with purified immobilised alpha 
protein were tested with different dilutions of affinity purified anti-alpha antibodies at 
the stock concentration of 0.11 mg/ml. 
 
Previously performed western blots with anti-alpha antibodies using cell lysates 
of the number of clinical isolates detected expression of alpha protein in 
majority of them (Parsons, 2003). Isolates from the laboratory stocks and 
clinical isolates analysis were similarly tested for presence of alpha protein. All 
isolates apart form H44/76 and NM7 showed detectable levels of a protein at 
the size of long alpha protein (Fig. 4.19).  
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Figure 4.19 Immunoblot of cell lysates of neisserial isolates with anti-alpha 
antibodies.  
Cell lysates of neisserial laboratory isolates: wild type MC58 (WT), ΔGly1ORF1 MC58 
(KO), H44/76 and six clinical isolates (NM1-NM7) were separated in SDS-PAGE gel 
next to the reference lanes containing purified MC58 alpha protein and NMB alpha 
protein. Alpha proteins were detected by western blot using anti-alpha polyclonal 
antibodies. An arrow indicates the bands corresponding to the long alpha protein. Other 
proteins with lower molecular weight may be a product of auto-proteolytic activity of 
IgA1 protease resulting in shorter fragments of alpha protein. Proteins with higher 
molecular weight than long alpha protein may be a result of incomplete proteolytic 
cleavege such as γ-alpha fragments. 
 
Finally, the serum bactericidal activity of anti-alpha antibodies was tested using 
affinity-purified rabbit antibodies. Results of the assay showed significant killing 
of NM MC58 WT with an antibody dilution at 1:20 (Fig.4.20). Further dilutions of 
the antibodies showed a reduction in percentage of killed bacteria. Controls with 
heat-inactivated human complement and first dilution of the antibody showed 
that the antibodies itself have no bactericidal activity as well as human 
complement itself as the colony forming units counts are similar for all the 
controls. It is worthy of note, that the percentage of killing is much higher than 
with anti-Gly1ORF1 antibodies even though the starting concentration of the 
antibodies was lower. Anti-Gly1ORF1 antibodies stock concentration was 0.8 
mg/ml and anti-alpha antibodies only 0.11 mg/ml.  
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Figure 4.20 Serum bactericidal activity of rabbit anti-alpha affinity purified 
antibodies with human complement.  
A stock concentration of anti-alpha antibodies used for the assay was 0.11 mg/ml. A. 
Changes in cfu counts upon treatment with anti-alpha antibody and human complement. 
Controls with heat-inactivated complement (HI HC), active human complement (HC) 
and heat-inactivated human complement with first dilution of the antibodies (20 HI HC) 
are shown. The data shown are from one out of three individual experiments. B. Mean 
percentage of killed bacteria from three individual experiments with affinity purified 
anti-alpha antibody. Error bars show SEM. 
 
The higher efficacy of anti-alpha antibodies in the SBA can be explained by 
higher concentrations of alpha-protein on the cell surface. This was confirmed 
by ELISA, western blots and FACS analysis performed in this study. IgA1 
protease was previously identified in microarray and proteomic analysis of 
neisserial proteins (Dietrich et al., 2003; Echenique-Rivera et al., 2011; Ferrari 
et al., 2006) and analysis of the protein content of outer membrane vesicles 
(Lappann et al., 2013), whereas Gly1ORF1 was not mentioned in those studies 
probably due to the low level of expression.  
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CHAPTER 5 CHARACTERISATION OF 
GLY1ORF1 HOMOLOGS 
5.5 Introduction 
The Gly1ORF1 protein sequence is very highly conserved in Neisseria spp. The 
closest sequence homolog from outside of the genus has been identified in 
Haemophilus sputorum (51% identity) The PSI-BLAST algorithm allows the 
identification of distant relatives of the protein by using a custom, position-
specific, scoring matrix (Altschul et al., 1997). The database search done 
previously by Sathyamurthy (Sathyamurthy, 2011) identified many interesting 
proteins encoded in the genomes of Proteo- and Cyanobacteria which colonise 
a wide range of organisms, from humans and mammals to fish and even hydra. 
As the database is constantly updated with new genome sequences, 
subsequent searches resulted in new, potentially interesting proteins.  
This study focuses on proteins encoded by the genomes of Mannheimia 
haemolytica, which is a known cattle pathogen residing in the respiratory tract, 
and Haemophilus influenzae, a common human pathogen that colonises similar 
niches to N. meningitidis, and is also a major causative agent of septicaemia 
and meningitis.  
The main aim of this study was to solve the crystal structures of the selected 
proteins to check if the novel fold found in the neisserial Gly1ORF1 structure is 
more widespread in the bacterial world, especially in pathogenic bacteria. This 
study also investigated if the selected proteins have similar functions to 
neisserial Gly1ORF1. The proteins were tested for the ability to bind haemin in 
vitro and interact with red blood cells. Finally, initial biophysical characterisation 
of the HinfGly1 protein, and the neisserial Gly1ORF1 paralog, were performed. 
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5.6 Results and Discussion 
5.6.1 Bioinformatics 
In order to identify distant relatives of Gly1ORF1 homologs, the PSI-BLAST 
algorithm was employed, and set to exclude the neisserial protein (Accession: 
NP_273818.1) (Altschul et al., 1997). Most of the results were hypothetical 
proteins from various Gram negative pathogenic bacteria. Several protein 
sequences were chosen for further analysis. These proteins were chosen based 
on the presence of an N-terminal signal peptide, and at least one predicted 
disulphide bond. The proteins are derived from pathogens which possess 
haemolytic activity and/or are responsible for septicaemia in either humans or 
animals. The development of animal models of septicaemia caused by 
pathogens expressing proteins homologous to the neisserial Gly1ORF1 protein 
would be beneficial in order to understand the role of this protein in neisserial 
infection. The multiple sequence alignment of several possible Gly1ORF1 
homologs identified in pathogenic microorganisms associated with septicaemia 
is shown in Fig. 5.1. Highly conserved residues (present in 50% or more 
analysed sequences) were identified on the structural model of Gly1ORF1 
K12A structure (Fig. 5.2) The results show that the majority of conserved 
residues are localised between two β-sheets of a single Gly1ORF1 monomer. 
This region of the protein might be important for the protein function or play a 
role in structural integrity of Gly1ORF1 protein family.  
The most interesting candidates for further study were proteins found in 
Haemophilus influenzae, a human pathogen that is one of the main causes of 
septicaemia, and Mannheimia haemolytica, a cattle pathogen that is also 
reported to cause septicaemia in sheep (Mackie et al., 1995).  
The search for Gly1ORF1 homologs and paralogs for further study was 
performed in April 2012. Since then, many new sequences appeared on the 
database; however, due to the time restrictions they were not investigated. The 
sequences were selected after five iterations. 
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Neis_meni    1 ----------ADTVFSCKTDNNKYIEVQKIN-----RNLYEYSFGSAA-KKEIAIR---- 
Manh_haem    1 ---------NNNVVYSCTTTDNQTLKVTKE------GGNYVYSHGNTTFKNPVKEA---- 
Hinf_infl    1 ----------ANNIFSCTAENGSPVSVTKN------GSDYEFTYGQVSFKNPVKQV---- 
Acin_niph    1 ----ACPSQSK-TVFNCTTTNNKVIQVCDA------GNTISYSFGKASAAPELAIT---- 
Vibr_n418    1 ----ASPSVFANTLFYCQTQSGKQVEVQDF------GSIIHYRFGKKLVEAELQLT---- 
Prot_mira    1 -------NTHTVTVFQCANKNQKQVNISLV------NEQYIYQFGKLNQKPDIIIT---- 
Ente_cloa    1 ---------NTELVFQCMTKSKKIIKIERT------DEILKYTYGNDKKNDLTLETRLFS 
Morg_morg    1 ------------QEFTCQLENNKYVSVVVEK-----GKTPAYRYGTLA-KPEITLP---- 
Prov_stua    1 -------NTHTVTVFQCVNKNQKKVNISLA------NGQYIYQFGKLNQKPDITMV---- 
Avib_para    1 ---------EDYIVFSCFTAKGKQIALIES------EGYYEYSFGKPG-KPELVFK---- 
Mora_capr    1 -----------ETVFLCDTTNGKQVKLIDN------GNSFTYEFSKGK-KTELNFS---- 
Pseu_M47T    1 STPPSNLCLDSVALFQCDTASGKQIALCGSYDAAGELSGLQYRYGRGP-QPELVYP---- 
Acti_pleu    1 ---------ENISIFSCTAEDGNQILIQKT------GADYQFSYGKILFKNPAKQV---- 
                           *&@   * * * & &         &  @ @*@&*   * *&        
 
Neis_meni   41 NSKADLLGRSDRWQG-MGSGRWATMKFQN----GEFMYTIWTGF-DSVT--HTESSGVVV 
Manh_haem   42 LKNP----ASEIAGG--SQFTTISLELRN----AGKSYIVGHIE-ADPKSPFEASVQIQD 
Hinf_infl   41 FANQ----DSYVATG--SGFITSSLEMRN----NGTSYTIQFVQ-PHNSNSIEE--PMLY 
Acin_niph   46 VPRD--KVTTYQWEG-FGRYENYAINIPN----GKTIYRVNDSL-DKMS--QEYTAGVEV 
Vibr_n418   47 VSRD--LASTYQWIG-AGSNEYYSVSIPNPSAQNAIVYRVFTSR-ERKPD-GKMESGIDV 
Prot_mira   44 RKPEQLEGRYLNPKGDTGTAQIYEMDFRN----GNYTYTISSSY-FDSK----HEALVDV 
Ente_cloa   46 EKIPTIFSSDVQLGNKSGPYVFNTVTFHN----GEYTYSVSALS-DINVPSDETFTGVYV 
Morg_morg   39 -VKGNAKNGVYVGQTMFSGGGSAYIRFEN----GPFNYVVYSGM-GRGW----EFTGLAV 
Prov_stua   44 RKPEQLAARYLTPKGDRFNGKIYEVDFRN----GDYTYTVSSSY-LDSK----HIAHVDV 
Avib_para   41 NKIADVEARSEKWNG-VGS-YWEAYNLKN----GQYYYVVYKSE-NRVSDEHEFSGGVTV 
Mora_capr   39 IAKHKIDYTEGAWKAESGYYWTMPYKGNTYTVFSSMINLDENSK-EFSEP--KKEAGVIV 
Pseu_M47T   56 AQLKDSLAKFKSNHYFRYQTDYSQISFTS----GSYAYSVYSNYDGEGSPGNPRTAGVTV 
Acti_pleu   42 LKNE----GSYVATG--SGFTTSALEMKS----KSHSYTIEFVQ-PRGTNVIDS--PMLY 
                        *    &  &      &  **    & @ @*&                && @ 
 
Neis_meni   93 ERRG-KEVARVGCTPKTAQANFNDDDFS--------------- 
Manh_haem   91 IKTG-NDITSFECRSDKPIRHNFDRKLMRKSGFAA-------- 
Hinf_infl   88 ITNG-SKMDTVSCKAGSAT-QNFERRSMKAS------------ 
Acin_niph   96 SNND-KLLATVECAANKKITSKIQGIKLRPEM----------- 
Vibr_n418  102 LSQG-KIMATILCQ-NESLYEQLIGVDLPAE------------ 
Prot_mira   95 YQND-KLLTTVNCLPNTIVDNLSEHIFAI-------------- 
Ente_cloa  101 SGNN-IKTNKIKCIEGTIQDNFESLFTFNSSRNK--------- 
Morg_morg   89 YKGD-KVINKKVCKTDLGIYDVLNYGLPEDESGEIYAMDPNSQ 
Prov_stua   95 YQKD-KLLTSISCLPNTIVDNLHEHIFDLPSDD---------- 
Avib_para   94 SKGD-KEIATVSC-----------ERF---------------- 
Mora_capr   96 NQDK-PNSKTILCNPKQIKVDELENYGTPN------------- 
Pseu_M47T  112 VSQAGAPVADIACKAIGKDTLQALTDKVACDADQALGCSQ--- 
Acti_pleu   89 ITKG-NNTTEIKCDTNKKVGQHFEYSKMNIL------------ 
                    * & *&       &    *                    
 
Figure 5.1 Multiple sequence alignment of the Gly1ORF1 homologs.  
The homologs were identified by PSI-BLAST search using processed neisserial 
sequence as a query The alignment was done by ClustalW2 (Larkin et al., 2007) and the 
Boxshade alignment. Residues with 100 % sequence conservation are highlighted in 
red, with 71-99% - in blue and with 50-70% - in green. The conserved residues based 
on their properties are marked as follows:’*’ - hydrophilic, ‘&’ – hydrophobic and ‘@’ 
– aromatic residues. Sequences used for the alignment: Neis_meni: N. meningitidis 
NP_273818.1, Manh_haem: Mannheimia haemolytica ZP_04977153.1, Hinf_infl: H. 
influenzae R2866 WP_005667853.1, Acin_niph: Acinetobacter sp. NIPH 284, 
ENW83788.1; Vibr_n418: Vibrio sp. N418, WP_009388134.1; Prot_mira: Proteus 
mirabilis WGLW6, EKA96180.1; Ente_cloa: Enterobacter cloacae P101, 
AHE73089.1; Morg_morg: Morganella morganii, WP_024473070.1; Prov_stua: 
Providencia stuartii MRSN 2154, AFH94386.1; Avib_para: Avibacterium 
paragallinarum, WP_017807504.1; Mora_capr: Moraxella caprae, WP_029102082.1; 
Pseu_M47T: Pseudomonas sp. M47T1, EIK98382.1; Acti_pleu: Actinobacillus 
pleuropneumoniae, WP_005607867.1.  
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Figure 5.2 Localisation of the conserved residues in the Gly1ORF1 homologs  
A. Surface representation of Gly1ORF1 K12A structure with the conserved residues 
(identity) shown in red; in 71-99% - in blue and 50-70% in green. B. A cartoon 
representation of the Gly1ORF1 K12A monomer structure with conserved residues 
shown as sticks. The images were generated and rendered using Pymol. 
 
Search of the database with PSI-blast algorithm came out with four interesting 
hits in Mannheimia haemolytica. Three proteins from different strains were 
almost identical, with a difference in one amino acid only, and one protein being 
similar to the other proteins only in 41% (MHA0579). The accession numbers 
and sequence similarity between hits in Mannheimia haemolytica are 
summarised in Table 5.1. 
A further search for homologs using the mh0603 sequence resulted in the 
identification of a potentially promising protein sequence in the Mannheimia 
haemolytica genome that is predicted to be an adhesin. The protein, referred to 
as ManhGly1ORF1 paralog or MHA2262, is surprisingly located in close 
proximity to genes involved in haemin transport, and an outer membrane Fe3+ 
receptor (Fig. 5.3). Using the ManhGly1ORF1 paralog another search with psi-
blast showed similarity with the neisserial Gly1ORF1 paralog, a possible 
adhesin encoded by the nmb2095 gene. 
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Table 5.1 Gly1ORF1 homologs and paralogs 
 Accession 
number 
Name of the 
protein and 
source 
Sequence Sequence 
similarity with 
NMB0776 
Protein physico-
chemical properties 
and subcellular 
localisation prediction 
1 NP_27381
8.1 
NMB0776 
[Neisseria 
meningitidis 
MC58] 
MKKMFLSAVLLLSAAAQTVWA
DTVFSCKTDNNKYIEVQKINRN
LYEYSFGSAAKKEIAIRNSKADL
LGRS 
DRWQGMGSGRWATMKFQNG
EFMYTIWTGFDSVTHTESSGV
VVERRGKEVARVGCTPKTAQA
NFNDDDFS 
N/A Unprocessed protein: 
139, MW: 15.6 kDa, 
pI: 9.14 
 
Processed protein: 
119aa, MW: 13.4 kDa, 
pI: 8.61 
 
2 ZP_04977
153.1 
hypothetical 
protein 
MHA_0579 
[Mannheimia 
haemolytica 
PHL213] 
MKKMAIVALSAFFSMNAFANN
NVVYSCTTTDNQTLKVTKEGG
NYVYSHGNTTFKNPVKEALKN
PASEIAG 
GSQFTTISLELRNAGKSYIVGHI
EADPKSPFEASVQIQDIKTGND
ITSFECRSDKPIRHNFDRKLMR
KSG 
FAA 
 
26 identical 
residues in the 
processed 
protein 
Unprocessed protein: 
143 aa, MW: 15.7 
kDa, pI: 9.27 
 
Processed protein: 
124 aa, MW: 13.66 
kDa, pI: 8.91 
 
3 ZP_05992
257.1 
hypothetical 
protein 
COI_1584 
[Mannheimia 
haemolytica 
serotype A2 str. 
OVINE] 
MRKLLVITALTLCTTPVFAADK
NVIFSCTSTEGKPLTVKRVGND
YEYSYDKTTFKNPIKKAVTNDG
SIIA 
RGSGFTTYALELENDGLKYLV
GFVQPNGNAKEFIEPGATISQS
KEQPSIGSVDCDTRKKIHYKFD
VHLMN 
TL 
 
20 identical 
residues over 
the processed 
protein  
Unprocessed protein: 
142 aa, MW: 15.7 
kDa, pI: 8.72 
 
Processed protein: 
123 aa, MW: 13.6 
kDa, pI: 7.95 
 
4 ZP_04977
739.1 
hypothetical 
protein 
MHA_1205 
[Mannheimia 
haemolytica 
PHL213] 
 
MRKLLVITALTLCTTPVFAADK
NVIFSCTSTEGKPLTVKRVGND
YEYSYDKTTFKNPIKKAVTNDG
SIIA 
RGSGFTTYALELENDGLKYLV
GFVQPNGNAKEFIEPGATISQS
KEQPSIGSVDCDTRKKSHYKF
DVHLMN 
TL 
 
20 identical 
residues inthe 
processed 
protein 
Unprocessed protein: 
142 aa, MW: 15.7 
kDa, pI: 8.72 
 
Processed protein: 
123 aa, MW: 13.6 
kDa, pI: 7.95 
 
5 ABG8917
9.1 
hypothetical 
protein 
MH_0603 
[Mannheimia 
haemolytica] 
 
MRKLLVITALTLCTTPVFAADK
NVIFSCTSTEGKPLTVKRVGND
YEYSYDKTTFKNPIKKAVTNDG
SIIA 
RGSGFTTYALELENDGLKYLV
GFVQPNGNAKEFIEPGATISQR
KEQPSIGSVDCDTRKKSHYKF
DVHLMNTL 
 
 
 
21 identical 
residues in the 
processed 
protein 
Unprocessed protein: 
142 aa, MW: 15.7 
kDa, pI: 8.94 
 
Processed protein: 
123 aa, MW: 13.66 
kDa, pI: 8.52 
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 Accession 
number 
Name of the 
protein and 
source 
Sequence Sequence 
similarity with 
NMB0776 
Protein physico-
chemical properties 
and subcellular 
localisation prediction 
6 ZP_04978
753.1 
possible adhesin  
MHA_2262 
[Mannheimia 
haemolytica 
PHL213] 
 
MKKLMIFATTAMIVSNLAHAAG
EQSDAREAHESTVKTSTVKYS
CQNGKKLSVKYGFNKQGIPTY
AEAKLS 
GKKRFMPINLYTTDATGTNFG
DENNFSLYGDPMEFTNHRKAS
VNIQSPASEILYKGCTPQK 
 
18 identical 
residues in the 
processed 
protein 
Unprocessed protein: 
131 aa, MW: 14.4 
kDa, pI: 9.34 
 
Processed protein: 
111 aa, MW: 12.26 
kDa, pI: 9.08 
 
7 WP_0056
67853.1 
hypothetical 
protein 
[Haemophilus 
influenzae] 
 
MKKLLTIGAVAMFATPAFAANN
IFSCTAENGSPVSVTKNGSDYE
FTYGQVSFKNPVKQVFANQDS
YVATG 
SGFITSSLEMRNNGTSYTIQFV
QPHNSNSIEEPMLYITNGSKMD
TVSCKAGSATQNFERRSMKAS 
 
26 identical 
residues in the 
processed 
protein 
Unprocessed protein: 
135 aa, MW: 14.6 
kDa, pI: 8.58 
 
Processed protein: 
116 aa, MW: 12.6 
kDa, pI: 6.81 
 
8 NP_27508
3.1 
adhesin complex 
protein 
NMB2095 
[Neisseria 
meningitidis 
MC58] 
 
MKLLTTAILSSAIALSSMAAAAG
TDNPTVAKKTVSYVCQQGKKV
KVTYGFNKQGLTTYASAVINGK
RVQM 
PVNLDKSDNVETFYGKEGGYV
LGTGVMDGKSYRKQPIMITAP
DNQIVFKDCSPR 
 
15 identcal 
residues in the 
processed  
Unprocessed protein: 
124 aa, MW: 13.3 
kDa, pI: 9.6 
 
Processed protein: 
103 aa, MW: 11.2 
kDa, pI: 9.52 
 
 
 
 
The MC58 Gly1ORF1 and a potential homolog in Haemophilus influenzae share 
26 identical residues in the processed protein. The identified homologs from 
Mannheimia haemolytica share between 20-26 identical residues with the MC58 
Gly1ORF1. Gly1ORF1 paralogs in Mannheimia and Neisseria share with 
neisserial Gly1ORF1 18 and 15 identical residues respectively, and 42 identical 
residues between each other. Homologs from Mannheimia show quite high 
similarity with the H. influenzae homolog, with 40-41 identical residues when 
analysed using the Multalin sequence alignment tool, on the default settings 
(URL: http://multalin.toulouse.inra.fr) (Corpet, 1988).  
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Figure 5.3 Mha2262 gene locus in the genome of Mannheimia haemolytica. 
Screen shot of the Mannheimia haemolytica genomic sequence (DS264670.1: 10048 to 
18800) showing the region that encodes the Gly1ORF1 paralog (mha2262). Three 
haemin ABS transporter genes and outer membrane iron (Fe
3+
) receptor are located 
downstream from mha2262.  
 
All analysed proteins have a predicted N-terminal signal peptide, and they all 
contain two cysteine residues that are predicted to form a disulphide bond 
(Disulfind server: http://disulfind.dsi.unifi.it/; (Ceroni et al., 2006). The secondary 
structure was predicted using the Sable server (URL: http://sable.cchmc.org/, 
(Adamczak et al., 2005)), and showed a consensus helical region in the N-
terminus that corresponds to the predicted N-terminal signal peptide. The 
secondary structure predictions have a high content of beta strand regions. The 
positions of the predicted β-strand regions are very similar, as are the positions 
of the two cysteine residues. The alignment of the secondary structure 
predictions for all the proteins shows that the proteins could form two groups. 
The first group would be comprised of the Mannheimia Gly1ORF1 paralog 
(MHA2262) and neisserial Gly1ORF1 paralog (NMB2095), as the similarities 
between these two are higher when compared to the other proteins. The 
second group is comprised of the Gly1ORF1 homologs from Mannheimia and 
H. influenzae together with neisserial Gly1ORF1. These proteins have similar 
positions of the alpha helical domains and strand regions (Fig. 5.2). 
All analysed Gly1ORF1 homologs and paralogs were predicted to have an 
extracellular localisation signal, when analysed by PSORTb version 3.0.2 and 
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SignalP 4.2. The H. influenzae Gly1ORF1 homolog was predicted to be 
secreted into the extracellular space with high confidence. 
The search for motifs using InterProScan did not detect any conserved motifs, 
apart from a signal peptide for all of the analysed proteins, and a 
transmembrane region for the H. influenzae protein. 
For further characterisation of proteins in this study, Hflu (referred to as 
HinfGly1ORF1), MHA1205 (referred to as ManhGly1ORF1), and NMB2095 
(referred to as neisserial Gly1ORF1 paralog) were cloned into expression 
vectors, expressed and purified. 
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Figure 5.4 Secondary structure prediction for Gly1ORF1 homologs and paralogs using the Sable online tool (Adamczak et al., 2005). 
 Green arrows indicate predicted β-strand regions, alpha helical regions are in red, and random coil-coil region are in blue. 
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5.7 Cloning of the Gly1ORF1 homologs and a paralog 
The templates for amplification of the Gly1ORF1 homolog sequences consisted 
of the boiled cells of H. influenzae AJ627386 and AM884334 and genomic DNA 
of Mannheimia haemolytica. The strains of Haemophilus influenzae were kindly 
donated by Dr David Wyllie from The University of Oxford. Mannheimia 
haemolytica (50 ng) genomic DNA was obtained from the Intervet Innovation 
GmbH, Schwabenheim, Germany. The oligonucleotides used for the cloning 
and PCR conditions are summarised in Table 7.2 in Materials and Methods 
Section 7.3.2. The PCR resulted in products with the expected sizes (480 and 
530 bps respectively) (Fig. 5.5). The neisserial Gly1ORF1 paralog gene 
(nmb2095) was amplified, using the appropriate oligonucleotides, from the 
genomic DNA of N. meningitidis MC58 (Table 7.2). 
 
Figure 5.5 PCR products of Gly1ORF1 homologs from H. influenzae (Panel. A), 
Mannheimia haemolytica (Panel B.) and neisserial Gly1ORF1 paralog (Panel C.).  
A. Lane 1 - Strain AJ 627386 with oligonucleotides for untagged Gly1ORF1 product, 
Lane 2 - AJ 627386 for C-histidine tag product, Lane 3 – strain AM884334 with 
primers for untagged product, Lane 4 – strain AM884334 with primer for C-histidine 
tag, Lane 5 - positive control with IgA1 protease β-core primers, Lane 6 – negative 
control with Hinf_Gly1 primers with no DNA. B. Lane 1 – ManhGly1ORF1 PCR 
product from pJONEX4 cloning; Lane 2 – ManhGly1ORF1 PCR product from cloning 
into pJONEX4 C-histidine tag; C. PCR products of Gly1ORF1 paralog for cloning into: 
Lane 1 – pJONEX4, Lane 2 – pJONEX4 C-histidine tag, Lane 3 – pET21, Lane 4 – 
negative control. 
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5.7.1 Expression and purification of the HinfGly1 homolog 
The HinfGly1ORF1 PCR product, derived from strain AJ627386, was 
successfully cloned into pJONEX4 and pJONEX4 C-histidine tag vectors and 
transformed into M72 CaCl2-competent cells as described in Materials and 
Methods Section 7.3.5. Analysis of the small scale heat-induction of the two 
constructs confirmed expression of the recombinant proteins in the cell pellet 
(Fig. 5.6). Analysis of the induced culture supernatants concentrated five times 
by acetone precipitation did not show presence of recombinant HinfGly1ORF1 
(data not shown).  
 
 
Figure 5.6 Small scale heat induction 
of HinfGly1ORF1 with and without 
histidine-tag  
Lane U – un-induced samples; Lane I 
– samples after induction. Cells 
carrying pJONEX4:T5FENΔ19 were 
used as a positive control for induction 
(the strong band running above at ~30 
kDa). Arrows indicate the induced 
bands corresponding to the untagged 
(~13 kDa) and tagged (~17 kDa) 
version of the protein. 
 
 
The HinfGly1ORF1 C-histidine tagged protein was expressed on a large scale 
in a 3 litre fermenter by heat induction as described in Materials and Methods 
Section 7.5.2. The protein was purified from the soluble fraction of the cell 
lysate on a Ni-affinity column, in the linear gradient of the imidazole 
concentration (see Materials and Methods Section 7.6.2.2. Fractions containing 
HinfGly1ORF1 were pooled together, dialysed against KP buffer, pH 6.5 and 
further purified by ion exchange chromatography on SP column (see Section 
7.6.4.2) This purification step enabled the separation of unprocessed and 
processed protein, and purification from other contaminants. Processed 
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HinfGly1ORF1 C-histidine tag was N-terminally sequenced by Professor Arthur 
Moir, and confirmed the signal peptide predictions. The processed form of 
HinfGly1ORF1 C-histidine tag starts with the sequence: ‘ANNIFSCT’. A 
summary of the 3 litre induction and purification of HinfGly1ORF1 C-histidine 
tagged protein is shown in Fig. 5.7. 
 
Figure 5.7 Summary of expression and 
purification of HinfGly1ORF1 C-
histidine tagged protein.  
Lane M – protein marker; Lane U – un-
induced cell pellet of M72-pJONEX4C-
HinfGly1 with histidine-tag; Lane I – 
induced cell pellet; Lane 3 – soluble 
fraction after cell lysis loaded onto Ni-
affinity column; Lane 4 – flow-through 
from the Ni-affinity column; Lane 5 – 
pooled fractions from the Ni-affinity column; Lane 6 – pooled fractions from the Ni-
affinity column after dialysis and centrifugation. This was loaded onto the SP column; 
Lane 7 – flow-through from the SP column; Lane 8 – pooled fractions 1-9 from the SP 
column; Lane 9 – fraction 10 from the SP column. 
 
5.7.2 ManhGly1ORF1 (MHA1205) expression and purification 
The ManhGly1ORF1 C-histidine tagged DNA fragment was successfully cloned 
into the pJONEX4 C-histidine tagged vector, and transformed into M72 CaCl2-
competent cells (see Materials and Methods Section 7.3). The protein was 
produced on a large scale by heat induction (see Materials and Methods 
Section 7.5.2). Analysis of the cell pellets and culture supernatants confirmed 
successful induction of the protein production. The cell pellets contained mostly 
insoluble protein Fig. 5.8). 
As the objective was the purification of the processed protein, the soluble 
fraction was passed through the Ni--affinity column, resulting in the purification 
of the processed protein as described in Materials and Methods Section 7.6.2.2 
(Fig. 5.9). 
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Figure 5.8 Analysis of the large scale expression and solubility of the 
ManhGly1ORF1 C-histidine tagged protein (MHA1205).  
A. Analysis of the cell pellets and culture supernatants before induction (Lanes U) and 
after induction (Lanes I) in the 5 litre fermenter culture. B. SDS-PAGE analysis of the 
solubility of the expressed ManhGly1ORF1 C-histidine tagged protein in the cell lysate. 
Lane 1 – the whole cell lysate; Lane 2 – the soluble fraction of the cell lysate. 
 
Attempts to purify ManhGly1ORF1 from the crude supernatant using a number 
of different types of resins (Ni--affinity, Q-Sepharose, SP-Sepharose, and 
Phenyl Sepharose) were unsuccessful. However, after precipitation of the 
proteins present in the supernatant with 3 M ammonium sulphate and dialysis of 
the precipitated proteins, the protein was successfully purified on the Ni-affinity 
column as described in Materials and Methods Section 7.6.1. 
Comparison of the protein purified from soluble fraction of cell pellet and culture 
supernatant was performed using SDS-PAGE, and showed that both proteins 
run at the same size (Fig. 5.9.B). This confirms that ManhGlyORF1 homolog 
with C-histidine tag in the soluble fraction must be processed by a signal 
peptidase as it is the same size as the secreted protein purified from the 
supernatant. Purified ManhGly1ORF1 was used for both crystallisation trials 
and for the production of rabbit polyclonal antibodies. 
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Figure 5.9 Purification of ManhGly1ORF1 homolog on Ni-affinity column  
A. Purification from the soluble fraction of the cell lysate. Lane L – The soluble 
fraction of the cell lysate loaded onto the Ni-affinity column; Lane F – flow-through 
from the column; Lane W – wash of the column; Lanes 1 – 11 – elution fractions in a 
linear gradient of imidazole. B. Comparison of ManhGly1ORF1 purified from the 
soluble fraction of the cell lysate (Lane 1), and from the ammonium sulphate 
precipitated supernatant (Lane 2).  
 
5.7.3 Expression and purification of neisserial Gly1ORF1 paralog 
The neisserial Gly1ORF1 paralog was successfully cloned into pJONEX4, with 
and without the C-histidine tag, and into the pET21 expression vector. Small 
scale expression of the construct showed best results for the auto-induction 
culture in BL21DE3:pET21 expression system (Fig. 5.10, Panel B.). The 
neisserial Gly1ORF1 paralog was mostly present in the soluble fraction (data 
not shown).  
 
Figure 5.10 SDS-PAGE 
analysis of the expression of the 
neisserial Gly1ORF1 paralog in 
pJONEX4 (Panel A) and 
pET21-(Panel B) expression 
vectors  
A. Small scale heat induction of 
M72 cells with following vectors: 
Lane 1 – induced empty 
pJONEX4; Lane 2 – neisserial 
Gly1ORF1 paralog in pJONEX4; Lane 3 – neisserial Gly1ORF1 paralog in pJONEX4 
C-histidine tag. B. Expression of neisserial Gly1ORF1 paralog in pET21 expression 
system by auto-induction in BL321DE3 cells. Lane U – un-induced sample; Lane I – 
sample after induction. An arrow indicates a protein corresponding to neisserial 
Gly1ORF1 paralog. Lane M contains a protein marker. 
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Attempts to purify the protein from the cell lysate using several steps of ion 
exchange chromatography were unsuccessful (data not shown). A different 
approach, involving purifying the protein from the periplasmic fraction was 
undertaken according to the protocol described in Materials and Methods 
Section 7.6.4.  
 
Figure 5.11 Summary of the purification of the neisserial Gly1ORF1 paralog 
(NMB2095).  
A. A protocol for an isolation of periplasmic proteins was used to purify neisserial 
Gly1ORF1 paralog. Cells after the protein induction were washed with an EDTA-wash 
buffer, followed by the incubation with the sucrose solution and an osmotic shock. Cells 
were centrifuged after each step and fractions were analysed by SDS-PAGE as follows: 
Lane M – protein marker; Lane 1 – whole cell suspension; Lane 2 –EDTA wash; Lane 
3 – sucrose fraction; Lane 4 – osmotic shock fraction; Lane 5 – cell pellet after 
periplasmic prep. B. The EDTA-wash fraction was treated with ammonium sulphate 
(3.5 M). Prepitated proteins containing contaminants (Lane P) were separated from the 
soluble Gly1ORF1 paralog (Lane L) by cenrifugation. Soluble protein fraction was 
dialysed and further purified using SP column and analysed as follows: Lane F – flow-
through from the SP column; Lane W – wash from the SP column; Lanes 1-11 – 
elution fraction in a linear gradient of the NaCl concentration, ranging from 50 mM to 1 
M.  
 
Gly1ORF1 paralog was mostly present in the first wash fraction with 5 mM 
EDTA and was >95% pure (Fig. 5.11, Panel A.). Further steps of the protocol 
for periplasmic purification of protein including osmotic shock did not produce 
significantly more protein. The wash fraction was very viscous, therefore DNA 
contamination was measured calculating the ratio of absorbance at 260 nm to 
280 nm; the ratio exceeded 1.4, which indicates high amount of DNA. Thus, 
polyethylenimine (PEI) precipitation of DNA was performed (see Materials and 
Methods section 7.6.4.1). The high solubility of the protein enabled further 
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purification by precipitation of the contaminating bands with 3.5 M ammonium 
sulphate. Final purification of the protein was achieved by performing the cation 
exchange chromatography using the HiTrap SP column in KP buffer, pH 7 as 
described in Materials and Methods Section 7.6.4.2. The summary of the 
purification is shown in Figure 5.11.  
 
5.7.4 Crystallisation trials for the Gly1ORF1 homologs and the neisserial 
Gly1ORF1 paralog 
All proteins were purified, buffer exchanged into 10 mM Tris-HCl, pH 8, and 
concentrated up to 30 mg/ml for crystallisation trials at the Department of 
Molecular Biology and Biotechnology, University of Sheffield. All proteins 
produced needle-like clusters in many of the screened conditions (Fig. 5.12 – 
5.14). 
 
 
 
Figure 5.12 Crystallisation trials of the H. influenzae GLY1ORF1 homolog. 
Proteins crystallised in the Classics Suite, with the sitting drop method, after two weeks 
incubation at 17°C. A. Needle clusters observed in well H7 in the buffer containing 0.2 
M ammonium sulphate and 30% (w/v) PEG 4000. B. Needle clusters in F12 conditions 
with 0.2 M ammonium sulphate and 30% (w/v) PEG 8000.  
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Figure 5.13 Crystals of the ManhGly1ORF1 homolog. 
Needle clusters obtained using hanging drop method in: A. 0.1 M SPG buffer, pH 8 and 
29% (w/v) PEG1500; B. in 0.2 M potassium fluoride and 26% (w/v) PEG3350. 
 
 
Figure 5.14 Crystals of neisserial 
Gly1ORF1 paralog (NMB2095).  
Crystals were obtained with 40 mg/ml of 
protein using the sitting drop method in 
0.1 M potassium thiocyanate and 30 % 
(w/v) PEG MME 2000. 
 
 
 
HinfGly1ORF1 optimisation trials did not produce crystals suitable for X-ray 
diffraction, due to their fragile nature. ManhGly1ORF1 did produce crystals at 
PACT G3 (Qiagen) 96 well screen condition that was big enough for X-ray 
diffraction. This enabled the collection of a full native data set to 2.6 Å, with a 
5.1 multiplicity that was 98.7% complete; however, the data were not good 
enough to solve the crystal structure of the protein. ManhGly1ORF1 shares little 
sequence homology with the neisserial Gly1ORF1. This prevented the use of 
the neisserial Gly1ORF1 structure for molecular replacement. Further 
optimisation results were unsuccessful.  
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Attempts to solve the structure of the neisserial Gly1ORF1 paralog (NMB2095) 
were unsuccessful also due to the very fragile nature of the crystals that were 
produced.  
 
5.7.5 Characterisation of the Gly1ORF1 homologs and paralog 
5.7.5.1 Haemin binding 
Purified Gly1ORF1 homologs and paralog were tested for the ability to bind to 
bovine haemin agarose beads in a qualitative assay (see Materials and 
Methods Section 7.8.1). Neisserial Gly1ORF1 was selectively removed from the 
solution and immobilised on the beads. Similarly, ManhGly1ORF1 was also 
completely removed from the solution. Only weak binding was observed for 
HinfGly1ORF1 (Fig. 5.15). The neisserial Gly1ORF1 paralog did not appear to 
bind to the haemin-agarose beads (Fig. 5.16). 
 
 
Figure 5.15 Haemin agarose pull down with Gly1ORF1 homologs and the 
neisserial Gly1ORF1 
Lane L – samples before incubation with agarose beads; Lane B – boiled haemin 
agarose beads – protein bound to the beads; Lane S – supernatant containing unbound 
proteins. An arrow shows bands corresponding to BSA. 
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Figure 5.16 Haemin agarose pull down of Gly1ORF1 and the neisserial Gly1ORF1 
paralog.  
Lane L – samples before incubating with beads, Lane S – supernatant containing 
unbound proteins; Lane W – sample containing wash with PBS with 0.5 M NaCl; Lane 
B – boiled haemin agarose beads with bound proteins. 
 
Another approach to test if the purified proteins were able to bind haemin 
involved haem and Congo red staining of proteins that were separated by 
denaturing SDS-PAGE, then refolded in the gel as described in Materials and 
Methods Section 7.10.2. Congo red binding correlates with haem binding 
activity as described previously (Daskaleros and Payne, 1987; Deneer and 
Potter, 1989; Smalley et al., 1995). Refolding of the proteins was achieved by 
subsequent washes of the SDS-PAGE gel with TBG buffer to remove SDS. The 
wash steps were followed by staining with haemin or Congo red solution 
dissolved in TBG, and de-staining in TBG buffer. The results are shown in 
Figure 5.17.  
The paralog shows some staining with Congo red and weaker staining with 
haemin. HinfGly1ORF1 was not detected by any of the staining steps. This 
experiment again confirms that neisserial Gly1ORF1 can interact with both 
haemin and Congo red. Although the Gly1ORF1 paralog did not bind to haemin-
agarose beads, it showed some evidence of binding to haemin and Congo red 
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when refolded in-gel. It is possible that steric hindrance, imposed by the 
immobilisation of haemin on the agarose beads by its carboxyl groups, affects 
the availability of haemin for this protein, whereas free haemin in solution did 
not show those limitations. HinfGly1ORF1 did not appear to show binding of 
either Congo red or haemin. However, this could be a result of incorrect 
refolding of the protein in the gel and needs to be investigated further.  
 
 
Figure 5.17 Haem and 
Congo red binding by 
proteins refolded in SDS-
PAGE gel. 
A. Staining with Congo red; 
B. staining with haemin 
solution; C. Coomasie 
stained SDS-PAGE gel used 
as a reference. Each lane 
contained 1.5 µg of protein. 
Lane 1 – Gly1ORF1; Lane 2 
– Gly1ORF1 paralog; Lane 3 – HinfGly1ORF1 paralog.  
 
5.7.5.2 Haemin spectra of the Gly1ORF1 homologs and paralog 
Gly1ORF1 homologs were analysed for their ability to cause changes in haem 
absorbance spectra as described in Materials and Methods Section 7.8.2. 
Results are shown in Figure 5.16. ManhGly1ORF1 caused a slight, but 
detectable, shift from 385nm to 390 nm (Δλ of 5 nm), which confirms the results 
obtained in haemin-agarose pull down experiment shown in Fig. 5.15.  
HinfGly1ORF1 and the Gly1ORF1 paralog did not cause a detectable shift in 
the maximum absorbance wavelength. However, changes in the shape of the 
curves were observed, indicating that there might be some interaction with 
haemin. It is possible that a higher concentration of the protein could show a 
more obvious shift in absorbance for ManhGly1ORF1; however, at higher 
concentrations the protein tends to precipitate out of solution in the presence of 
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haem. Initial experiments with higher concentrations of the HinfGly1ORF1 
protein and the Gly1ORF1 paralog gave similar results (data not shown) 
 
 
 
Figure 5.18 Haemin absorbance spectra in the presence and absence of the 
Gly1ORF1 homologs. 
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5.7.5.3 Oligomerisation of the Gly1ORF1 homologs and paralog 
The crystal structure of Gly1ORF1 shows dimer formation. However, the 
formation of higher molecular weight complexes was also observed when 
analysed on SDS PAGE in non-reducing conditions. It was hypothesised that 
HinfGly1ORF1 and the Gly1ORF1 paralog may also form dimeric or more 
complex multimeric structures. Analysis of the purified proteins by SDS-PAGE 
in non-reducing and reducing conditions showed the presence of a higher 
molecular weight band the Gly1ORF1 paralog at the size of a predicted dimer 
(Fig. 5.19, Panel A.). The dimeric forms of the Gly1ORF1 paralog were mostly 
removed from the sample by centrifugation, indicating that dimeric forms, which 
may be the result of intramolecular disulphide bond formation, might be more 
prone to aggregation (Fig. 5.20, Panel B.). The formation of multimeric forms 
was observed after treatment of the protein with glutaraldehyde (see Materials 
and Methods Section 7.8.5) for both analysed proteins (Fig. 5.19, Panel C). 
 
 
Figure 5.19 Multimerisation of neisserial Gly1ORF1 paralog (NMB2095).  
A. Natural formation of the insoluble dimer (indicated with an arrow) – SDS-PAGE in 
non-reducing conditions of the sample before centrifugation. Lane 1 and 2 show the 
neisserial paralog at 4 µg per lane and 200 µg per lane respectively. B. The soluble 
fraction after pelleting the precipitant, run in non-reducing (-DTT) and reducing 
(+DTT) conditions. C. Multimer formation after treatment with increasing 
concentrations of glutaraldehyde. (SDS-PAGE performed under reducing conditions). 
Gly1ORF1 multimers are indicated with arrows. 
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Figure 5.20 Multimerisation of the HinfGly1ORF1 C-histidine tagged protein.  
A. Natural dimerisation – SDS-PAGE in reducing (+DTT) and non-reducing (-DTT) 
conditions (shown with an arrow). B. Cross-linking of the HinfGly1ORF1 C-histidine 
tagged protein with different concentrations of glutaraldehyde. The gel was run in the 
presence of DTT. Dimers and higher molecular weight oligomers are shown with 
arrows. 
 
Concentrated HinfGly1ORF1 also shows the formation of dimers and higher 
molecular weight complexes (Fig. 5.20, Panel B and 5.21, Panel C). Treatment 
with glutaraldehyde shifts the equilibrium towards higher multimeric forms (5.20, 
Panel B). Separating the protein using size exclusion chromatography shows 
three elution peaks, with the main peak corresponding to the dimer when the 
elution pattern is compared with the known standard Fig. 5.21 Panel A). The 
second peak likely corresponds to the monomeric form, and a much smaller 
peak may be a degradation product that cannot be visualised by SDS-PAGE. 
Analysis of eluted fractions using non-reducing SDS-PAGE shows the presence 
of faint bands corresponding to molecular weight of the dimer. However, the 
most intensive band runs at the monomer size (5.21, Panels C. and D.). 
Analysis of HinfGly1ORF1 migration in the native gel (Fig. 21, Panel B.) before 
and after size exclusion chromatography does not show any obvious difference 
in the samples; three populations of bands are observed, with the most 
intensive band probably being that of the dimer.  
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Figure 5.21 Size exclusion chromatography of the HinfGly1 C-histidine tagged 
protein.  
A. UV traces of elution fractions from the SEC column.. B. Native gel of the HinfGly1 
C-histidine tagged protein. Lane 1 – the Hinf-Gly1 C-histidine tagged protein before 
loading on a SEC column. Lane 2 – Pooled fractions 4-7 from the SEC column. C. and 
D. Non-reducing SDS-PAGE analysis of the SEC fractions. Lane L – sample loaded on 
to the column. Lane 1 – 21 – elution fractions; Lane 22 – pooled fractions 4-7. Arrows 
show oligomeric forms of HinfGly1ORF1. 
 
5.7.5.4 CD spectra of HinfGly1ORF1 and the Gly1ORF1 paralog 
In order to look at the secondary structure content of the Gly1ORF1 paralog and 
HinfGly1ORF1, the proteins were analysed by circular dichroism in the 
Staniforth’s laboratory in the Department of Molecular Biology and 
Biotechnology, University of Sheffield. The spectra for both analysed proteins 
are shown in Figure 5.22. HinfGly1ORF1 CD spectra of molar elipticity, 
normalised against the dialysis buffer (PBS), showed a spectrum typical for a 
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protein that consists mainly of beta-sheet structures. Spectra for the neisserial 
Gly1ORF1 paralog displayed a double dip, which is an indication of a 
predominantly helical structure within the protein. The data for HinfGly1ORF1 
confirm the secondary structure predictions produced by the JPRED3 software 
shown previously in Fig. 5.4. However, the fact that the neisserial Gly1ORF1 
paralog shows a spectrum that might be indicative of a high content of alpha-
helical motifs is surprising. 
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Figure 5.22 CD spectra of HinfGly1ORF1 and the neisserial Gly1ORF paralog, 
normalised against the dialysis buffer. 
 
5.7.5.5 Binding to red blood cells – FACS analysis 
It was previously demonstrated using FACS that Gly1ORF1 is able to bind to 
red blood cells. This was shown by analysing a shift in the fluorescence of red 
blood cells upon incubation with FITC-labelled protein (Meadows, 2004). In 
order to establish if the HinfGly1ORF1 homolog and the neisserial Gly1ORF1 
paralog are also able to interact with human red blood cells, both proteins were 
fluorescently labelled with FITC and incubated with human red blood cells (see 
Materials and Methods Section 7.9.5). The ability of these proteins to bind to 
red blood cells were analysed on FACS Callibur. 
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Figure 5.23 FACS analysis of FITC-labelled HinfGly1ORF1 binding to human red 
blood cells.  
A slight dose dependent increase in fluorescence of red blood cells was observed. 
Neisserial Gly1ORF1 at a concentration of 100 µg/ml was used as a positive control. 
The negative control shows unstained red blood cells. 
 
Figure 5.24 FACS analysis of the FITC-labelled neisserial Gly1ORF1 paralog 
binding to human red blood cells.  
The positive control consists of 100 µg/ml of neisserial Gly1ORF1. The negative 
control consists of unstained red blood cells. No obvious increase in fluorescence was 
observed with increased dose of the Gly1ORF1 paralog.  
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HinfGly1ORF1 shows some level of binding to red blood cells, which appears to 
be dose dependent. The interactions are much weaker than that displayed by 
Gly1ORF1 (Fig. 5.23). The neisserial Gly1ORF1 paralog shows weak binding to 
red blood cells (Fig. 5.24). This might be a result of unspecific interactions, as 
increasing the protein concentration does not increase the shift in fluorescence.  
In summary, this chapter aimed to identify and characterise the potential 
structural homologs of the neisserial Gly1ORF1. The results from a 
bioinformatics analysis identified a large number of small secreted proteins with 
conserved positions of cysteine residues and high β-strands content. The 
largest proportion of hits was from bacteria that are known to be pathogenic to 
humans or to other animals. Three proteins were identified for further studies: 
ManhGly1ORF1, HinfGly1ORF1 and the neisserial Gly1ORF1 paralog 
(NMB2095). These were successfully cloned and expressed in E.coli. The main 
objective of the study was to solve the structure of these proteins in order to see 
if the bioinformatics predictions correlate with a structural similarity to 
Gly1ORF1. Although all the proteins did crystallise, they all formed fragile, 
needle-like clusters, and further optimisation trials proved to be unsuccessful. 
The fact that all the tested proteins formed similar crystal morphologies might 
indicate that they share structural features.  
The haem-agarose pull-down assay showed detectable binding in the case of 
the ManhGly1ORF1 protein, with no obvious binding for the other proteins. 
Although measuring shifts in the maximum absorbance spectra does require 
further optimisation of the conditions, there was some indication that 
ManhGly1ORF1 can bind haem. The observation that ManhGly1ORF1 
precipitated in the presence of haem, like the neisserial Gly1ORF1 protein 
does, indicates that these proteins might not only be structurally related, but 
may also share similar functions. As a result of these findings, a separate, 
collaborative project was set up with the Department of Food and Rural Affairs 
(DEFRA) in order to study Gly1ORF1 related proteins in Mannheimia 
haemolytica.  
Surprisingly, no obvious binding to haem or Congo red was observed for the 
HinfGly1ORF1 protein. Although HinfGly1ORF1 shares higher sequence 
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homology with neisserial Gly1ORF1 than ManhGly1ORF1 does, the main 
difference is a much lower pI of the mature protein (pI 6.81) compared to the 
Gly1ORF1-like proteins. One can speculate that this might indicate that the 
protein, despite having a similar structure, may have a different function.  
All tested proteins showed some level of oligomerisation when tested by SDS 
PAGE in non-reducing conditions. This indicates the presence of intramolecular 
disulphide bonds. HinfGly1ORF1 was also analysed in a native polyacrylamide 
gel and separated on a size exclusion column, confirming the formation of 
dimers and higher molecular weight complexes. Formation of higher molecular 
weight oligomers was also induced in the presence of glutaraldehyde. 
The neisserial Gly1ORF1 paralog seems to be the least similar protein to 
Gly1ORF1. Differences were detected when comparing the secondary structure 
predictions of these two proteins. Also, the CD spectra differ from the spectra 
typical for proteins with high β-strand content. Additionally, there is no evidence 
of this proteins binding to haem or red blood cells. The neisserial Gly1ORF1 
paralog, like the Mannheimia GlyORF1 paralog, are predicted to be adhesins, 
which may explain these differences. 
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CHAPTER 6 DISCUSSION  
Neisseria meningitidis is a successful human commensal and an example of a 
bacterium with invasive potential. It adapted to human nasopharynx as its stable 
ecological niche and in most of the cases causes no harm. However, 
occasionally, the bacteria cross the epithelial barrier and reach the blood stream 
causing septicaemia and meningitis. The meningococci mastered the art of 
evasion of the host immune response and exploiting human resources; and can 
survive and disseminate in the blood stream. The consequences of 
meningococcal infection can be devastating. The high mortality rate and long-
term disability among survivors place N. meningitidis in the category of 
pathogens with high epidemiological and clinical importance. Therefore, there is 
a great research interest in identifying neisserial virulence factors that would be 
a basis for the design of novel preventive and therapeutic treatments. 
The subject of this study was a small, secreted protein Gly1ORF1 expressed by 
Neisseria spp. The protein is highly conserved in the genus and present in all 
invasive isolates. The fact that the protein seems to be involved in haem 
acquisition and an interaction with red blood cells (Meadows, 2004; 
Sathyamurthy, 2011) suggested that it may be an important, yet 
uncharacterised neisserial virulence factor. 
Gly1ORF1 - structure function study 
One of the aims of the study was to determine the crystal structure of the MC58 
Gly1ORF1. Previous attempts to crystallise Gly1ORF1 were unsuccessful due 
to low solubility and aggregation problems. This has been overcome by 
introducing a single-amino-acid-substitution in the protein. It greatly enhanced 
the protein solubility enabling successful crystal trials. This mutation also 
reduced protein precipitation in the presence of haemin. This property of the 
mutant was of great importance when setting up co-crystallisation trials with 
haemin. The co-crystallisation trials were also successful. 
However, due to technical difficulties, the quality of the collected data for the 
Gly1ORF1-haemin crystals was not sufficient for solving the structure and 
identification of the haemin binding site. Further experiments are under way.  
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The attempts to identify the haem binding site in Gly1ORF1 by other methods 
were unsuccessful. Mutations previously introduced by Sathyamurthy 
(Sathyamurthy, 2011) did not inhibit Gly1ORF1 interactions when analysed 
spectrophotometrically or by the haem-agarose pull-down assay. The mutations 
were located in the region corresponding to the predicted pocket in the cavity at 
the dimer’s interface. This region was also identified as a potential haem-
binding site by several ligand docking servers described in Chapter 2. It cannot 
be ruled out that single point mutations were not sufficient for the disruption of 
the haem binding activity of Gly1ORF1. However, it is also plausible that this 
region despite the prediction is not the actual binding site. Therefore, new 
mutations were proposed. Many of them were the residues conserved in the 
Gly1ORF1 homologs. Most of the mutations in this study were targeting 
residues located in the region between two β-sheets (Fig. 2.2) or in the loops at 
the predicted dimer interface (Fig. 2.1). None of the mutations disrupted the 
interactions with the haemin when tested by haemin-agarose pull-down. Also 
the difficulties in determining the Kd for the wild type Gly1ORF1 were limiting 
factors in the interpretation of the MST data for three tested mutants. Therefore 
the attempts should be concentrated on the optimisation of the conditions for 
determination of the binding activity for the wild-type and the generated 
mutants. 
The Kd data for three Gly1ORF1 mutants gives a clear indication that 
Gly1ORF1 haem binding affinity is relatively low compared to haemophores in 
other bacteria. As an example, HasA in Serratia marcescens binds haem with 
the Kd of 18 nM (Izadi et al., 1997). Such low affinity rules out the possibility that 
Gly1ORF1 could outcompete host haem binding proteins, like HasA does. 
However, it is possible that it might bind haem in the event of spontaneous lysis 
and release of haem from haemoglobin, which can be observed in the later 
stages of meningococcal infection. Haem could be then captured by neisserial 
haem receptors, such as HmbR by passive transport due their higher affinity to 
haem than Gly1ORF1 (13 nM and ~300 nM respectively) (Perkins-Balding et 
al., 2004; Rohde and Dyer, 2004). It is also possible that Gly1ORF1 in presence 
of some other unknown cofactor or receptor has much higher affinity to the 
ligand. One such example is HpuA in N. meningitidis. This lipoprotein can bind 
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haemoglobin only when the functional outer membrane receptor HpuB is co-
expressed. The interaction between the outer membrane receptor and the 
lipoprotein is required for efficient binding of the ligand (Rohde and Dyer, 2004). 
Therefore it would be interesting to see if Gly1ORF1’s affinity to haem would 
also increase in the presence of the HmbR receptor. 
The dynamic light scattering experiment confirmed that Gly1ORF1 is present in 
solution as a mixture of monomeric and oligomeric forms. Although the solved 
crystal structure shows a dimer formed by two monomers interacting by 
unknown mechanism (hydrophobic or electrostatic interaction), the experimental 
data show evidence of formation of inter- and intramolecular disulphide bonds. 
We hypothesised that the higher molecular weight Gly1ORF1 complexes might 
be a result of the domain swapping. The reduction of the disulphide bridges 
linking two β-sheet domains in a monomer of Gly1ORF1 could enable 
interaction between two reduced monomers and formation of the intra-
molecular disulphide links. As a result, the domain-swap dimers and oligomers 
could be formed. The proposed model for domain-swapping by Gly1ORF1 is 
demonstrated in Figure 6.1. 
Many human plasma proteins have been reported to be controlled by the 
cleavage of the functional disulphide bonds in the protein backbones. This 
mechanism has been shown to play an important role in blood homeostasis, 
thrombosis, blood pressure control and complement regulation (Butera et al., 
2014). The reduction of functional disulphide bonds can be mediated by the 
oxidoreductases circulating in the blood or by thiol/disulphide exchange 
triggered by conformational change caused by protein-ligand binding or shear of 
the protein. Therefore, Gly1ORF1 disulphide bonds reduction followed by 
formation of domain-swapped oligomers could be a mechanism of the 
modulation of the protein function as a result of protein-host interaction. 
The domain-swapping hypothesis could be supported by the fact that mutations 
of the residues glycine 47 and arginine 48 localised at the dimer interface did 
not prevent the oligomerisation when analysed by the cross-linking approach. 
However, the method was not quantitative. Therefore, the mutants could be 
analysed by dynamic light scattering to study the size distribution of the 
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Gly1ORF1 oligomers. This would enable detecting subtle differences between 
mutants in the ability to form oligomers. However, the limited amount of the 
purified proteins at the time of this study prevented performing the analysis. 
 
 
Figure 6.1 Proposed model for domain-swapping in Gly1ORF1.  
The rectangles represent two β-sheets domains connected by the linker domain (blue or 
red line) and a single disulphide bridge (orange line), yellow bolts indicate the 
oxidoreductases. See description in the text. 
 
Interaction of Gly1ORF1 with red blood cells and EPB4.2 
Iron availability is a limiting factor for the growth of Neisseria in the blood 
stream. Iron is almost totally sequestered as a haem complex with haemoglobin 
and is enclosed within red blood cells. Even during the spontaneous lysis of red 
blood cells, free haemoglobin and haem are quickly bound by the proteins 
haptoglobin and haemopoexin, respectively, which circulate in the blood. It is 
indicative that Neisseria meningitidis might have evolved a mechanism that 
would enable it to acquire the haem from the most abundant source in the blood 
stream – red blood cells. Neisseria meningitidis is not associated with 
haemolytic activity, apart from few exceptions (verbal communication from Prof. 
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R. Read). To date, only two potential haemolysins were described in Neisseria: 
FrpA and FrpC. These share sequence homology with the RTX protein family, 
which is a group of proteins with cytotoxic activity. However, no haemolytic 
activity mediated by the expression of FrpA and FrpC was observed when these 
proteins were expressed in vitro (Thompson and Sparling, 1993; Thompson et 
al., 1993).  
Therefore, Gly1ORF1 raised research interests when the protein was shown to 
confer a weak haemolytic activity in E. coli (Arvidson et al., 1999). Further 
experiments performed in our laboratory confirmed that the protein is able to 
interact with red blood cells causing them to aggregate, and lose their normal 
discoid shape but the meningococcal protein did not appear to cause 
haemolysis. In addition, Gly1ORF1 seems to be involved in haem acquisition, 
as a Gly1ORF1 knock out MC58 strain is unable to grow on haem or 
haemoglobin as the sole iron source (Sathyamurthy, 2011). The data gathered 
in our laboratory also suggest that the changes in the morphology of red blood 
cells can be explained with the interaction of Gly1ORF1 with the EPB4.2 protein 
– a major component of the RBC’s cytoskeleton (Meadows, 2004; 
Sathyamurthy, 2011). 
The protein EPB4.2 accounts for 5% of the erythrocyte membrane content with 
approximately 2.5x105 copies in a single cell (Satchwell et al., 2009). The 
protein shares sequence homology with the protein family of transglutaminases. 
However, it lacks the transglutaminase activity due to the absence of a crucial 
residue in the catalytic site (Korsgren et al., 1990). The EPB4.2 is present in two 
isoforms, the most prevalent isoform 2 has a molecular weight of 72 kDa and 
the other, bigger isoform is predicted to be 74 kDa (Sung et al., 1990). The 
protein EPB4.2 plays a role of the complex linker in the cytoskeleton of the red 
blood cells. It is involved in maintaining the discoid shape and elasticity of the 
red blood cells through the interaction with other components of the 
cytoskeleton. It has been shown that the EPB4.2 is anchored to the plasma 
membrane by the band 3 protein – a multispanning membrane protein involved 
in ion transport across the membrane (Bruce, 2008). EPB4.2 also interacts with 
a transmembrane spanning protein CD47 belonging to the RH complex of 
proteins (Dahl et al., 2004). From the cytoplasmic site of the membrane, 
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EPB4.2 binds the protein 4.1, spectrin and ankyrin – proteins responsible for 
membrane integrity and the characteristic erythrocyte shape. Mutations in the 
EPB4.2 gene are associated with the hereditary spherocytosis (Satchwell et al., 
2009).  
Although no crystal structure of the EPB4.2 is available, a homology model was 
proposed by Toye and co-workers (Toye et al., 2005) (Fig. 6.2). According to 
this model, the Gly1ORF1 binding site identified by Meadows (corresponding to 
residues 174-225) is located in the core Domain-1 of the EPB4.2 protein. The 
Gly1ORF1 binding site encompasses the asparagine residue at the position 
175, which is located in the hinge region between Domain-1 and 2. The variant 
of the protein with the single point mutation of this residue to tyrosine is 
described as P4.2 Komatsu and is also manifested as a hereditary 
spherocytosis (Kanzaki et al., 1995).  
 
 
Figure 6.2 Protein EPB4.2 
homology model.  
Cartoon representation of 
the EPB4.2 homology model 
produced using Phyre2 
server (Kelley and 
Sternberg, 2009). The region 
in red corresponds to 
residues 174-225 identified 
as a Gly1ORF1 binding site 
(Meadows, 2004). The 
asparagine 175 that is 
mutated in the Komatsu 
variant of EPB4.2 is 
represented as cyan spheres. 
The image was generated 
and rendered using Pymol. 
 
The Gly1ORF1 binding region overlaps also with the band 3 protein binding 
region (residues 187-211) proposed by Bhattacharyya (Bhattacharyya et al., 
1999) and the ankyrin binding site (residues 187-200) (Su et al., 2006 ). The 
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fact, that Gly1ORF1 has been shown to bind the EPB4.2 region also involved in 
the interaction with other crucial cytoskeleton proteins might explain the 
morphological changes in the red blood cells when incubated with Gly1ORF1 
observed by Sathyamurthy (Sathyamurthy, 2011)  
This study aimed to further investigate the interactions between Gly1ORF1 and 
the EPB4.2 protein and measure the affinity of the interactions. It also aimed to 
co-crystallise both proteins to confirm the binding sites identified by Meadows. 
In order to achieve this, a codon optimised gene was custom-synthesised, sub-
cloned and expressed in E. coli. The yields of the protein were too low for the 
crystallisation trials. In addition to this the protein was prone to degradation. 
However, sufficient protein was purified for the initial test of the interactions with 
Gly1ORF1 using the BLItz (biolayer interferometry) machine (ForteBio).  
The experiments did not show any interactions between the purified Gly1ORF1 
and EPB4.2. This could be explained by improper refolding of the denatured 
EPB4.2 protein during purification. In addition, the protein expressed in E. coli 
lacks post-translational modifications; the EPB4.2 protein undergoes 
phosphorylation at many sites. It is also myristylated at the N-terminus and 
palmitoylated at cysteine 203 (in the region identified as a Gly1ORF1 binding 
site) (Das et al., 1994). It is unlikely that lack of myristoylation would affect the 
interaction of the protein with Gly1ORF1 as it is far from the predicted 
Gly1ORF1 binding site. However, the absence of the palmitoyl group on the 
cysteine 203 might have much more far reaching consequences for the protein-
protein interactions. It has been previously reported that the EPB4.2 devoid of 
the palmitoyl group exhibits greatly reduced incorporation into red blood cell 
membranes. It has also been suggested that palmitoylation might be important 
for the interaction with the band 3 protein (Bhattacharyya et al., 1999). 
Therefore, it is conceivable that the Gly1ORF1 recognising similar region of the 
protein might display lower affinity to the EPB4.2 protein lacking this group.  
Thus, to study protein-protein interactions, the EPB4.2 protein should ideally be 
purified from the eukaryotic cells to ensure the presence of post-translational 
modifications. One possible solution is to purify the protein directly from the red 
blood cell membranes. Our attempts to purify the protein from this source failed 
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(data not shown). However, the methodology for the purification of EPB4.2 from 
RBCs employs very harsh conditions, such as high pH or the presence of the 
chaotropic reagents (Friedrichs et al., 1989); these could also affect protein 
function.  
In future studies, a novel approach avoiding protein purification could be used 
for studying the EPB4.2 binding affinity. Recently, Khavrutskii and co-workers 
published a protein purification-free method for measuring kinetics of protein 
interaction using the microscale thermophoresis approach (Khavrutskii et al., 
2013). The protein of the interest was expressed as a GFP-fusion protein in a 
mammalian cell line and the whole cell lysates were used for the affinity studies. 
This method reduces the risk of the protein degradation and denaturation during 
protein purification. In addition, it does not require high levels of expression of 
the target protein. It by-passes the protein labelling step which can also affect 
protein stability. .In addition, the proteins expressed in the mammalian cell line 
should undergo the post-translational modifications that might be vital for their 
function. This method requires only the ligand to be of high purity.  
The purification of functional full-length EPB4.2 for the crystallisation trials seem 
to be very challenging due to its instability. Therefore, to confirm that the region 
identified by Meadows (Meadows, 2004) was the actual binding site, point 
mutations might be introduced into the protein and the affinity to Gly1ORF1 
could be analysed as described above. The reduction in the affinity of the 
interaction would be indicative of the identification of the binding site 
A possible solution for the generation of enough protein for crystallisation would 
be to express and purify only a fragment of EPB4.2. The Gly1ORF1 binding site 
seems to be localised in the groove between Domain-1 and Domain-2 of 
EPB4.2 according to the homology model shown in Figure 6.2. Therefore, it is 
plausible that a fragment containing those two domains would maintain 
structural integrity of the protein and allow co-crystallisation trials with 
Gly1ORF1. Expression of the smaller fragment of the EPB4.2 might increase 
the yields of the expressed proteins and also reduce protein degradation.  
The EPB4.2 protein is localised on the inner side of the erythrocyte membrane. 
Therefore, Gly1ORF1 needs to enter the red blood cells in order to interact with 
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the EPB4.2 protein. Sathyamurthy suggested that Gly1ORF1 entry inside the 
red blood cells might be vesicle mediated as Gly1ORF1 has been shown to be 
incorporated in the OMV when expressed in E. coli. Another hypothesis 
considers interactions of Gly1ORF1 with the erythrocyte membrane lipids 
leading to a conformational change in the protein. This would enable threading 
of the protein through the erythrocyte membrane thus accessing the cytoplasm 
(Sathyamurthy, 2011). Another suggested explanation takes into account 
involvement of other erythrocyte membrane proteins in the interaction with 
Gly1ORF1. The proteins could play a role of the receptor for Gly1ORF1 and 
enable the internalisation of Gly1ORF1 into the cell.  
This study tried to establish if Gly1ORF1 can interact with other erythrocyte 
proteins. The protein was incubated with red blood cells or with the red blood 
cell ghosts (erythrocytes devoid of haemoglobin) and reversible cross-linkers 
were added to stabilise transient interactions. The lysed red blood cells and 
ghosts treated with the detergent were subjected to pull-down experiments 
using Ni-affinity agarose (data not shown). However, no binding of other than 
Gly1ORF1 proteins was observed. The western blot analysis also failed to 
detect any other binding partners at higher than Gly1ORF1 molecular weight – 
even the band corresponding to the EPB4.2 protein. Interestingly, the analysis 
of the red blood cell lysates with bound Gly1ORF1 by western blot with anti-
Gly1ORF1 antibodies showed the presence of additional proteins slightly 
smaller than the monomeric and dimeric Gly1ORF1. The proteins were not 
present in the reducing conditions. It might be indicative of the conformational 
changes of Gly1ORF1 upon binding to red blood cells affecting protein 
migration in the non-reducing conditions. This might point towards the 
hypothesis proposing conformational changes of Gly1ORF1 in the presence of 
the lipids. It is not clear why similar changes were not observed when 
Gly1ORF1 was incubated with the ghost membranes.  
The future work on this subject could include methods to study structural 
changes of Gly1ORF1 in the presence of the membrane lipids such as X-ray 
diffraction and NMR-analysis. The incorporation of the Gly1ORF1 protein in the 
phospholipid bilayers could be investigated by analysing the protein 
incorporation into liposomes as described by Saliba (Saliba et al., 2014). 
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Interaction with the HmbR receptor 
The proposed role of Gly1ORF1 in iron acquisition seems to be plausible. The 
facts that it interacts with red blood cells and is implicated in utilising haem and 
haemoglobin as the sole iron source for growth of N. meningitidis strongly 
support this hypothesis. However, it is not clear how Gly1ORF1 delivers the 
haem-cargo into the neisserial cells. The hypothesis proposed in this study 
considered involvement of the haem/haemoglobin receptors HmbR or HpuAB in 
the transport of haem across the outer membrane. Gly1ORF1 function in this 
model would be limited to the role of the extracellular haem transporter 
delivering haem. HmbR and HpuAB receptors have been described in Section 
1.2.6.3. As HpuAB receptor was not detected by PCR in strain MC58 of 
Neisseria meningitidis (which was also previously reported in the literature), the 
study focused on the interactions of Gly1ORF1 with HmbR receptor.  
HmbR expression has been shown to correlate with invasiveness of 
meningococci (Harrison et al., 2009; Tauseef et al., 2011). Although the HmbR 
sequence is conserved in Neisseria meningitidis with sequence identity of over 
90%, the phase variation of this gene results in its lack of expression in some 
strains. Surprisingly, Hmbr sequence homologs can be found in many Gram-
negative bacteria that were also identified when searching for potential 
Gly1ORF1 homologs. HmbR’s nearest sequence homologs outside of Neisseria 
genus with approximately 50% identical residues were identified in 
Haemophilus spp., Mannheimia spp., Pasteurella spp., Actinobacillus spp., 
Moraxella spp., or Avibacterium spp. Those Gram-negative bacteria are human 
or animal pathogens and in some cases can cause septicaemia. 
The hmbR gene was successfully expressed in E. coli. Initial experiments 
showed some level of interaction of Gly1ORF1 with the E. coli cells producing 
HmbR compared to cells with an empty expression vector. This preliminary data 
are promising. However, more experiments must be performed to authenticate 
this finding. The most urgent experiments would involve pull-down experiments 
with the cell lysates of E. coli expressing hmbR with Gly1ORF1. It would be also 
interesting to invesitigate if Gly1ORF1 binding to HmbR is increased in the 
presence of haemin. It is possible that no difference would be observed. The 
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haemophore HasA in Serratia marcenscens binds to its outer membrane 
receptor HasR with similar affinity (Kd = 5 nM) irrespective of its haem-loaded 
status (Létoffé et al., 2001). These experiments could not be performed in this 
study due to the time restrictions. However, the work on the Gly1ORF1 – HmbR 
interaction will be continued. If the experiments confirm the initial findings, 
further work will involve purification of HmbR receptor and co-crystallisation 
trials with Gly1ORF1 with and without haem. Further work would also involve 
binding affinity studies of HmbR-Gly1ORF1 interaction with and without haemin.  
It is very unlikely that Gly1ORF1 and HmbR receptor could act as a typical 
bipartite haem/haemoglobin TonB-dependent receptor as the genes are 
distantly localised in the neisserial genome. Many of the typical bipartite 
receptors are co-transcribed from one operon and their expression is regulated 
by iron levels as they often contain the Fur box. The examples of such operons 
are HasAR form Yersinia pestis, HmuYR in Porphyromonas gingivalis or HpuAB 
in Neisseria meningitidis. However, one of the identified neisserial Gly1ORF1 
homologs in Mannheimia haemolytica – mha2262, is localised close to the 
hmbR2 gene (predicted to be a haem outer membrane receptor) and other 
genes which encode protein belonging to the haem ABC-transporter family (Fig. 
5.3). The characterisation of this homolog and its interaction with the HmbR 
receptor in Mannheimia haemolytica is a part of another project in the 
collaboration with the DEFRA.  
HmbR expression is upregulated in the iron-replete condition as are many other 
iron receptors in Neisseria. It contains the Fur box in the promoter region. 
However, the iron-independent mechanism of hmbR gene-regulation based on 
the MisS/R two-component system activates the gene expression as a 
response to uncharacterised environment stimuli (Zhao et al., 2010). Gly1ORF1 
does not possess a Fur box in the promoter region and there are no reports of 
Gly1ORF1 up-regulation in response to iron limitation. However, a 150 bp long 
sequence referred to as the Contact Regulatory Element of Neisseria (CREN) 
was identified upstream of the gly1ORF1 gene. The CREN is believed to be 
involved in the regulation of gene expression in response to the adhesion to the 
host cells. The study by Deghmane and co-workers demonstrated that 
gly1ORF1 expression is indeed upregulated in the cell associated bacteria 
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(Deghmane et al., 2003). Therefore, neisserial gly1ORF1 expression could be 
upregulated upon bacterial contact with red blood cells. It has been reported 
that N. meningitidis binds to RBCs utilising the erythrocyte complement receptor 
1 (Brekke et al., 2011). The independence of Fur up-regulation of hmbR could 
be also an adaptation to the iron acquisition in response to Neisseria binding to 
red blood cells. This could explain the higher invasiveness of the strains that 
express hmbR. 
It is also possible that Gly1ORF1 might play a role of storage protein for haem. 
Gly1ORF1 has been shown to form dimers and higher molecular weight 
structures and was detected in the outer membrane vesicles. It is possible that 
Gly1ORF1 with bound haem is attached to the surface of the cells and acts as a 
reservoir of haem. It is also suspected that Gly1ORF1 might undergo a domain 
swapping oligomerization process as discussed above. It cannot be ruled out 
that the monomeric and dimeric form of Gly1ORF1 can play different roles 
during meningococcal pathogenesis. A similar observation was seen in the case 
of HasA haemophore from Serratia marcenscens as previously mentioned in 
Section 1.2.6.2. The protein as a monomer binds haem with high affinity and 
interacts with the outer membrane receptor HasR. The HasA can be also 
present as a dimer (DHasA) formed by the domain swap. The DHasA is not 
able to interact to HasR but was found attached on the surface of the cells 
(Czjzek et al., 2007). Therefore, it would be interesting to investigate if 
Gly1ORF1 dimers and monomers differ in the affinity to haem and HmbR 
receptor. It is also possible that as a monomer, Gly1ORF1 might be responsible 
for the interaction with red blood cells and EPB4.2, whereas upon binding of 
haem it would form a dimer and function as a haem transporter.  
Immunogenic studies on Gly1ORF1 
Septicaemia and bacterial meningitis caused by Neisseria meningitidis are still a 
serious concern for parents and health professionals despite available antibiotic 
therapies. So far, prevention by vaccination has proven to be the most effective 
way of controlling the invasive meningococcal disease (IMV) especially in 
infants and toddlers with the highest rate of IMV incidence. 
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The MenAfriVac conjugate vaccine, which was designed specifically for the 
serogroup A strain causing the epidemics in the so called ‘Meningitis Belt’ in 
Africa, not only protects vaccinated individuals from carriage and disease, but 
also significantly reduced the carriage rate in unvaccinated individuals (Frasch 
et al., 2012; Kristiansen et al., 2013). The introduction of a routine vaccination 
program with the MenC vaccine against serogroup C eradicated the disease 
caused by this serogroup in England, Wales, Australia and Ireland (Andrews 
and Pollard, 2014). Serogroup B, therefore, became the main causative agent 
of meningococcal disease in high-income countries.  
The first available MenB vaccines were based on outer membrane vesicles, 
which are produced by some bacteria during growth. The immunogenicity of 
such vaccines is conferred by the presence of the endogenous neisserial 
surface antigens, mainly PorA. The tailor-made vaccines that were developed 
during meningococcal epidemics in Norway (MenBVac) (Bjune et al., 1991), 
Cuba (Va-Mengococ BC) (Sotolongo et al., 2007) or New Zealand (MenZB) 
(Oster et al., 2005) proved to be very effective in controlling the local outbreaks. 
However, the main drawback of these vaccines is the narrow strain specificity, 
limited by the presence of a monovalent PorA antigen which is extremely 
heterogeneous between strains (Tan et al., 2010). Also, the vaccine based on 
PorA, which undergoes phase variation, poses a risk of antigenic selection for 
strains that are not covered by the vaccine. 
An innovative approach based on the bioinformatics analysis of the MC58 
genome resulted in the development of a new universal vaccine 4CMenB, 
commercially known as 4CMenB or Bexsero. The reverse vaccinology 
approach identified initially over 600 genes encoding extracellular antigens. Of 
these over 350 were expressed in E. coli and used to vaccinate mice to select 
for antigens with the highest immunogenicity and ability to elicit bactericidal 
response. Five antigens were selected for the vaccine formulation: factor H 
binding protein in complex with GNA2091, neisserial adhesion A protein (NadA) 
and neisserial heparin binding protein (NHBA) in fusion with GNA1030. In 
addition, the 4CMenB vaccine contains outer membrane vesicles that were 
used in the MenZB vaccine with PorA protein serosubtype B (Serruto et al., 
2012) 
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As previously mentioned, the strain coverage of Bexsero was predicted to be 
less than 80%, which poses a risk of positive selection for strains that are not 
covered by the vaccine (Vogel et al., 2013). The emergence of invasive strains 
that do not express the main vaccine antigens  like factor H binding protein as 
reported by Lucidarme and co-workers (Lucidarme et al., 2011) is a cause for 
concern with regards to the efficacy of the vaccine in the future. Therefore, the 
search for new antigens with higher strain coverage continues.  
For successful vaccine formulation the candidates should meet a number of 
criteria which include: ability to elicit immunogenic response in humans, 
reaching protective bactericidal titres and cell surface expression allowing for 
efficient activation of complement mediated killing. To ensure broad strain 
coverage, the antigens must ideally be expressed in all strains with a high 
degree of sequence identity. From a safety point of view, antigens showing 
cross-reactive activity with a host protein should be avoided due to the risk of an 
auto-immune response. Finally, after meeting all those criteria, the candidate 
should be suitable for large-scale production (Sathyamurthy, 2011). 
The experiments performed in our laboratory (Meadows, 2004) and 
bioinformatic analysis of the available neisserial genomes proved that 
Gly1ORF1 is highly conserved and widespread in neisserial genomes 
guaranteeing broad strain coverage. The Gly1ORF1 has no homologs in the 
human genome. This indicates that it is extremely unlikely that the protein would 
elicit cross-reactive immune response with human proteins.  
The data in the pilot study show that Gly1ORF1 can elicit an immunogenic 
response in humans, as high antibody titres against Gly1ORF1 were detected in 
the sera one patient with invasive meningococcal infection. It would be 
interesting to test larger numbers of sera, however samples from septic patients 
are extremely rare. Also, a high response to Gly1ORF1 was detected in sera 
from patients with no suspected meningococcal infection. The fact that not all 
studied sera from septic patients showed a high antibody response to 
Gly1ORF1 can be attributed to the fact that the direct ELISA method used in 
this study has major drawbacks of a high background in negative samples and 
low specificity. A more sophisticated method for the detection of antibodies 
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against factor H binding protein - fHBP (a component of Bexsero vaccine) was 
described by Ala’Aldeen and co-workers (Ala'aldeen et al., 2010). The Luminex-
based immunoassay used in this study allowed very sensitive quantification of 
anti-fHBP antibodies in sera of septic patients greatly reducing the background. 
It detected subtle differences in antibody levels even in highly diluted sera, 
which is not possible with the direct ELISA method. Also, this method allowed 
reliable monitoring of the changes in the antibody levels against the antigen of 
interest throughout the course of infection. Ala’Aldeen and co-workers showed 
that antibody levels against fHBP varied significantly between septic patients. In 
most of the cases of invasive meningococcal disease the levels of anti-fHBP 
antibodies were rising after admission to the hospital; however, in two 
individuals there was no increase in response to the antigen during infection 
and convalescence, although the antigen was expressed in both strains 
responsible for the disease. Also, it has been shown that antibody levels, after 
reaching a peak during infection, were decreasing during long term 
convalescence except in one case. So, the fact that in this study not all isolates 
showed a high response to Gly1ORF1 with no obvious increase in the antibody 
titres after a month from the onset of symptoms is not unusual and can be 
explained by the differences in the immunogenic response between affected 
individuals.  
The ELISA test shows a response to Gly1ORF1 and OMV in most of the 
samples from patients with no suspected meningococcal disease. It is not 
surprising, as asymptomatic carriage has an immunogenic effect (Jordens et al., 
2004; Yazdankhah and Caugant, 2004) and most people at some point in their 
lives were colonised by N. meninigitidis. The fact that the mean response to 
OMV was higher than to Gly1ORF1 in the tested samples is something that was 
expected as OMVs contain many antigens and are known to be strongly 
immunogenic. However, the higher response to Gly1ORF1 than to OMVs in 
some individuals can indicate that Gly1ORF1 can also be highly immunogenic 
and elicit an antibody response as a result of carriage. There is also a chance 
that the individuals showing a higher response to Gly1ORF1 than to OMVs 
were colonised with a strain that was very divergent from MC58 N. meningitidis 
in the OMV antigen composition and sequence. Thus, detected antibody 
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response to MC58 OMVs could be lower than that of the colonising strain, 
whereas the response to a conserved Gly1ORF1 would be the same 
irrespective of the colonising strain. It would also be very interesting to see if the 
high Gly1ORF1 antibody levels in those samples correspond with high 
bactericidal titres of the sera against N. meningitidis. However, the low volume 
of the samples obtained from the Health Protection Agency limited the 
possibility of investigating it further. 
Previous initial experiments in our laboratory to test if Gly1ORF1 antibodies 
have a bactericidal effect on N. meningitis gave promising results 
(Sathyamurthy S., 2011). This subject was therefore investigated in more detail. 
The data in this study shows that mouse anti-sera raised against soluble 
Gly1ORF1 meet current Health Protection Agency criteria to be regarded as 
protective against meningococcal infection as they reach 50% killing in a serum 
dilution of up to 1:16. The next step would also involve testing if the bactericidal 
effect of the Gly1ORF1 can provide broad strain protection. In this study only 
two strains were compared for susceptibility to anti-Gly1ORF1 antibodies: 
MC58 and H44/76 and showed no statistically significant difference.  
Most crucial for the activation of complement-mediated killing is the availability 
of the antigen to the bactericidal antibodies circulating in the blood. This study 
showed that the levels of expression of Gly1ORF1 are probably very low as the 
expression of the protein was not readily detectable with polyclonal antibodies. 
Therefore, it is still important to generate monoclonal antibodies against 
Gly1ORF1 for future experiments. Although Gly1ORF1 expression levels might 
be low, it does not mean this protein should be disregarded as a good 
immunogen. The expression of other surface antigens, like factor H binding 
protein (hHBP) can vary significantly between strains (McNeil et al., 2009). 
However, according to the literature, there is no correlation between levels of 
surface expressed hHBP and the antibody response elicited against this protein 
during invasive infection (Ala'aldeen et al., 2010). Also, the fact that tested 
strains MC58 and H44/46 were much more susceptible to complement 
mediated killing than the MC58 gly1ORF1 null mutant strain indicates that the 
levels of protein were sufficient for eliciting a bactericidal response in serum. 
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Finally, Gly1ORF1 without the histidine-tag can be obtained with high yields as 
inclusion bodies with a reduced number of purification steps. This might be 
significant for large scale production of the antigen for vaccine formulation. 
The data show some promising features of Gly1ORF1 to be considered for 
further studies evaluating its potential as a vaccine candidate. 
 
Alpha protein – another promising vaccine candidate? 
Just by chance this study identified that another neisserial protein may have 
potential for vaccine development: the alpha protein of IgA1 protease. This 
protein was subject to an earlier study in our lab (Parsons, 2003) and was 
shown to be expressed in the majority of clinical isolates tested. Thus, 
antibodies against this protein were used as a positive control for FACS 
analysis when seeking to measure surface expression of Gly1ORF1 on MC58.  
 
 
Figure 6.3 Schematic representation of the product of iga gene.  
The arrows show different autoproteolytic cleavage sites (red arrows) and NalP 
cleavage site (orange arrow). The purple arrows represent Nuclear Localisation Signals 
(NLS) in long alpha-proteins containing four NLS, where the open arrow indicates NLS 
in short alpha-peptides with only one NLS. The proteolytic cleavage generates mature 
IgA1 protease and different variants of alpha protein depending on the site of cleavage.  
 
Alpha protein is expressed as a part of the IgA1 protease precursor protein, 
which undergoes auto-proteolytic cleavage to yield the mature IgA1 protease, β-
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core translocator domain and variable alpha-protein (Fig. 6.3). Recent studies 
also showed involvement of NalP proteases in the variable processing of the iga 
gene. The NalP cleavage yields different variants of alpha protein which are 
either released outside the cells, where they remain covalently attached to the 
translocator domain or loosely attached to the outer membrane (Roussel-
Jazédé et al., 2014; Roussel-Jazédé et al., 2013). The role of IgA1 protease in 
neisserial pathogenesis has been studied extensively (Ayala et al., 2001; Beck 
and Meyer, 2000; Hauck and Meyer, 1997; Lorenzen et al., 1999). Alpha protein 
function, in turn, remains highly enigmatic. Although the alpha protein is highly 
variable in length, it contains a varying number of 10-amino acid long repeats 
which are highly conserved between strains of Neisseria spp. Moreover, the 
crystal structure of the neisserial alpha-protein solved in our laboratory 
(Parsons, 2003) showed that it forms amphipathic alpha helices. The structure 
of alpha protein has many features similar to the motifs that bind to MHCII class 
molecules of T-cells (Jose et al., 2000), which indicates that it might have strong 
immunogenic properties. This was confirmed by the initial results in this study 
were the anti-alpha antibody titers in the tested sera were comparable or even 
higher than the response to outer membrane vesicles. Our initial data also 
demonstrate that the anti-alpha antibodies might have a strong bactericidal 
effect on N. meningitidis, however this needs to be further confirmed by 
comparison of pre- and post-immunization sera which were not available at the 
time of the study. 
Our experiments were a preliminary investigation into the potential of alpha 
protein in vaccine development. In-depth analysis of alpha protein was set up 
as a separate project in our laboratory. It will be also investigated if the fusion of 
Gly1ORF1 and alpha protein increases the serum bactericidal titre. The 
gly1ORF1 gene is present in all analysed clinical isolates with over 90% 
identity, whereas alpha protein has an advantage of high immunogenicity (Jose 
et al., 2000). In addition, alpha protein is also highly conserved in neisserial 
species and can be detected in most of the clinical isolates tested in our 
laboratory. Indeed, IgA1 protease expression levels have been correlated with 
virulence in N. meningitidis (Vitovski et al., 1999). Such fusion of two antigens 
was used in the recently approved Bexsero (4CMenB) vaccine. In the 
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formulation of the vaccine factor H binding protein, fusion with GNA2095 and 
neisserial heparin binding antigen and fusion with GNA1030 were used to 
stabilise the antigens and increase their immunogenicity (Serruto et al., 2012). It 
can be hypothesised that the fusion Gly1ORF1 and alpha protein could induce 
production of protective antibodies that would give broad coverage of strains 
and could be a basis for the development of universal meningococcal vaccine 
against multiple serotypes (Patent WO 2013079970 A1). 
Identification of Gly1ORF1 homologs 
The Gly1ORF1 protein sequence was originally thought to be unique to the 
Neisseria when the protein was first described in 1999 (Arvidson et al., 1999); 
however, as the databases have expanded, subsequent searches for structural 
homologs reveal several interesting protein sequences that are encoded in the 
genomes of other human and animal pathogens. This study focused on 
characterization of Gly1ORF1 homologs and paralogs found in Haemophilus 
influenzae, Mannheimia haemolytica and Neisseria meningitidis. 
Since 2012 a number of new potential homologs were added to the databases. 
Many of these proteins are encoded by genomes of human pathogens with 
emerging clinical importance due to the increasing incidence of bacteraemia 
and drug resistance. The most interesting examples are: Proteus mirabilis and 
Providencia stuartii, which are human uropathogens (Armbruster et al., 2014); 
Acinetobacter baumanii (Doughari et al., 2011) or Morganella morganii (Lin et 
al., 2014). Some of the pathogens are associated with hospital-acquired 
infections and target immunocompromised patients (Williams et al., 1983). The 
closest Gly1ORF1 homolog, with 51% sequence identity, was recently identified 
in a novel species of Haemophilus – haemolytic H. sputorum (Nørskov-
Lauritsen et al., 2012).  
The similarity of the predicted secondary structure of these proteins, and the 
fact that they were found in pathogens causing septicaemia, suggests that 
together with neisserial Gly1 they might constitute a novel group of virulence 
factors probably being a result of convergent evolution of pathogens colonising 
similar niches. The fact that the mha2262 gene in Mannheimia haemolytica 
(referred to as Mannhemia Gly1ORF1 paralog) is also in close proximity to a 
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gene involved in haem transport suggests that this group of proteins could be 
also responsible for iron acquisition. 
Our attempts to solve the crystal structure of Gly1ORF1 homologs in M. 
haemolytica and H. influenzae and neisserial Gly1ORF1 paralog were 
unsuccessful. It has been shown in this study that homologs and the Gly1ORF1 
paralog are able to form homo-oligomeric structures.  
The structure of Gly1ORF1 paralog in M. haemolytica (MHA2262) was solved 
as a part of the parallel project in the laboratories of Profs. Artymiuk and 
Sayers. The Gly1ORF1 paralog structure showed a similar fold to neisserial 
Gly1ORF1 and also forms a dimer. However, there was no observed haemin 
binding by this paralog (unpublished data, verbal communication from H. 
McMellon). This is quite surprising as the gene encoding this paralog lies next 
to the gene encoding an HmbR2 receptor-like protein. On the other hand, 
neisserial Gly1ORF1 paralog did not show convincing evidence of haemin 
binding either. Therefore, it is conceivable that the Gly1ORF1 paralogs have 
different functions to Gly1ORF1 and its homologs despite some structural 
similarity.  
This hypothesis is supported by the recently published data on the neisserial 
Gly1ORF1 paralog, also referred to as Adhesin Complex Protein (ACP) (Hung 
et al., 2013). The study showed that ACP is involved in adhesion; the ΔACP 
mutant strain of N. meningitidis adhered to different types of mammalian cells to 
a lesser extent than the WT (up to 75% reduction). The protein has been shown 
to be surface exposed (Hung et al., 2013) and was also identified in outer 
membrane vesicles (Ferrari et al., 2006; Post et al., 2005). Although ACP was 
reported to be up-regulated in iron-replete conditions (Grifantini et al., 2003), no 
obvious motif corresponding to the Fur box could be detected upstream of the 
sequence. Similarly to Gly1ORF1, ACP is widely distributed in Neisseria. It is 
highly conserved and the ACP variants between strains differ only with 1 or 2 
residues. ACP was shown to be highly immunogenic and the ACP-immunised 
mouse sera were eliciting high bactericidal titres (up to 1024) (Hung et al., 
2013). It would be interesting to see if the paralog in M. haemolytica (also 
predicted to be adhesin) shares similar functions and if it can also elicit strong 
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immunogenic responses. This is the objective of another project in the Sayers’ 
laboratory; investigating potential vaccine candidates in Mannheimia 
haemolytica. This would also be beneficial for identification of potential vaccine 
targets against other pathogenic bacteria that encode members of the 
Gly1ORF1-paralog protein family. An ACP sequence homolog can be found by 
PSI-Blast search in Moraxella catarrhalis, which is an emerging human 
pathogen. It is the third most common cause of the acute otitis media in children 
and it becomes much more prevalent after introduction of anti-pneumoccocal 
vaccine (Bernhard et al., 2012). This pathogen is of rising clinical importance 
and imposes an increasing economic burden; however, no vaccine has yet 
been developed against it.   
Gly1 homologs do not share high sequence homology. However, there are 
numbers of residues that are conserved in the sequences (Fig. 5.1 and 5.2). As 
the structures of the homologs could not be solved, the structure of neisserial 
Gly1ORF1 K12A mutant was used as a model to identify the position of 
conserved residues. 
Most of the residues with over 50% conservation are localised between the two 
β-sheet domains of the monomer. The residues are localised in the Gly1ORF1 
structure in the cavity that has not been identified as a potential haem-binding 
site in the docking experiments.  
Many of these residues were subjected to point mutations in this study. 
However, the replacement of these residues did not affect the ability of 
neisserial Gly1ORF1 to bind haem. This might indicate that the main function of 
the Gly1ORF1 homolog family is not haem binding in Neisseria. This conserved 
site might be responsible for interactions with other host factors, e.g. EPB4.2. 
However, the FACS analysis did not show convincing results for the interactions 
of the HinfGly1ORF1 homolog and neisserial paralog with red blood cells. It 
does not rule out the possibility that the protein interacts with the EPB4.2. The 
proteins might be transported into the red blood cells by the outer membrane 
vesicles. HinfGly1ORF1 and ManhGly1ORF1 subcellular localisation prediction 
could also be indicative of OMV association, but it is something that would need 
to be confirmed experimentally.  
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Gly1ORF1 homolog protein family is a very interesting, uncharacterised group 
of proteins that may be involved in pathogenesis. However, more work needs to 
be done to confirm the structural similarities between these proteins and to 
determine their function in the interaction with the host. The facts that many of 
these homologs are widely spread and conserved within the species encoding 
them and are surface exposed and immunogenic raises a possibility of their 
potential as vaccine targets. It is something that is definitely worth further 
investigation. 
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CHAPTER 7 Materials and Methods 
7.1 Bacterial strains, vectors and culturing conditions 
Escherichia coli M72 (Δbio-uvrB) lacZ(Am) rpsL  Δ(trpEA2) (λ Nam7 Nam53 
cI857 ΔH1) (O'Connor and Timmis, 1987) was used to express Gly1 constructs 
cloned into the pJONEX4 plasmid (Sayers et al., 1992) which had been 
modified by inserting a hexa-histidine-encoding cassette to generate histidine-
tagged proteins (Meadows, 2004). Genes cloned into the pJONEX4 vector are 
under the control of the bacteriophage promoter λPL which is repressed at lower 
temperatures by the chromosomally encoded repressor cI857. Therefore the E. 
coli M72 cells were grown at temperatures below 30°C in Luria-Bertani (LB) 
media containing ampicillin at a final concentration of 100 µg/ml. Induction of 
protein expression was achieved by increasing the culture temperature to 42°C, 
which results in the dissociation of the repressor from the promoter region 
allowing transcription to occur.  
E. coli XL1 Blue (endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F’[:: Tn10 
TetR proAB+ lacIqΔ(lacZ)M15] hsdR17(rK- mK
+)) was used to propagate the other 
vectors used in this study and M13mp18 bacteriophage (Sayers et al., 1992). 
This strain is characterised by absence of endonuclease (endA) and 
recombination activity (recA) resulting in higher yields of cloned DNA and stable 
inserts. Mutation in the gene hsdR additionally prevents cleavage of the cloned 
DNA by the EcoK endonuclease system. Presence of the F’ plasmid also 
enables infection M13mp18 bacteriophage. E. coli XL1 Blue cells were grown at 
37°C in 2xYT  in the presence of tetracycline at a final concentration of 12.5 
µg/ml with the addition of suitable cognate antibiotics (e.g. ampicillin) when a 
vector was present within the cells. 
E. coli BL21(DE3) (fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5) and 
E.coli BL21 StarTM (DE3) (ompT hsd SB (rB-mB-) gal dcm rne 131 (DE3)) 
(Invitrogen Life Sciences) were used for high yield expression of proteins from 
the vector pET21a+ (Novagen). Genes cloned in the pET21a+ vector are under 
control of strong promoter derived from T7 bacteriophage. Expression of a 
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cloned gene can be repressed by addition of glucose to the growth media at the 
concentration of 0.1 % (w/v). Induction of gene expression was initiated by 
addition of isopropyl-beta-D-thiogalactopyranoside (IPTG) to the final 
concentration of 0.1 mM.. E. coli BL21 StarTM (DE3) strain was only used when 
expression from BL21(DE3) was undetectable or low; E. coli BL21 StarTM (DE3) 
has a truncated version of RNaseE which is unable to degrade the mRNA 
template and thus shows increased stability of mRNA for heterologous genes 
cloned into the expression vector. This can result in improved yields of 
recombinant proteins.  
 
7.2 Preparation of CaCl2 competent cells 
The desired strain of E. coli was streaked on to a LB agar plate supplemented 
with the appropriate antibiotics (if required); this was then incubated overnight at 
an appropriate temperature for the E. coli strain being used.  
A single colony was picked up from the agar plate inoculated into 3 ml of LB 
media supplemented with the appropriate antibiotic (if required) and grown 
overnight at the appropriate temperature.  
The following day 100 ml of LB media (with antibiotic if required) was seeded 
with 1 ml of the overnight culture and grown until the A600nm reached 
approximately 0.4.  
The culture was centrifuged at 3000 x g for 10 min at 4°C and the supernatant 
was discarded. Pelleted cells were resuspended in 30 ml of ice cold sterile 0.1 
M MgCl2 and then centrifuged again at 1000 x g for 20 min at 4°C.  
The supernatant was discarded and cells were gently resuspended in 5 ml of 
sterile ice cold 0.1 M CaCl2 by gentle pipetting. Once resuspended, another 35 
ml of sterile ice cold 0.1. M CaCl2 was added. Cells were incubated for 1 hour on 
ice and then pelleted by centrifugation at 1000 x g for 20 min at 4°C. The 
competent cells were gently resuspended into 6 ml ice-cold sterile 85 mM CaCl2 
containing 20% (v/v) glycerol and aliquoted into pre-chilled tubes. Competent 
cells were stored at -80°C. 
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7.3 Cloning 
7.3.1 Plasmid DNA preparation 
Plasmid DNA was prepared using a DNA purification kit E.Z.N.A. (Omega Bio-
Tek). The protocol was provided by the manufacturer. 
 
7.3.2 PCR 
The PCR mix composition used for all genes amplification in this study was 
containing: 25 µl of 2xPCR mix (Thermo Scientific), 2 µl of template DNA 
(approximately 50 ng), 2 µl of each primer at 10 µM concentration and 
deionised water up to 50 µl. 
Oligonucleotides used in this study are summarised in the Tables 7.1-7.3 with 
the oligonucleotide’s sequences, restriction enzyme recognition sites and PCR 
conditions. 
 
 Table 7.1 Oligonucleotides sequences for amplification of haemoglobin receptor 
genes. 
Primer sequence ID Primer sequence Restriction 
enzyme –
recognition 
site 
HmbR_for d(TTATACATATGAAACCATTACAAATGCTCCCTA) NdeI 
HmbR_rev d(TATTAAGCTTTCAAAACTTCCATTCCAGCG) HindIII 
HpuA_for d(ATGCCATATGAAATACAAAGCCC NdeI 
HpuA_rev d(TTAGAAGCTTCCTTATTTTGTGAGATGGG) HindIII 
HpuB_for d(TAATCATATGCCCATCCCCTTCA) NdeI 
HpuB_rev d(TATTAAGCTTGCTTAGAACTTCGCTT) HindIII 
*PCR program: initial denaturation at 95°C for 1 minute, 25 cycles of denaturation at 
94°C for 1 minute, annealing at 55°C for 1 minute and elongation at 72°C for 3 min 30 
seconds finished by final elongation for 3 minutes.  
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Table 7.2 Oligonucleotides sequences for amplification of Gly1ORF1 homologs and 
neisserial Gly1ORF1 paralog genes. 
Name of the 
oligonucleotide 
Sequence of the Oligonucleotide Restriction 
enzyme 
recognition 
sites 
Gly1_man.f  d(TTTCGAATTCTAGAGGAAACAAAAATGCGTAAATTATTA
GTAATT) 
EcoRI 
Gly1_man.h6.r d(TGTTGGATCCCTAAAGTATTCATCAAATGAACATC) BamHI 
Gly1_man.r d(ACAAAAGCTTACTTAAAGTATTCATCAAATGAACATC) HindIII 
Gly1_ManS2.f: 
EcoR1 
d(TTTAGAATTCTAAGGAGTTACATTTATGAGTAAATTATT
AGTAATTACTGC) 
EcoRI 
Hinf_gly1.r d(TATTCGATCCCTCAAGCTTTCATACTGCGACGT) HindIII 
Hinf_Gly1H6.r d(AAATGTCGACGCTTATTTTATCTCTATTTACGCTTATGA) SalI 
Gly1_hinf_K.f  
 
d(AATAGGTACCTGAGGAGAAACAAATGACAAAATTACTC
ACTCACTATTGGAGC) 
KpnI 
NGly_Par_for d(AAGGAAAACATATGAACTTCTGACCACC) NdeI 
NGly_Par_rev d(ATTTAAGCTTCATTAACGTGGGGAACAGTC) HindIII 
* PCR program: initial denaturation:95°C for 1 min; 25 cycles of: denaturation at 94°C 
for 1 min, annealing for 1min at 50°C for H. influenzae and 55°C for M. haemolytica, 
58°C for N. meningitidis, elongation at 72°C for 1 min and a final elongation at 72°C 
for 5 min.  
 
Table 7.3 Oligonucleotides sequences for amplification of the native non-histidine 
tagged Gly1ORF1 gene. 
Name of the 
oligonucleotide 
Sequence of the Oligonucleotide Restriction 
enzyme 
recognition 
sites 
Gly1_NheI d(TTTTATGGCTAGCATGTTCCTTTCTGCCGTATTG) NheI 
universal M13 d(CAGGAAACAGCTATGAC) N/A 
*PCR program: initial denaturation: 95°C for 2 minutes; 25 cycles of: denaturation at 
94°C for 30 seconds, annealing at 56°C for 30 seconds, elongation at 72°C for 45 
seconds and final elongation at 72°C for 2 minutes. 
 
7.3.3 Restriction digest  
Plasmid DNA and PCR products were digested by restriction enzymes 
(restriction enzymes were purchased from Promega) according to 
manufacturer’s protocol. Digested DNA was separated on 1% (w/v) agarose gel 
in TAE buffer at 60V and bands corresponding to digested vectors and inserts 
were excised from the gel. The DNA in the excised agarose gel was then 
purified using the QIAEX II Gel Extraction Kit (QIAGEN) according to the 
manufacturer’s instructions. 
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7.3.4 Ligation 
Band purified DNA was ligated at a molar ratio of 3:1 (insert : vector) with 2.5 U 
of T4 ligase (Thermo Scientific) in a final volume of 20 µl in the buffer provided 
by the manufacturer. Ligation reaction was incubated for 2 hours at 25°C 
followed by heat inactivation at 70°C for 5 minutes. 
7.3.5 Transformation 
An aliquot of 10 µl of ligation product was added to 100 µl Ca-competent E. coli 
M72 cells. Cells were incubated on ice for 1 hour with occasional gentle mixing 
and then plated onto LB agar plate supplemented with the appropriate 
antibiotics. Plates were incubated overnight at 30°C.  
Single colonies were used to inoculate 5 ml of LB media with the appropriate 
antibiotics and these cultures were grown overnight at the appropriate 
temperature. Plasmid DNA was isolated from the centrifuged cells using the 
E.Z.N.A Mini Kit II (Omega Bio-Tek) according to the manufacturer’s protocol.  
Presence of the insert was confirmed by sequencing of the plasmids at the Core 
Genomic Facility, School of Medicine, Sheffield. 
 
7.4 Site directed mutagenesis 
7.4.1 Site directed mutagenesis by phosphorothioate approach 
A bacteriophage M13mp18 derivative carrying the wild type glyORF1 gene was 
used as the template for site directed mutagenesis; this was kindly provided by 
Sathyamurthy. The method described previously (Sayers et al., 1992) was 
followed, with minor modifications.  
7.4.1.1 Propagation of M13mp18 in XL1Blue cell cultures and preparation 
of single stranded DNA template 
Serial ten-fold dilution of bacteriophage were prepared in sterile distilled water 
and 5 µl of 1:107 to 1:109 dilutions were added to 200 µl of log phase E. coli XL1 
Blue cell culture grown in 2YT media supplemented with 12.5 µg/ml tetracycline. 
The E. coli XL1 Blue cells and bacteriophage were mixed with top agar and 
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poured onto LB plates supplemented with tetracycline at the final concentration 
of 12.5 µg/ml. Plates were then incubated overnight at 37°C.  
The following day a single plaque was transferred into 100 µl of fresh log phase 
XL1 Blue culture in 2YT with tetracycline (12.5 µg/ml) and incubated overnight 
at 37°C. Large scale bacteriophage preparation was prepared by adding the 
100 µl of overnight propagated bacteriophage into 100 ml of fresh culture of XL1 
Blue at the optical density A600nm of 0.3 and incubation at 37°C for 5 hours.  
Bacteriophage was separated from the E. coli cells by centrifugation at 3500 x g 
for 20 min at 4°C. The bacteriophage was then precipitated from the resulting 
supernatant by adding 1/5 volume of 20% PEG 6000 (w/v) in 2.5 M NaCl and 
incubating at 4°C overnight. Precipitated bacteriophage was pelleted by 
centrifugation at 3500 x g for 20 min at 4°C. The pellet was then resuspended in 
1 ml of TE buffer (10mM Tris-HCl pH 8, 1 mM EDTA) and 9 ml of sterile distilled 
water and then centrifuged again at 3500 x g for 20 min at 4°C. The supernatant 
was transferred into a clean tube and bacteriophage was precipitated again by 
adding 2.2 ml of 20% PEG 6000 (w/v) in 2.5 M NaCl and incubating at 4°C for 
another 30 min  followed by centrifugation at 3500 x g for 20 min at 4°C. The 
pellet was then resuspended in 500 µl of NTE buffer (100 mM NaCl; 10 mM 
Tris-HCl, pH8; 1 mM EDTA). DNA purification from bacteriophage proteins was 
performed using standard phenol-chloroform extraction and the resulting DNA 
was precipitated with standard ethanol precipitation. The precipitated DNA 
pellet was resuspended in 50 µl of TE buffer (10 mM Tis-HCl, 1 mM EDTA) and 
concentration of DNA was determined using UV spectrophotometer; 37 µg/ml of 
single stranded DNA gives an absorbance of 1AU at 260 nm.  
7.4.1.2 Homoduplex of mutant DNA preparation 
Phosphorylation of primers 
Custom synthesized oligonucleotides were resuspended in TE buffer and 
diluted to 5AU at 260nm. A mixture of 2 µl primer, 6 µl 500 mM Tris-HCl, pH 8, 
3 µl 100 mM MgCl2, 2 µl 100 mM DTT, 3 µl ATP, 5 U of T4 Polynucleotide 
Kinase and 14 µl of sterile distilled water was incubated for 15 min at 37°C and 
heat then inactivated at 70°C for 10 min. The sequences of the oligonucleotides 
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are shown in Table 7.4. Nucleotides encoding introduced mutant codons are 
underlined. 
Table 7.4 Oligonucleotides used for SDM by phosphorothioate method.  
Primer ID Primer sequence 
Gly_G47R d(CCTTGCCACCTGTCGGAACGCCGCAACAGGTCAGCTTTGCT) 
Gly_R48G d(CCTTGCCACCTGTCGGACTCCCCCAACAGGTCAGC) 
Gly_K12E d(GATTTTTTGGACTTCTATGTATTCGTTGTTGTCCGTTTTACA) 
Gly_Y26F d(CCGCCATGCCGAACGAAAATTCGTAAAGATTGCGGTT) 
Gly_F28R d(CTTTTTTTGCCGCACTGCCGCGCGAATATTCGTAAAG) 
Gly_E35K d(GCTGTTGCGTATGGCAATTTTTTTTTTTGCCGCACT) 
Gly_N67D/A d(GGTGTACATAAATTCGCCGKCTTGGAATTTCATCGTTGC 
Gly_Y72F d(CGAAGCCTGTCCATATGGTGAACATAAATTCGCCGTTTTG) 
 
Annealing of primers 
A mixture of 10 µl 500 mM Tris-HCl, pH 8; 10 µl 500 mM NaCl, 3 µl the 
phosphorylated primer (as described above) and 10 µg of single stranded 
M13mp18Gly1ORF1 DNA was prepared and the final volume was adjusted to 
36 µl with sterile distilled water. The mixture was incubated in a water bath for 5 
min at 80°C and then allowed to cool slowly to room temperature over a period 
of at least an hour. 
Polymerisation 
The following were added to the tube containing the phosphorylated primers 
(see above); 10 µl 10 mM ATP, 10 µl 100 mM MgCl2, 3 µl 500 mM Tris H-Cl, pH 
8; 5 µl 1 M DTT; 2.5 µl 10 mM dATP, 2.5 µl 10 mM dGTP, 2.5 µl 10 mM dTTP, 
2.5 µl 10 mM dCTPαS, 10 U of Klenow fragment, 15 U of T4 DNA ligase 
(Thermo Scientific) and sterile distilled water to a final volume of 100 µl. 
Polymerisation was carried out overnight at room temperature. 
Treatment with T5FEN Exonuclease 
2 µg of T5FEN exonuclease were added to the polymerisation reaction to 
remove linear and nicked DNA; the mixture was incubated at 37°C for 30 min 
and the reaction was stopped by incubation at 70°C for 10 min. 
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Nicking reaction 
A mixture containing 10 µl of T5 endonuclease digested DNA (from the previous 
step), 5 µl of 100 mM DTT, 5 µl of 500 mM NaCl, 1 µl of 500 mM Tris-HCl, pH 8; 
4 µl of 100 mM MgCl2, and 12.5 U AvaI restriction enzyme was prepared and 
the final volume was adjusted to 50 µl with sterile distilled water. The reaction 
was allowed to proceed for 90 min at room temperature and was then heat 
inactivated by incubation at 70°C for 10 min. 
DNA Gapping 
Gapping of the nicked DNA was achieved by incubation of 100 µl of reaction 
mixture from previous step with 40 U of gene 6 of T7 exonuclease at 37°C for 
60 min. The reaction was then inactivated by incubation at 70°C for 10 min. 
Generation of Double-Stranded DNA 
Double stranded DNA was obtained by incubation of 100 µl of the gapping 
reaction (from above) with 10 µl of 10 mM ATP, 2.5 µl of 10 mM dNTPs (10 mM 
of each: dATP, dGTP, dCTP, dTTP), 10 U of T4 DNA ligase and 5 U of DNA 
polymerase I at 37°C for 3 hours. 
7.4.1.3 Transformation of the M13mp18Gly1 into XL1 Blue cells 
Double stranded DNA containing desired mutation was transformed into CaCl2 
competent E. coli XL1 Blue cells. Briefly, 10 µl of double-stranded DNA was 
added to 100 µl of CaCl2 competent E. coli XL1 Blue cells and incubated on ice 
for 1 hour with occasional gentle mixing. Transformed cells were then mixed 
with previously prepared 250 µl of fresh mid-log culture of XL1 Blue (A600nm=0.3) 
and added to 3 ml of LB top agar containing 12.5 µg/ml of tetracycline kept at 
50°C. The top agar containing the transformed XL1 Blue was poured over a LB 
agar plate supplemented with 12.5 µg/ml tetracycline. Plates were allowed to 
set at room temperature and were then incubated overnight at 37°C. 
7.4.1.4 Miniprep of phage DNA 
To identify clones with the desired mutation small scale isolation of phage DNA 
was performed. Single plaques were transferred into 6 ml aliquots of fresh 
culture of XL1 Blue at the A600nm of 0.3 and were incubated at 37°C for 5 hours. 
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Cells were centrifuged down at 13000 x g for 1 minute and double stranded 
DNA (RFIV) was isolated using Omega E.Z.N.A. Plasmid Miniprep kit as 
directed by the manufacturer’s instructions. DNA was sequenced at the Core 
Genomic Facility at the Medical School, University of Sheffield. 
 
7.4.2 Site directed mutagenesis by PCR 
A single step polymerise chain reaction (PCR) based site directed mutagenesis 
was used to make mutants of Gly1ORF1; the methodology was based on the 
protocol for Q5 Site Directed Mutagenesis (New England Biolabs) with 
modifications. The pJONEX4-Gly1 C-histidine tag plasmid, previously 
synthesised in the Sayer’s laboratory by Meadows (Meadows, 2004), was used 
as a template for the creation of single-amino-acid substitutions. The vector 
pET21-Gly1ORF1 was used as a template for the deletion of the signal peptide 
in the native Gly1ORF1 construct in T7-inducible vector. 
7.4.2.1 PCR 
The whole plasmid DNA was amplified using a pair of oligonucleotides which 
were designed to introduce the desired mutations into the gene of interest. 
Sequences of oligonucleotides are shown in Table 7.5. Nucleotides encoding 
introduced mutant codons are underlined.  
Table 7.5 Oligonucleotides used for SDM by single step PCR method. 
Primer ID Primer sequence 
Gly1_F4A_for d(GGACAACAACGCGTACATAGAAGTCCAAAAAATC) 
Gly1_F4A_rev d(GCCCACACGGTTTGGGCG) 
Gly1_K12A_for d(GGACAACAACGCGTACATAGAAGTCCAAAAAATC) 
Gly1_K12A_rev d(GTTTTACAGGAAAACACCG) 
Gly1_M63A_for d(TTGGGCAACGGCGAAATTCCAAAACGGCG) 
Gly1_M63A_rev d(CGACCGCTGCCCATACCT) 
Gly1_dSTOP_for d(TCACCATCATTAATAATTGGCGTAATCATGG) 
Gly1_dSTOP_rev d(TGATGGTGTTTGTCATCG) 
Gly1_del.for d(GATACGGTGTTTTCCTGTAAAAC) 
Gly1_del.rev d(CATATGTATATCTCCTTCTTAAAGTTAAC). 
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The PCR mixture was prepared by mixing 25 µl KAPA Hifi Hot Start PCR mix 
(Kapa Biosystems), 1.5 µl 10 µM forward primer, 1.5 µl 10 µM reverse primer, 
0.1 µg template DNA and the volume adjusted to 50 µl with sterile distilled 
water. PCR was carried out in the thermal cycler (Eppendorf, Mastercycler 
Personal); the following PCR protocol was used: initial denaturation at 95°C for 
3 min, followed by 25 cycles of denaturation step at 98°C for 20 sec, annealing 
at 59°C for 15 sec and elongation at 72°C for 1 min 30 sec finished by final 
elongation step at 72° for 3 minutes.  
PCR products were separated on a 0.8% (w/v) agarose gel and linearised 
mutagenized constructs were band purified and gel extracted using the QIAEXII 
Gel Extraction Kit (QIAGEN).  
7.4.2.2 Ligation of the linear plasmid and treatment with DpnI 
Linear DNA PCR product (5µl of 125 ng/µl) was first phosphorylated with 5 U of 
T4 PNK (T4 polynucleotide kinase) in the buffer provided by the manufacturer 
(Promega); the reaction was carried out at 37°C for 30 min. The original 
template DNA was removed by treatment with DpnI restriction enzyme which 
cuts only methylated DNA, followed by circularisation of the vector with T4 
ligase. This was achieved by adding 5 U of DpnI (Promega), 1.5 U of T4 ligase 
(Promega) and 1x ligase buffer to the phosphorylated linear DNA PCR product. 
Samples were incubated for 30 min at room temperature and heat inactivated 
by incubation at 70°C for 5 min.  
The circularised construct with desired mutations was then transformed into 
CaCl2-competent E. coli M72 cells as described previously (Section 7.3.5).  
 
7.5 Protein production 
7.5.1 Small scale production of proteins by heat induction 
A single colony of freshly transformed E. coli M72 cells containing the pJONEX4 
plasmid an insert of the choice were used to inoculate 3 ml LB media with 100 
µg/ml of ampicillin and incubated overnight at 30°C in a shaking incubator. The 
following day, 5 ml of LB media with ampicillin were inoculated with 100 µl of the 
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overnight culture and incubated for 3 hours at 30°C. Protein production was 
induced by increasing the temperature to 42°C for 3 hours. After induction 
cultures were incubated overnight at room temperature. Samples were then 
analysed on SDS-polyacrylamide gel. 
 
7.5.2 Large scale protein production in the heat inducible system 
A fermenter containing 3 litres of 4YT with 100 µg/ml of carbenicillin and 300 µl 
of Antifoam 204 (Sigma) was inoculated with 200 ml of the overnight culture. 
The culture was incubated at 30°C with shaking at 450 rpm until optical density 
reached A600nm = 2 and the temperature was increased to 42°C for 3 hours. 
After induction temperature was lowered to 20°C and the fermenter culture was 
incubated overnight. Protein production was confirmed by SDS PAGE 
comparing samples of cell lysates and supernatant before and after induction. 
Cells were separated from the supernatant by centrifuging at 9000 x g for 45 
min at 15 C and supernatant was transferred into sterile bottles and stored at 
4°C. The cell pellets were stored at -80°C. 
 
7.5.3 Large scale protein production in the IPTG inducible system 
Freshly transformed E. coli BL21(DE3) with the pET21 vector containing an 
insert of the choice were grown on LB plates supplemented with 0.1% (w/v) 
glucose and 100 µg/ml ampicillin. A single colony was inoculated into 5 ml of LB 
liquid media with 0.1% (w/v) glucose and ampicillin (100 µg/ml) and grown 
overnight at 37°C. A 100 ml inoculum in the same liquid media was prepared by 
adding 1 ml of an overnight culture and incubation was continued overnight at 
37°C.  
A 1 litre flask with 4YT media containing 0.1% glucose and 100 µg/ml 
carbenicillin was inoculated with 50 ml of an overnight culture and was 
incubated at room temperature for 5 hours. Cultures were induced with 0.1 mM 
IPTG and incubated a further 2.5 hours at room temperature. Cultures were 
centrifuged at 9000 x g for 30 minutes at 4°C. Induced cell pellets were stored 
at -80°C. 
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7.5.4 Protein production in the auto-induction culture medium 
Protocols for the auto-induction of genes expressed from T7 promoter 
expression vector were previously described by Studier (Studier, 2005). 
Auto-induction medium ZYM-5052 used for this study was prepared by mixing 
959 ml of autoclaved ZY medium (10 g tryptone, 5 g yeast extract in 1 l of 
distilled water) with 2 ml autoclaved MgSO4, 20 ml autoclaved solution 50xM 
(1.25 M Na2HPO4, 1.25  M KH2PO4, 2.5 M NH4Cl, 0.25 M Na2SO3) and 20 ml 
filter-sterilised solution 50x5052 (0.5% (w/v) glycerol, 0.05% w/v) glucose, 0.2% 
(w/v) α-lactose monohydrate). ZYM-5052 medium was supplement with the 
appropriate selection antibiotics. 
A 1-litre ZYM-5052 media flask was inoculated with 40 ml of overnight culture of 
BL21(DE3) cells, harbouring the expression vector, grown in LB media with 
0.2% (w/v) glucose and the appropriate antibiotic. 
Cells were first grown at 37°C for the first four hours and then culture was 
incubated overnight at room temperature. Presence of the protein was analysed 
by SDS-PAGE gel by comparing protein band pattern of the inoculum culture 
with the auto-induction culture. Cells after induction were harvested by 
centrifuging at 9000 x g for 30 min at 15°C. Aliquots of 10 g were stored at  
-80°C. 
 
7.6 Protein purification 
7.6.1 Ni-affinity purification of histidine-tagged proteins from the 
supernatant  
Supernatant containing secreted histidine-tagged protein was filtered through a 
Whatmann paper to remove any particulates which could block the column. To 
reduce nonspecific binding to the column, 200 mM NaCl and 20 mM imidazole 
was added to supernatant. The pH was adjusted to pH 8 with 0.5 M NaOAc, pH 
4, if required.  
211 
 
Ni-chelate agarose beads (Amocol) were loaded into the column and washed 
with 10 column volumes (CV) of distilled water. Column was washed with 5 CV 
of wash buffer (50 mM NaOAc, pH 3.7; 300 mM NaCl) to remove loosely bound 
nickel ions. The column was then equilibrated with 10 CV of buffer A (25 mM 
Tris-HCl, pH 8; 500 mM NaCl, 20 mM imidazole, pH 8; 5% (v/v) glycerol). 
Equilibrated Ni-chelate agarose beads were then transferred into a container 
with culture supernatant and were incubated for at least an hour with mixing. 
After incubation the beads were allowed to sediment and supernatant was 
carefully decanted. Remaining Ni-chelate resin was loaded into the column. 
Supernatant was passed through the column and the column was washed with 
10 CV of buffer A. The histidine-tagged protein was eluted from the column with 
a 10 CV linear gradient of imidazole from 20-500 mM in the same buffer; 1 CV 
fractions were collected during the elution. Following a wash with high imidazole 
buffer (250 mM), the column was washed with 6 M guanidine hydrochloride with 
10 mM EDTA to remove any tightly bound proteins and the nickel ions. Agarose 
beads were then washed with water and the column was recharged with 100 
mM NiCl2 in 20% (v/v) ethanol. 
The eluted 1CV fractions were analysed by SDS-PAGE and fractions containing 
the histidine-tagged protein were pooled together, concentrated on VIVA spin 
column (Sartorius) with the membrane cut-off of 5 kDa and dialysed into 25 mM 
NaOAc, 50 mM NaCl, pH 4. Purified protein was stored at 4°C or flash frozen in 
liquid nitrogen and stored at -80°C.  
 
7.6.2 Purification of proteins from the cell pellet 
7.6.2.1 Crude cell extract preparations 
Approximately 5 g of the induced cell paste was thawed on ice and then 
resuspended in 50 ml of lysis buffer (50 mM Tris-HCl, pH 8.2; 2 mM EDTA, 200 
mM NaCl, 5% glycerol (v/v)). A freshly prepared solution of lysozyme was 
added to a final concentration of 200 µg/ml and the cell suspension was stirred 
on ice for approximately 30 min. A 2.3 mg/ml stock solution of 
phenylmethanesulfonyl fluoride (PMSF) in 100% ethanol was added to a final 
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concentration of 23 µg/ml followed by addition of sodium deoxycholate to a final 
concentration of 500 µg/ml and DTT to a final concentration of 5 mM. The cell 
lysate was stirred for 30 min on ice until it became viscous. The suspension was 
sonicated at 10 kHz and 28 μm amplitude three times for 30 seconds (5 sec 
pulse, 5 sec pause) and centrifuged at 40000 x g for 30 minutes at 4°C. Soluble 
and insoluble fractions were analysed by SDS-PAGE for the presence of native 
GlyΔSP. 
 
7.6.2.2 Purification of histidine-tagged proteins from the soluble fraction 
on Ni-affinity column 
Crude cell extract were prepared as described in Section 7.6.2.1; however, 
EDTA and DTT were not added to the cell lysate as they would interfere with Ni-
affinity column. Cell lysates were spun down at 40000 x g for 30 min. The 
soluble faction was filtered through a Whatman paper filter to remove any 
precipitant and supernatant was diluted 1:1 with Buffer A (see Section 7.6.1). 
The protocol for protein purification on Ni-affinity column was followed as 
described in Section 7.6.1.  
 
7.6.3 Ni-affinity purification of the histidine tagged proteins in denaturing 
conditions 
N-histidine tagged EPB4.2 was purified on the Ni-affinity column under 
denaturing conditions due to its instability. Cell pellet was thawed on ice and 
resuspended in lysis buffer (50 mM Tris-HCl, pH8; 200 mM NaCl, 5% glucose, 5 
mM imidazole) containing EDTA-free protease inhibitor (Thermo Scientific). 
Solid guanidine hydrochloride (GuHCl) was added to the suspension to the final 
concentration of approximately 6.5 M. The cell lysate was briefly sonicated to 
reduce viscosity and centrifuged at 40000 x g for 30 minutes at 4°C. The 
method for standard Ni-affinity chromatography described in Section 7.6.1 was 
followed with modifications. Clear cell lysate was passed through Ni-affinity 
column (Amocol) equilibrated in Buffer A (see Section 7.6.1) containing 3 M 
GuHCl. The column was washed with 5 CV of Buffer A + 3 M GuHCl. The 
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denaturing buffer was removed by the column wash with 10 CV of the Buffer A. 
EPB4.2 was eluted in linear gradient of imidazole ranging from 20 mM to 500 
mM in the same buffer Fractions equal to one CV were continuously collected. 
Elution fractions were analysed by SDS-PAGE. 
 
7.6.3.1 Gly1ORF1ΔSP purification from the insoluble fraction 
Inclusion bodies isolation and resolubilisation 
The crude cell lysate of the induced BL21(DE3):pET21-Gly1ΔSP was prepared 
as described in Section 7.6.2.1. The insoluble cell fraction was washed three 
times with 1% (w/v) sodium deoxycholate with 1 mM EDTA (10 ml per 1 g of 
initial cell pellet weight). Insoluble clumps were resuspended by brief sonication. 
The sodium deoxycholate was then removed by two washes with sterile distilled 
water. The purified inclusion bodies were stored at -20°C. 
Approximately 20 mg of wet mass of inclusion bodies was solubilised in 1 ml of 
8 M guanidine hydrochloride in 50 mM Tris-HCl, pH 8, 5 mM DTT for 2 hours at 
room temperature. For small scale refolding screen the DTT was removed using 
GE Healthcare PD TrapTM G-25 desalting columns equilibrated with 8 M GuHCl 
in 50 mM Tris-HCl, pH 8. Samples before refolding trials were centrifuged for 20 
min at 40000 x g to remove any aggregates that could form aggregation starting 
points during refolding.  
Refolding screen 
The Thermo Scientific Pierce Refolding Kit was used to determine the optimal 
conditions for protein refolding. As Gly1ORF1 has one disulphide bond it is 
expected that for correct refolding protein needs an optimal reducing 
environment. The manufacturer’s protocol for the primary screen examining the 
effect on refolding of denaturant concentration, reducing environment 
(GSH:GSSG) and protein concentration was followed. Stocks of 1.1 x base 
refolding buffers contained 55 mM Tris, 21 mM NaCl, 0.88 mM KCl and varying 
concentrations of guanidine hydrochloride and L- arginine were prepared. To 
900 µl those buffers were added 1 mM EDTA and different concentration of 
GSH and GSSG; the volume of the buffer was made up to 950 µl with distilled 
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water. Two stock concentrations of the protein were tested; 10 mg/ml and 1 
mg/ml.  
Denatured protein was added in 10 µl aliquots to the refolding buffers and 
mixed by immediate vortexing. At least 2 minutes were allowed between adding 
additional aliquots. Once the protein was added to all the buffers, refolding was 
allowed to proceed overnight at room temperature. The next day, samples were 
examined for presence of aggregation by measuring absorbance at 450 nm. 
Samples with little or no aggregation were dialysed in 50 mM Tris-HCl, 200 mM 
NaCl and 100 mM L-arginine, pH 8.2.  
Separation of native Gly1ΔSP on Size exclusion Chromatography (SEC) 
After overnight incubation in the refolding buffer the native Gly1ΔSP was 
concentrated using VivaSpin columns with the membrane cut-off of 5 kDa 
(Sartorius Staedim). A GE Healthcare Superose 6 10/300 GL column was 
equilibrated with separation buffer (50 mM Tris, 200 mM NaCl, 100 mM L-
arginine, 1 mM EDTA, pH 8.2). The protein sample was loaded onto the column 
and eluted at 0.5 ml/min collecting 0.5 ml fractions. Fractions that showed 
detectable absorbance at UV 260 nm, were analysed by SDS-PAGE in 
reducing and non-reducing conditions.  
 
7.6.4 Purification of proteins from the periplasmic fraction 
A 1 g aliquot of induced cells was first washed with 5 ml of EDTA wash buffer 
(20 mM Tris-HCl, pH 8; 150 mM NaCl, 5 mM EDTA) for 15 min on the roller. 
The cells were centrifuged at 5000 x g for 10 min at 15 °C. The resulting pellet 
was resuspended in 4 ml of ice-cold sucrose solution (20 mM Tris-HCl, pH 8, 
25% (w/v) sucrose, 5 mM EDTA) and incubated on ice for 15 min. Cells were 
centrifuged at 8500 x g for 10 min at 4°C and exposed to osmotic shock by 
adding 5 ml of ice-cold 4 mM MgCl2 containing 0.023 µg/ml PMSF and then 
gently resuspended. Lysozyme was added to a final concentration of 150 µg/ml 
and the sample incubated for 30 min on ice.  
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7.6.4.1 Polyethylenamine (PEI) precipitation 
First, 0.5 M of solid ammonium sulphate was added to the EDTA wash fraction 
and dissolved. Polyethylenimine (PEI) solution at the concentration of 5% (w/v) 
was then added to a final concentration of approximately 0.075% (w/v). The 
precipitation of nucleic acid was carried out for 30 minutes at 4°C and sample 
was centrifuged for 30 minutes at 40000 x g. Protein in the supernatant 
containing the neisserial Gly1ORF1 paralog was precipitated by adding solid 
ammonium sulphate to a final concentration of 3.5 M followed by stirring for 1 
hour at 4°C. Precipitated proteins were pelleted by centrifugation at 40000 x g 
for 30 minutes. Pellet was resuspended in the buffer of the choice. 
Resuspended pellet and the supernatant were dialysed against the buffer of 
choice.  
 
7.6.4.2 Ion exchange chromatography 
Ion exchange chromatography was used to remove remaining contaminants 
after Ni-affinity purification of the histidine-tagged proteins and after purification 
of neisserial Gly1ORF1 paralog from the periplasmic fraction. The ion exchange 
chromatography was carried out using either anion exchange column (Hi-Trap 
Q) or cation exchange columns: (Hi-Trap SP and/or(Hi-Trap SP). Pre-packed 
columns (1 ml and 5 ml) were purchased from GE Healthcare. SP and heparin 
columns were equilibrated with KP buffer at the pH optimised experimentally for 
each protein (25 mM potassium phosphate, 100 mM NaCl, 5% (v/v) glycerol, 1 
mM EDTA and 1 mM DTT). Q columns were equilibrated with Q buffer (25 mM 
Tris-HCl pH 8, 100 mM NaCl, 5% (v/v) glycerol, 1mM EDTA and 1mM DTT). 
Clear sample was loaded onto the equilibrated column. Proteins were eluted 
from the column with 20 CV of the appropriate buffer at the linear salt gradient 
ranging from 100 mM to 1 M NaCl. Fractions at a size of 1 CV were collected 
continuously and analysed by SDS-PAGE gel. 
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7.7 Electrophoresis methods 
7.7.1 Separation of DNA using agarose gel electrophoresis 
Plasmid DNA and PCR amplification products were separated using 0.8% - 1.5 
% (w/v) agarose gels. Powdered agarose was dissolved by boiling in 1x TAE 
buffer. The solution was allowed to cool down to the temperature of 
approximately 55°C and ethidium bromide was added to a final concentration of 
0.5 μg/ml. The agarose solution was poured in the appropriate plate and 
allowed to set with an inserted comb. The DNA separation was carried in the 
electrophoresis tank in the 1 x TAE buffer at a voltage of 1-5 V/cm. DNA bands 
were visualised using UV-trans-illuminator. 
 
7.7.2 SDS-Polyacrylamide gel electrophoresis 
A 10 ml resolving gel was prepared by mixing: 4.5 ml of distilled water, 3.3 ml 
30% acrylamide (0.8% bisacrylamide), 2 ml 200 mM Tris/bicine pH 8.3/1 mM 
EDTA, 100 µl 10% (w/v) SDS, 54 µl ammonium persulphate (100 mg/ml) and 
16 µl TEMED (N,N, N’,N’-tetramethylethylenediamine). Stacking gels were 
prepared by mixing 0.5 ml 30% acrylamide (0.8% bisacrylamide), 1 ml 250 mM 
Tris-HCl pH 6.8, 1.5 ml distilled water, 30 µl of 10% (w/v) SDS, 15 µl ammonium 
persulphate (100 mg/ml) and 7.5 µl of TEMED. The stacking gel was poured on 
the top of solidified resolving gel and the comb forming wells was immediately 
inserted.  
The protein samples were mixed 1:1 with 2xSDS loading buffer (90 mM Tris-
HCl, pH 6.8; 20 mM EDTA, 35 % (v/v) glycerol, 0.05% (w/v) bromophenol blue, 
1.8% (w/v) SDS, 1.3 mM DTT) and boiled for 3-5 min. The samples were 
loaded into the wells of the SDS-PAGE gel plates. Electrophoresis was carried 
out in the electrophoresis buffer (100 mM Tris-Bicine pH 8.3, 1 mM EDTA, 1% 
(w/v) SDS) initially at 20 mV and the voltage was increased to 40 mV after the 
proteins reached the resolving gel.  
After completion of SDS-PAGE electrophoresis gels were stained in Coomassie 
blue stain comprising of 0.05% (w/v) Coomassie brilliant blue R-250 dissolved 
in the mixture of distilled water, methanol and glacial acetic acid in a ratio of 
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5:4:1. The stained gels were then destained in the destain solution comprising 
of distilled water, methanol and glacial acetic acid in a ratio of 7:2:1. 
 
7.7.3 Separation of proteins on the native PAGE gel 
Polyacrylamide gel was prepared as previously described in Section 7.7.2 but 
without the addition of SDS. Similarly the composition of the PAGE running 
buffer and 2 x sample loading buffer were the same as previously used except 
for the absence of SDS. Protein samples were mixed 1:1 with 2x sample 
loading buffer and the samples loaded onto the gel. The PAGE was run at 100 
V for four hours at 4°C. The gels were stained with Coomasie stain and 
destained with destaining solution as described in Section 7.7.2. 
 
7.7.4 Protein detection by western blot 
The protein samples were first separated by SDS-PAGE as described in 
Section 7.7.2. The gel and a nitrocellulose membrane were soaked for 15 
minutes in the transfer buffer (2.9 g Tris-HCl, 1 g of glycine and 100 ml of 
methanol, the volume was adjusted to 500 ml with sterile distilled water). The 
protein bands were transferred onto a cellulose membrane in the semi-dry 
transfer cell (BIO-RAD, CA, USA) at 10 V for 1 hour. After the transfer, the 
membrane was incubated in the blocking buffer (PBS with 0.05% (v/v) Tween-
20 – PBS-T containing 5% (w/v) milk powder) overnight at 4°C or for one hour 
at room temperature. The membrane was washed with PBS-T at room 
temperature for 30 minutes and the membrane was probed with the primary 
antibody in PBS-T containing 1% (w/v) milk powder for one hour at room 
temperature. The excess of the antibody was removed by the wash step with 
PBS-T for 30 minutes. The membrane was than probed with appropriate 
secondary antibody conjugated with HRP for one hour at room temperature, 
followed by the wash step with PBST. The proteins were detected after adding 
the HRP substrate (Clarity Western ECL Substrate, BIO-RAD) and visualised 
on the X-ray film (KODAK). 
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7.8 Analytical methods for studying physico-biochemical 
properties of proteins 
7.8.1 Haemin agarose pull-down assay  
Haemin agarose pull down is a commonly used analytical tool to identify haem 
binding proteins. An aliquot of haemin agarose beads suspension (25 µl) 
(Sigma) was washed three times with 1 ml of PBS buffer to remove the storage 
buffer. A 0.5 ml aliquot of protein samples in PBS at the concentration of 
approximately 100 µg/mL containing BSA was mixed with the beads and 
incubated on the roller at room temperature for 30 min. Samples were 
centrifuged at 5000 x g for 2 min to sediment the beads and supernatant was 
removed. Beads were incubated in PBS with addition of 0.5 M NaCl for 15 min 
and then sedimented by centrifugation. Two more washes with PBS were 
performed and the sedimented beads were resuspended in 30 µl 2x SDS 
loading buffer and boiled for 5 minutes. Samples were then analysed by SDS-
PAGE. 
 
7.8.2 Haemin absorbance spectra in presence of Gly1ORF1 
A 0.5 mM stock of monomeric haemin was prepared as described previously 
(Cuív et al., 2008). Solid haemin (3.3 mg) was dissolved in 500 µl 0.1 M NaOH 
and the pH of the solution was reduced by addition of an equal volume of 1 M 
Tris-HCl, pH 8. Solubilised haem was diluted with 20 mM Tris-HCl, pH 7.5, 150 
mM NaCl to a final volume of 10 ml. The concentration of the haemin stock was 
confirmed by measuring absorbance of the stock at 385 nm and calculating the 
actual concentration using an extinction coefficient (ε) of 58400 M-1cm-1. 
Gly1ORF solution was prepared in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl to a 
final concentration of 5 µM and this was mixed with an increasing concentration 
of haemin. Spectra were recorded from 260 nm to 600 mM with 5 nm steps.  
 
219 
 
7.8.3 Microscale thermophoresis (MST) 
Protein labelling 
Proteins for analysis were fluorescently labelled using the NanoTemper 
Monolith RED labelling kit according to the manufacturer’s instruction. Briefly, 
proteins were diluted to a concentration of 10 µM and then buffer exchanged 
into PBS using Zeba desalting spin columns (Thermo Scientific). The dye was 
dissolved in DMSO and diluted in PBS to the final concentration of 20 µM. The 
dye was mixed with an equal volume of the protein solution resulting in a 
dye:protein ratio of 2:1. The reaction was then incubated in the dark at room 
temperature for 1 hour. Uncoupled dye was removed from the solution using PD 
MiniTrapTM G-25 columns and proteins eluted in 500 µl of MST buffer provided 
by NanoTemper Technologies GmbH (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 
10 mM MgCl2, 0.05% (v/v) Tween-20). The samples were then stored in 
aliquots at -80°C until further analysis.  
 
Gly1ORF1 – haemin binding analysis by microscale thermophoresis (MST) 
Protein samples were first centrifuged for 5 min at 15000 x g. Haemin was 
dissolved in DMSO and diluted in MST to a final concentration of 100 diluted in 
MST to a final concentration of 100 µM. Protein concentration was kept 
constant at 0.2 µM throughout the experiment. Haemin concentrations ranged 
from 50 µM to 0.181 µM in serial 3:2 dilution steps in MST buffer + 1% (v/v) 
DMSO to avoid the dilution effect of DMSO during experiment. Serial dilutions 
of haemin were made in NanoTemper tubes to a final volume of 10 µl and an 
equal volume of protein solution at 400 nM were added to each tube. Samples 
were left for 5 minutes at room temperature to equilibrate and then loaded into 
MST NT.115 hydrophilic glass capillaries. The measurements were taken using 
a Monolith NT.115 instrument (NanoTemper Technologies GmbH) at 25°C with 
the LED and MST powers set at 20%. Data were analysed using the NT 
Analysis Software (NanoTemper Technologis GmbH). 
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Two models were used for data fitting: 
1. Kd formula (law of mass action): 
𝐹𝑁𝑂𝑅𝑀(𝐶𝑇) =  𝐹𝑁𝑂𝑅𝑀,𝐹 +  
𝐹𝑁𝑂𝑅𝑀,𝐵 −  𝐹𝑁𝑂𝑅𝑀,𝐹
2
 (𝐶𝐹 +  𝐶𝑇 + 𝐾𝑑 − √(𝐶𝐹 + 𝐶𝑇 +  𝐾𝑑)2 − 4𝐶𝐹𝐶𝑇) 
 
2. Hill equation 
𝐹𝑁𝑂𝑅𝑀 (𝐶𝑇) = 𝐹𝑁𝑂𝑅𝑀,𝐹 +  
𝐹𝑁𝑂𝑅𝑀,𝐵 − 𝐹𝑁𝑂𝑅𝑀,𝐹
1 +  (
𝐸𝐶50
𝐶𝑇
)
𝑛  
FNORM - normalised fluorescence, measured for the respective titrant 
concentration (CT) 
FNORM,F - normalised fluorescence of the unbound (free) state of the 
fluorescently labelled molecules, 
FNORM,B - normalised fluorescence of the bound state of the fluorescently 
labelled molecules, 
CF- concentration of the fluorescently labelled molecules (constant), 
CT- concentration of the titrant, 
Kd - equilibrium dissociation constant, 
EC50 - half maximal effective concentration (concentration at which half of the 
fluorescently 
labelled molecules are bound), 
n - Hill coefficient. 
 
7.8.4 Dynamic Light Scattering 
Dynamic light scattering was carried out to determine the hydrodynamic size of 
Gly1ORF1 in the solution and to determine the distribution of the population of 
its multimeric forms. For the experiments, Gly1ORF1 C-his was dialysed 
against 25 mM NaOAC, 50 mM NaCl, pH 4.  
The sterile filtered solution at 0.5 mg/ml concentration was analysed in triplicate 
on Malvern Zetasizer Nano Spectrophotometer, Serial number MAL1057018 
(The Department of Chemistry, University of Sheffield). 
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To check if multimeric forms could be disrupted in the reducing condition, DTT 
was added at different concentration and sample was incubated on ice for 10 
minutes before taking the measurement.  
 
7.8.5 Analysis of oligomerisation by cross-linking approach 
Gly1ORF1 was previously shown to exhibit multimeric forms due to 
intermolecular disulphide bond formation. This multimerisation can be visualised 
on SDS PAGE gel under non-reducing conditions. To force the formation of 
multimers, samples were treated with a non-reversible cross-linker - 
glutaraldehyde. All Gly1ORF1 mutants created in this study were tested for their 
levels of multimerisation to check if any of the mutations causes structural 
changes which could disrupt the intermolecular interaction between Gly1 
monomers. 
Gly1ORF1 was diluted in PBS to a final concentration of 100 µg/ml. Aliquots of 
Gly1ORF1 mutant solution were mixed in a ratio 1:1 with varying concentration 
of glutaraldehyde diluted in PBS. The oligomerisation reaction was carried for 
one hour and reaction stopped by adding 1 M Tris-HCl, pH 8 to a final 
concentration of 50 mM and incubation was carried out for another 15 minutes. 
Samples were analysed by western blot using anti-Gly1ORF1 antibodies and 
appropriate HRP-labelled antibody. 
 
7.9 Methods for studying Gly1ORF1 interactions with red blood 
cells 
7.9.1 Preparation of red blood cell suspension. 
Blood from the healthy volunteer was collected by venepuncture into 
heparinised sterile container after written consent had been obtained (University 
of Sheffield Ethical Approval No SMBRER39). 
An aliquot of 5 ml of fresh blood was washed three times with ten volumes of 
PBS and the red blood cells (RBC) were resuspended in PBS to a haematocrit 
of approximately 10%. 
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7.9.2 Preparation of red blood cell ghosts 
Ghosts were obtained by lysing RBC in hypotonic conditions and removing the 
haemoglobin. Resuspending membranes in PBS resulted in formation of empty 
red blood cell membrane vesicles. 
Freshly drawn blood in heparin was washed three times with ten volumes of 
PBS. Red blood cells were resuspended in 10 ml of sterile distilled water and 
incubated for 15 minutes at room temperature with gentle rolling. Lysed RBCs 
were spun down for 10 minutes at 13000 x g and membranes were washed 
three times or until white with distilled water for 15 minutes. Ghosts were 
resuspended in PBS and stored at 4°C. 
 
7.9.3 Cross-linking of red blood cells with Gly1ORF1 
A 50 µl aliquots of red blood cell suspension from a healthy volunteer 
resuspended in PBS to a 10% haematocrit were mixed with an equal volume of 
Gly1 at 100 µg/ml in PBS with addition the of 400 µg/ml of BSA as a carrier. 
Samples were incubated for one hour either at 37°C or 4°C. Control with 
Gly1ORF1 without red blood cells was also prepared in parallel. After pre-
probing of Gly1 with red blood cells, 100 µl of glutaraldehyde dilutions in PBS 
were added resulting in samples with final glutaraldehyde concentration of 0, 
0.05, 0.25, 0.5, 1 and 2%. The cross linking reaction was allowed to proceed for 
one hour under the same conditions as the pre-probing with Gly1. The reaction 
was stopped by adding 1 M Tris-HCl, pH 8 to a final concentration of 20 mM 
Tris-HCl.  
The interaction of Gly1 with RBCs and ghost were also analysed using 
reversible cross-linkers: 3,3’-dithiobis[sulfosuccinimidylpropionate] – DTSSP, 
anddimethyl 3,3’-dithiobispropionimidate*2HCl – DTBP. DTBP is membrane 
permeable, whereas DTSSP can be only used for cross-linking on the cell 
surface. Stock concentrations of DTBP and DTSSP were prepared in PBS 
buffer and added to the reaction to a required final concentration. The reactions 
were carried out as described above. The cross-linked samples were analysed 
in the non-reducing SDS-PAGE gel. 
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7.9.4 Analysis of dissociation of Gly1ORF1 from red blood cells  
A 50 µl aliquot of red blood cell suspension was incubated with 50 µl of 
Gly1ORF1 C-histidine tagged at 100 µg/ml in PBS with BSA at 400 µg/ml for 
one hour at room temperature with gentle rolling. After incubation red blood 
cells were gently spun down at 100 x g for 30 sec and the supernatant was 
removed. Red blood cells were then washed with multiple washes with 200 µl of 
PBS for 15 minutes. After each wash and resuspending the RBCs in fresh 
buffer, a 10 µl sample of the suspension was analysed by western blot using 
anti-Gly1ORF polyclonal antibodies. 
 
7.9.5 FACS analysis of protein interactions with red blood cells 
Red blood cells prepared as described in Section 7.9.1 were washed four times 
in ten volumes of PBS and diluted in PBS to a haematocrit of approximately 0.5 
%. A 250 µl aliquot of diluted RBCs in PBS was mixed with 250 µl of 100 µg/ml 
Gly1ORF1 in PBS containing four times molar excess of BSA. This was 
incubated overnight at 4°C. Negative control with RBCs mixed with PBS was 
carried out in parallel. After overnight incubation RBCs were washed twice with 
PBS. 
The samples were probed with primary rabbit anti-Gly1ORF1 antibodies affinity 
purified in PBS containing 1.5% (w/v) of BSA at a 1:100 dilution for 1 hour at 
room temperature followed by two washes with PBS and 20 min probing at 4°C 
with FITC – labelled anti-rabbit secondary antibody (BD Biosciences) at a 1:250 
dilution. Samples were washed twice in PBS and resuspended in the same 
buffer to the final volume of 500 µl. Samples were analysed on FACS Calibur at 
the Flow-Cytometry Core Facility, University of Sheffield  
Alternatively, a FITC-labelled protein was incubated with red blood cells and 
incubated in the conditions described above. The red blood cells were then 
washed four times with PBS and analysed on FACS Calibur.  
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7.10 Methods for studying haemoglobin receptor HmbR interactions 
7.10.1 Congo red binding plates 
The method was based on previously described protocol (Liu et al., 2012a) with 
modifications. Cells grown in LB media containing 0.1% (w/v) glucose and 
ampicillin were grown to mid log phase and then streaked out on BHI plate 
containing 0.005% (w/v) Congo red, 0.05% (w/v) α-mono lactose and ampicillin 
at 100 µg.ml and grown overnight. at 30°C. BL21 StarTM (DE3) cells with an 
empty pET21 vector were used as a negative control.  
 
7.10.2 Congo red and haemin binding analysis by SDS-PAGE gel staining 
Cell lysates of induced and control cells were separated by SDS PAGE gel 
described previously (see Section 7.7.2). After SDS-PAGE, gels were washed 
first with TBG-buffer (100 mM TRIS, 100 mM Bicine, 50 mM NaCl, 10 mM 
MgCl2, KCl, 10% (v/v) glycerol; pH 8.3) containing 5 mM DTT for 20 minutes 
followed by two washes with TBG buffer without DTT. Ability to bind Congo red 
and haemin was determined by incubating the gels with TBG buffer containing 
80 µg/ml of Congo red or 100 µM haemin in TBG buffer with no DTT. The gels 
were destained by several washes with TBG buffer. 
 
7.10.3 Binding of haem and haemoglobin by the E. coli cells expressing 
HmbR 
In order to establish if expressed HmbR is present on the surface of the cells, a 
whole cell binding assay was performed with E. coli BL21 StarTM (DE3) 
overproducing the protein of interests as described previously (Simpson et al., 
2000). 
Freshly transformed E. coli BL21 StarTM (DE3) cells with an empty pET21 vector 
and a vector containing hmbR gene were inoculated into LB media containing 
0.1% (w/v) glucose and ampicillin and incubated overnight at 37°C. The 
overnight cultures were used as inoculates for 100 ml cultures containing 
glucose and ampicillin. Cultures were grown at 30°C until they reached an 
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OD600 nm of approximately 0.6 and were induced by adding 0.1 mM IPTG. 
Aliquots of induced cultures were taken at 0, 30, 60, 90 and 120 minutes post 
induction. Cultures were pelleted at 50000 x g and resuspended in PBS to an 
OD600 nm of 1. Aliquots of 0.8 ml of cell suspensions were transferred into sterile 
tubes and 0.2 ml of human haemoglobin and haemin solutions in PBS were 
added to a final concentration of 10 µM and 5 µM, respectively. Cells were 
incubated with haem and haemoglobin for an hour at 37°C and centrifuged at 
5000 x g. The absorbance of the supernatants was measured on the 
spectrophotometer at 385 nm (haemin) and at 410 nm (haemoglobin). 
 
7.10.4 Binding of Gly1ORF1 to E. coli cells expressing HmbR 
Cell cultures of induced HmbR and control with an empty pET21 vector were 
prepared as described in Section 7.10.3. Cell suspensions of un-induced and 
induced cultures were incubated with Gly1ORF1 at a final concentration of 2.5 
µM at 37°V for 1 hour. The cells were centrifuged at 5000 x g for 3 minutes. 
Binding of Gly1ORF1 to the cells was determined by western blot comparing 
amount of Gly1ORF1 in supernatants with control sample with no added cells. 
Gly1ORF1 bound to the E. coli cells was also detected by western blot in the 
cell lysates. Images were analysed by ImageJ software (Schneider et al., 2012). 
 
7.11 Methods for evaluation of immunogenic properties of the 
proteins 
7.11.1 Analysing antibody titres of mouse anti-Gly1ORF1 serum by the 
enzyme-linked immuno-absorbent assay (ELISA) 
Mouse sera against Gly1ORF1 protein were raised and provided by BioServ UK 
Ltd., Sheffield. Six mice were injected with soluble Gly1ORF1 protein followed 
by a booster vaccination after four weeks. Control mice were injected with PBS. 
Sera from individual mice showed cross-reactivity with Gly1ORF1 when tested 
by western blot by Dr R. Walton.  
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ELISA method 
Sera from six mice were pooled and antibody titre was determined by ELISA. 
96-well ELISA plates were coated with 50 µl of Gly1ORF1 in PBS at the 
concentration of 5 µg/ml and then incubated overnight at 4°C. Plates coated 
with antigen were washed three times with PBST (PBS containing 0.05% (v/v) 
Tween 20). Individual wells were blocked with 100 µl of blocking buffer (PBST 
containing 5% (w/v) skimmed milk powder) for 1 hour at room temperature with 
shaking. The blocking step was followed by three washes with PBST. Twelve, 
two-fold dilutions of mouse sera in blocking buffer starting from 1:80 were 
added to sequential wells in duplicate. Plates were incubated for 1 hour at room 
temperature with shaking and then washed three times with PBST buffer. Anti-
mouse IgG – HRP secondary antibody (Cell Signalling) in blocking buffer at 
1:10000 dilution were then added and incubation was carried out for another 
hour at room temperature with shaking. After washing it three times with PBST, 
80 µl of substrate for HRP ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid) was added. The reaction was stopped after 10 minutes by adding 
equal volume of 1% (w/v) SDS in each well and plates were read on the plate 
reader at 405 nm. 
Controls in this assay included wells without antigen incubated with first dilution 
of sera to test unspecific interactions and antigen incubated only with secondary 
antibody. 
 
7.11.2 Detection of antibody response against Gly1ORF1 in human sera 
Sera form 6 patients with acute meningococcal infection taken during admission 
to the hospital and one month after infection were obtained as a kind gift from 
Prof. RC. Read. The 96 sera samples from patients with no suspected 
meningococcal infection from the Serum Epidemiological Unit (SEU) were 
obtained from the Health Protection Agency. The method described in Section 
7.11.1 was followed with slight modifications.  
To reduce the background, the Tween 20 in blocking buffer and in the wash 
buffer was increased to 0.1% (w/v) concentration and skimmed milk powder 
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was replaced with BSA 3% (w/v). The secondary antibody used in this assay 
was goat HRP-conjugated anti-human IgG (alpha chain) antibody (Sigma). Sera 
from 96 patients from SEU were initially tested at a 1:20 dilution with three 
repeats. Samples with the highest anti-Gly1ORF1 levels were re-tested at two-
fold serial dilutions.  
 
7.11.3 Measuring of Serum Bactericidal Activities of anti-Gly1ORF1 
antibodies 
7.11.3.1 Preparation of the human complement for SBA 
Freshly drawn blood from a healthy volunteer obtained under written consent 
(local ethics permission, SMBRER39) was transferred into a sterile tube and left 
on the bench to clot for 30 min. The tube containing clotted blood was then 
placed on ice and incubated for an hour. A blood clot was pelleted by 
centrifugation at 800 x g for 10 min at 4°C and serum was carefully aspirated to 
a fresh tube. Serum was then incubated for an hour on ice with suspension of 
N. meningitidis MC58 prepared in PBS. This procedure removed the antibodies 
cross-reacting with NM MC58 and reduced the background killing of the 
complement. Bacteria were removed by centrifugation and human complement 
was filter-sterilised, dispensed into aliquots and stored at -80°C until needed. 
7.11.3.2 Affinity purification of anti-Gly1ORF1 rabbit polyclonal 
antibodies. 
CNBr-activated Sepharose 4B beads (1 g, Sigma) were washed and swollen 
with 200 ml of ice cold 1 mM HCl on a sintered glass filter (porosity G3). The 
beads were rapidly washed three times with the coupling buffer (0.1 M 
carbonate buffer, 0.5 M NaCl, pH 8.3) in a 50 ml polypropylene tube and 
centrifuged for 2-3 min at 50 x g after each wash. Approximately 10 mg of 
protein in 10 ml of coupling buffer was added to 1 ml of washed beads. Tubes 
were incubated overnight at 4°C on the rotating mixer. Samples were taken 
immediately at the start and at end of incubation to determine the coupling 
efficiency. 
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Beads were centrifuged for 2 min at 70 x g and washed twice with coupling 
buffer, then resuspended with 15 ml of 0.1 M Tris-HCl, pH 8.0 to inactivate any 
remaining active groups on the beads. Beads were incubated for 2 hours at 
room temperature on a shaker. Three washes at 4°C were performed, first with 
0.1 M Tris-HCl, pH 8 followed with 0.1 M acetate buffer, pH 4.0. Finally, beads 
were washed three times with PBS. 
Gly1ORF1-coupled beads (1 ml) were resuspended in 10 ml PBS and an equal 
volume of rabbit serum raised against Gly1ORF1 was added. Binding of 
antiserum to the beads was performed overnight at 4°C on a rotating mixer. 
Elution of the antibodies was performed in the cold room. First, the beads were 
washed three times with PBS and then resuspended in 10 ml of PBS. The 
beads were loaded into a disposable plastic column  and washed approximately 
with 10 column volumes of PBS or until no protein was detected 
spectrophotometrically at 280 nm.  
Bound antibodies were eluted with 200 mM glycine, pH 2.8 and 1 ml fractions 
were collected into tubes containing 27 µl of 3 M Tris-HCl, pH 8.8 and 100 µl of 
3 M KCl. Purified antibodies were dialysed against PBS with three buffer 
changes. The dialysed antibodies were concentrated, filter-sterilised and 
aliquots were stored at -80°C.  
7.11.3.3 SBA – serum bactericidal assay 
N. meningitidis MC58 WT and isogenic Gly1ORF1 knock-out bacteria were 
grown for 16-18 h on Columbia Blood Agar (CBA) plates at 37°C in an 
atmosphere of 5% CO2. Isogenic Gly1ORF1 mutant NM MC58 was grown on 
plates supplemented with 5 µg/ml of erythromycin. A loopful of bacteria was 
transferred from the plate into 2 ml of PBSB (PBS with 0.9 mM CaCl2 0.5 mM 
MgCl2) containing 2% (v/v) de-complemented foetal calf serum (FCS). Cells 
were gently resuspended and centrifuged for 2 min at 200 x g to remove any 
bacterial aggregates. Supernatant containing homogenous suspension of 
bacteria was transferred to a clean tube. 
Polyclonal sera and FCS were de-complemented by incubation at 56°C for 30 
min. Bacterial suspension containing approximately 1000 cfu (25 µl) was added 
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to the wells of a sterile 96-well culture plate. Serial dilutions of de-
complemented serum were prepared in PBS and added to the bacterial 
suspensions. Human serum as an exogenous complement source was freshly 
thawed and added to a final concentration of 5% (v/v). The volume was made 
up to 100 µl with PBSB containing 2% (v/v) FCS. Plates were agitated briefly 
and incubated for 30 min at 37°C with 5% (v/v) CO2. After incubation, 15 µl from 
each well was plated on CBA plates in triplicate to determine viable count. 
Controls included samples with bacteria only, bacteria with human complement 
and bacteria with heat-inactivated human complement. The first dilution of 
polyclonal antibodies with heat inactivated complement was also tested. The 
percentage of killing was calculated by using control sample with bacteria and 
human complement as a 100% and calculating percentage difference in cfu in 
tested samples. 
 
7.11.4 Whole Cell ELISA with Neisseria spp. 
Coating of the ELISA microtitre plates with suspension of homogenised bacteria 
was performed as previously described (Abdillahi and Poolman, 1987). Different 
strains of Neisseria were grown on CBA plates for 16-18 hours at 37°C with 5% 
CO2. Bacteria were scraped from the plates with a sterile swab and 
resuspended in PBS. The bacterial suspension was adjusted to an optical 
density of OD600 0.1. Bacterial suspension was pasteurised for 30 min at 56°C 
in a water bath and aliquots of 100 µl were transferred into individual wells of 
ELISA microtitre plates. Plates were incubated uncovered overnight at 37°C to 
allow evaporation of the buffer and fixation of the cells.  
Plates were then washed three times with deionised water containing 0.025% 
(v/v) Tween 20. Primary antibodies were diluted in blocking buffer (PBS, 3% 
(w/v) BSA, 0.01% Tween 20) and probed with immobilised cells for one hour at 
37°C on the shaker. Plates were then washed three times with deionised water 
with 0.025% (v/v) Tween and secondary antibody was added at a 1:1000 
dilution in blocking buffer. Plates were incubated for 1 h at room temperature 
with gentle shaking. After washing the plates three times with deionised water 
with 0.025% (v/v) Tween 20, a substrate for HRP (ABTS) was added and the 
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colour development was allowed to proceed for 20 min and absorbance at 405 
nm was measured on the plate reader. 
 
7.11.5 Detection of the antigen on the surface of the Neisseria using flow 
cytometry 
A protocol for the procedure was adapted from Hung and co-workers (Hung et 
al., 2013). Analysed strains were grown overnight at 37°C on CBA plates in an 
atmosphere of 5% (v/v) CO2. Cells were scraped from the plates and 
resuspended in PBS. Cells were washed two times with PBS and resuspended 
in 2 ml of ice cold 70% (v/v) ethanol and incubated for one hour at -20°C. This 
step allowed permeabilisation of the bacterial capsule and allowed interaction of 
the surface antigens with the primary antibody. Cells were then washed three 
times with PBS containing 1% (w/v) BSA and resuspended in PBS + 1% (BSA) 
to a density of approximately 106 cfu/ml of suspension. Bacterial suspensions 
were aliqouted into sterile tubes (final volume of 0.5 ml) and affinity purified 
rabbit antibodies against Gly1ORF1 and alpha protein were added to the final 
dilution of 1:100. Cells were incubated with primary antibodies for 30 min at 
37°C. Negative controls were incubated with PBS + 1% (w/v) BSA only. 
 
7.12 Gly1ORF1 homologs bioinformatic analysis 
The protein sequence of the neisserial Gly1ORF1 was submitted to blastp with 
PSI-blast algorithm (NCBI). The hits from the blast search were further iterated. 
From a number of PSI-blast results following protein sequences has been 
chosen: hypothetical protein Hflu203001319 (Ref. ID ZP_00157632.2) of 
Haemophilus influenzae R2866 and hypothetical protein mh0603 (Ref. ID 
ABG89179.1) of Mannheimia haemolytica 
The physico-chemical properties of the protein were analysed by ProtParam 
Expasy Proteomics Server (URL: http://expasy.org/tools/protparam.html) and 
the search for motifs and conserved domains was done with the InterProScan 
server (URL: http://www.ebi.ac.uk/Tools/InterProScan/). The subcellular 
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localisation of the hypothetical proteins was determined with the PSORTb 
version 3.0.2 (URL: http://www.psort.org/psortb/). The site of the cleavage of the 
N-terminal signal peptide was predicted by SignalP 3.0 software (URL: 
http://www.cbs.dtu.dk/services/SignalP/). To predict the secondary structure 
topology the GLY1ORF1 homolog sequences were submitted to SABLE server 
(URL: http://sable.cchmc.org/), whereas the disulphide bonds formation 
probability was analysed with the help of DISULFIND server (URL: 
http://disulfind.dsi.unifi.it/). 
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